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Abstract 
Diabetes mellitus is a multifactorial disorder characterised by hyperglycaemia and leads to 
complications. These complications are caused by advanced glycation endproducts (AGEs) 
that form through protein glycation as a consequence of hyperglycaemia. A diversity of plants 
are utilised worldwide as traditional medications for the treatment of diabetes mellitus, 
particularly in developing nations. A considerable quantity of literature has been published on 
Momordica charantia (MC) as a potent folk medicine for diabetes mellitus.  
The aim of this study was to investigate the antiglycation and antioxidant effects of HWE and 
CWE of MC on protein glycation. To examine whether MC can inhibit oxidative stress in 
endothelial cells by studying oxidative stress-related transcription factor parameters and their 
expression.  
Model proteins such as lysozyme and BSA were glycated using sugars (glucose and 
methylglyoxal) as glycating agents both in the presence and absence of MC extracts. AGE 
formation and inhibition were monitored by a number of methods. Furthermore, different 
antioxidant assays were used to study the antioxidant properties of MC. The inhibitory effects 
of AGEs, glucose, methylglyoxal and MC extracts on proliferation of cultured BAEC were 
determined in this research. Western blotting was used to examine the potential modulation of 
the oxidative stress signalling pathways induced by AGEs. Both extracts of MC inhibited the 
production of AGEs in a dose-dependent fashion and the HWE exhibited the more potent 
inhibitory effect on AGEs production. Moreover, parameters of oxidative stress including the 
expression of oxidative stress-related transcription factors were assessed using real-time PCR 
to study the protective effects of MC. 
The expressional inhibition of pro-oxidaive genes and enhancement anti-oidative enzymes 
could be potent element of vascular complications effect of MC extracts. Thus the aqueous 
extracts of MC, an edible vegetable, may have therapeutic potential in the management of 
diabetes mellitus. 
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Chapter 1. General introduction 
1. Introduction 
Diabetes mellitus (DM) is a metabolic disorder characterised by increased blood glucose 
concentrations resulting from a lack or partial deficiency of insulin, or insulin resistance. 
Diabetic patients are susceptible to chronic complications such as nephropathy, retinopathy, 
atherosclerosis and delayed wound-healing. Hyperglycaemia plays a critical role in the 
pathogenesis of long-term complications and its toxicity is mediated by increased glycation of 
proteins. Protein glycation is a simple chemical reaction initiated by a nucleophilic addition 
reaction between a free amino group from a protein and carbonyl groups of sugars to form 
freely reversible Schiff bases that subsequently form more stable and relatively irreversible 
ketoamine or Amadori products. The Amadori product goes through a number of reactions 
involving dicarbonyl intermediates, such as 3-deoxyglucosones and methylglyoxal, and 
eventually gives rise to poorly characterised structures called advanced glycation end products 
(AGEs) (Ahmed, 2005). Glycation causes damage to proteins, lipids and nucleic acids and 
leads to oxidative stress in chronic conditions (Elosta et al, 2012). The accumulation of toxic 
AGEs can permanently alter the structure and function of proteins as observed in diabetes 
mellitus, cancer, Alzheimer’s disease and inflammatory conditions (Mashilipa et al, 2011). The 
molecular mechanism of oxidative stress leads to diabetic complications are not fully 
understood. It has been reported that the hyperglycaemia result in generation of ROS, leading 
to elevated oxidative stress, thus, causing the activation of oxidative-stress signalling pathways, 
such as NADPH oxidase (NOX family), NF-κB, p38 MAPK, P21, JAK family, JNK/STAT, 
AGE-RAGE, sorbitol and others. Subsequently leading generation of gene products, such as 
tissue factor and VEGF, which cause cellular injury and are play key role in long-term of 
diabetic complications. Therefore, the activation of these pathways appears to enhance insulin 
resistance and impaired insulin secretion. The location and longevity of endothelial cells mean 
they are prime targets for hyperglycaemia-induced cellular toxicity. Therefore, endothelial 
dysfunction may underpin the pathogenesis of diabetic vascular complications (Endemann & 
Schiffrin, 2004). 
Momordica charantia (MC) is used worldwide, especially in Africa and Asia for its valuable 
medicinal properties. It is used as a fruit juice or leaf tea for several chronic conditions such as 
diabetes mellitus, colic and hypertension. Several studies have indicated that MC may provide 
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protection against oxidative stress (Kumar et al, 2009; Tupe et al, 2014; Umukoro & Ashoro, 
2006). Antiglycation agents with antioxidant properties and reduced side effects may provide 
a therapeutic approach for delaying and preventing diabetic complications (Ramkissoon et al, 
2012). However, the protective action of MC is still not fully understood. Further studies are 
needed to understand the antioxidant and antiglycation properties of MC and its protective role 
in preventing glycation-mediated damage to proteins and endothelial cells. 
1.1 Glucose 
Glucose is a main energy source for the human body and plays a key role in maintaining health. 
Adenosine triphosphate (ATP) molecules are a fuel for almost every cellular process, which 
form as a result of the metabolism of glucose molecules in most cells. A constant level of 
glucose is required for cells to function (Deng, 2012). Glucose consists of six carbons and has 
two isomeric forms, acyclic and cyclic, as shown in Figure 1.1. The high stability of glucose is 
related to its ring structure and this makes it less reactive with amine residues of proteins. 
Conversely, the presence of free carbonyl residues in the open configuration of glucose 
accounts for the more reactive form. Furthermore, in addition to  glucose, there are other 
intracellular reducing sugars such as fructose, glucose-6-phosphate (G-6-P), fructose-6-
phosphate (F-6-P), galactose, and ribose and their derivatives, that are more reactive and 
contribute to AGEs formation more than glucose. Moreover, glucose is five times less reactive 
with amines than galactose; eight times less than fructose; 25 times less than deoxyglucose; 
and 100 times less than ribose.  In this respect, glucose is a very important type of reducing 
sugar because it is less reactive with protein and therefore contributes less to AGEs formation. 
Conversely, the body feedback mechanism tightly regulates blood glucose levels in a low range 
of concentrations (3-6 mM). However, the blood concentration of other more reactive sugars 
such as fructose, ribose, and methylglyoxal is maintained at  much lower (µM) concentrations 
(Salvayre et al, 2009; Takeuchi et al, 2010). Glucose is therefore the most abundant type of 
reducing sugar in the blood. 
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Figure 1.1: Chemical structures of glucose molecules. Acyclic form of D-glucose (centre) 
and cyclic forms of  α-D-glucose (left) and β-D-glucose (right) (Deng, 2012). 
 
1.2 Hyperglycaemia 
The level of glucose above normal that is due to inadequate secretion or insufficiency of insulin 
is defined as hyperglycaemia. Research on clinical and animal models has indicated that excess 
glucose levels above the baseline are the main cause of metabolic disorder, resulting in diabetic 
microvascular and macrovascular complications (Verzelloni et al, 2011). In humans, insulin 
and glucagon are important hormones in controlling glucose levels tightly between 3.0 and 7.8 
mmol/L. However, initial hyperglycaemic clinical features appear at concentrations of between 
15-20 mmol/L (Cox et al, 2005; Meijering et al, 2006). Hyperglycaemia  leads  to increased 
levels of intracellular sugars such glucose, fructose, fructose-3-phosphate (F-3-P), glucose-6-
phosphate (G-6-P) and the accumulation of highly reactive dicarbonyl molecules, for example 
methylglyoxal and glyoxal. It has been known that AGEs form as a result of non-enzymatic 
reactions between these sugars and their derivatives with other type of molecules (Mashilipa 
et al, 2011). Microvascular and macrovascular complications are associated with diabetes 
mellitus. The major types of microvascular complications are neuropathy, nephropathy and 
retinopathy, which are develop in diabetic patients over a period of 10-15 years (Nathan et al, 
2005). Elevated vascular permeability and prothrombotic conditions, the thickening of 
basement memberane and reduced blood flow are pathological alterations of microvascular 
disease (Elosta et al, 2012). On the other hand, macrovascular complications play a vital role 
in a range of pathological changes occurring in most types of blood vessels leading to structural 
and functional changes. These changes cause endothelial dysfunction, elevated arterial wall 
stiffness and decreased compliance of the vascular system, thus eventually enhancing 
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macrovascular complications. One of the most well known macrovascular complications is 
atherosclerosis, which is believed to cause cardiovascular disorders such as myocardial 
infarction, peripheral vascular pathologies and increased risk factors of diabetes mellitus. 
Furthermore, in humans, many organs such as kidney, eye, and blood vessels are dependent on 
insulin for the production of fuel from glucose, such compartments are more susceptible to the 
cellular and molecular complications  of hyperglycaemia (Verzelloni et al, 2011). 
1.3 Diabetes mellitus 
Diabetes mellitus is a metabolic disorder characterised by long-term hyperglycaemia. When 
untreated, it may cause severe medical conditions such as chronic hyperglycaemia and 
disturbances in the metabolism of protein, fats and carbohydrates (Elosta et al, 2012). In 
recent years, the incidence of DM has increased dramatically. Such an increase has occurred 
in all parts of the world and is believed to be the result of many factors, for instance obesity, 
the increased intake of fatty food, lack of physical activity, social influence and increasing 
ageing populations (Romao & Roth, 2008). Moreover, in 2010 the WHO predicted that there 
will be around 366 million adults suffering from DM in 2030, in contrast, this figure was 171 
million  in 2007 (WHO, 2007). At present, there are around 344 million people worldwide who 
have diabetes (WHO, 2013). Additionally, the WHO estimated that DM will be the 7th leading 
cause of death worldwide in 2030 (WHO, 2011). Generally, DM can be classified into three 
types; type І and type ІІ are based on the dependence of insulin. It has been reported that both 
type І and type ІІ are associated with major long-term complications such neuropathy, 
retinopathy, nephropathy, angiopathy (delay in wound-healing), vascular diseases and diabetic 
foot and digestive insufficiencies (Ahmed et al, 2004). 
Type І DM, formerly known as insulin-dependent diabetes mellitus (IDDM), or juvenile 
diabetes, is recognised by the lack of insulin secretion and results from the autoimmune 
destruction pancreatic beta cells. Approximately, 10% of people with diabetes have this type 
of diabetes mellitus (WHO, 2013).  
Type ІІ DM, formerly known as a non-insulin-dependent diabetes mellitus (NIDDM), is caused 
by a combination of insulin insufficiency and/or insulin resistance (Rolo & Palmeira, 2006). 
At present, type ІІ DM represents for about 90% of people with diabetes  worldwide (WHO, 
2013).  
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The third type is known as gestational diabetes mellitus occurs in pregnancy. This form is 
described as any degree of glucose intolerance, even if the patient has pre-existing diabetic 
symptoms (Nakata et al, 2013). 
1.4  Maillard reaction 
This is a chemical reaction between amines of protiens and carbonyl compounds of reducing 
sugars. The importance of the Maillard reaction was not recognised until the mid 1970s when 
the relation between diabetic complications and  glycated haemoglobin  A1c (HbA1c) was 
established. For the first time, in 1980, the term glycation products was used by scientists 
instead of the Maillard reaction. One of the most important sources of amines in biological 
systems are the primary amino groups of free amino acids, the ԑ-amino group of lysine and 
arginine residues of proteins and peptides. In contrast, reducing sugars such as glucose, ribose, 
galactose, and fructose and their derivatives, are the prominent sources of carbonyl compounds 
donating to the Maillard reaction (Ahmad et al, 2007). 
1.5 Biochemistry of protein  glycation 
Protein glycation is a series of complex reactions between the free amino groups of proteins 
and the carbonyl groups of a reducing sugar. The reaction generally includes three stages 
named initiation, propagation and an advanced stage. Moreover, the reaction rate is very slow 
because no enzymatic catalyst contributes, and usually it requires several days to several weeks 
to complete. 
1.5.1 Protein glycation: Initiation stage 
The first step of protein glycation is initiated by the nucleophilic addition reaction between  
amino groups of  proteins, lipids and nucleic acids, with carbonyl groups of reducing sugars 
such as glucose to produce a freely reversible Schiff base such as glycosaylamine (Mashilipa 
et al, 2011). This reaction needs hours to occur. Once this product is formed, it rearranges itself 
further to form a more stable structure called an Amadori product or ketomine like 
haemoglobin A1c or 1-amino-α-deoxyketose as illustrated in Figure 1.2. The Amadori products  
need days to form and, once formed, they are stable and almost irreversibe (Marchetti, 2009; 
Mashilipa et al, 2011).   
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Figure 1.2: Formation of glycated haemoglobin A1c (HbA1c) (Marchetti, 2009) 
1.5.2 Protein glycation: Propagation stage 
Amadori products undergo a number of chemical rearrangements, dehydration, degradation 
and oxidation reactions to produce other amino or carbonyl compounds  which may act with 
other amino molecules (Mashilipa et al, 2011). These post-Amadori products react at higher 
rates than the original sugar from which they are derived. Glyoxal, methylglyoxal and 3-
deoxyglucosone (3-DG) are the most well known and  potent types of post-Amadori products 
in the glycation reaction (Elosta et al, 2012). 
1.5.3 Protein glycation: Advanced stage 
The advanced stage of protein glycation is characterised by formation of AGEs molecules, 
which starts with the reaction of post-Amadori products with the free amino groups of proteins. 
Similar to an intermediate stage of protein glycation, the post- Amadori products within this 
stage undergo further degradation, dehydration, condensation, oxidations and cyclisation 
reactions within the amino-carbonyl compounds to create different types of AGEs such as 
fluorescent or non-fluorescent and cross-linked or non-cross-linked forms (Mashilipa et al, 
2011). 
1.5.4 Autoxidative glycation (Wolf pathway) 
Autoxidative glycation is characterised by a non-enzymatic reaction between the                            
α-hydroxycarbonyl group of reducing sugars and oxygen molecules. Subsequently,                        
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α- oxoaldehydes and hydrogen peroxide are regarded as main products of this reaction. It has 
been reported that free radicals play a vital role in this process and the reaction is started by the 
enolisation of the initial monocarbohydrates (Ahmed, 2005; Ahmad et al, 2007). Consequently, 
the enediol formed is dehydrated to a dicarbonyl compound and other types of AGEs. Within 
the above reaction, a number of additional AGEs and dicarbonyl molecules are formed. Hence, 
erythrose or erythitol split from glucose molecules to provide more reactive reducing sugars 
such as glyoxal and 3-deoxyglucosone. Eventually, these products react with other production 
of methylglyoxal and glyceraldehyde (Giacco & Brownlee, 2010) The following reactions  
illustrate some steps of autoxidative glycation as shown in Figure 1.3 
 
Figure 1.3: Autoxidative glycation (Wolff pathway) (Semchyshyn HM, 2013). 
1.5.5 Schiff base fragmentation (Namiki pathway) 
Previous research has indicated that there is another pathway for the production of AGEs, prior 
to the formation of Amadori products. Fragmentation of the Schiff base may take place to 
produce dicarbonyl molecules; hence, this leads to the production of free radical species as 
shown in Figure 1.4. Moreover, glyoxal and methylglyoxal are formed via Schiff base 
fragmentation through the Namiki pathway (Elosta et al, 2012). 
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Figure 1.4: Oxidative Schiff base fragmentation (Namiki pathway) (Semchyshyn HM, 
2013). 
1.5.6 Glycoxidation 
Autoxidation of Amadori products, commonly known as glycoxidation products, defines the 
characteristic products formed by consecutive glycation and oxidation reactions (Giacco & 
Brownlee, 2010). The free carbonyl group in the enediol form of glucose in the reacting 
medium may undergo oxidation in a transition metal-dependent reaction to an enediol radical 
anion. Hence, these products change to superoxide anion radicals through the production of 
ketoaldedydes. Superoxide anion dismutase produces H2O2 and in the presence of  oxygen 
species produces free radical species like hydroxyl radicals (OH˙) and dicarbonyl compounds 
(Ahmad et al, 2007). This process is defined as glucose autoxidation (Dean, 1987) and it is 
outlined in Figure 1.5. Consequently, the glycoxidation reaction of Amadori products generates 
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AGEs  which are believed to play a key role in diabetic complications (Giacco & Brownlee, 
2010). 
 
Figure 1.5: Metal-catalysed autoxidation of glucose molecules to protein-reactive 
dicarbonyls is paralled by the production of superoxide (O–2). Superoxide free radicals  can 
dismutalse  to hydrogen peroxide (H2O2), then are changed to reactive hydroxyl radicals in the 
presence of transition metals (Ahmed, 2005). 
1.6 Factors influencing protein glycation 
The first step of the non-enzymatic reaction between free carbonyl reducing sugars and the 
amino residues of  proteins are primarily dependent on several factors such as pH, metal ions, 
oxygen and the electrophilicity of the sugar carbonyl carbon (Ahmed, 2007; Mashilipa et al, 
2011). Therefore, temperature, water activity and the percentage of the reducing sugar in the 
open ring form may also have a direct influence on the rate and extent of the Amadori 
rearrangement (Elosta et al, 2012). Subsequent studies  indicated that protein glycation is 
influenced by the presence of adjacent histidine residues, carboxylate residues and negatively 
charged ions, for example phosphates, present in the reaction medium (Ahmed, 2005). Several 
studies have highlighted that the production of glycated proteins in vivo is dependent on the 
degree and duration of hyperglycaemia, the half-life of the protein and the inherent reactivity 
of particular amino residues (Smit & Lutgers, 2004). 
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1.7 Types of AGEs 
AGEs are a large family of complex heterogeneous molecules that  consist of both fluorescent 
and non-fluorescent residues characterised by yellow-brown pigmentation and their capability 
to produce cross-links between free amino groups of proteins (Ramasamy et al, 2005). 
However, all types of AGEs can be divided into four classes according to their chemical and 
physical properties (Ahmad et al, 2007). Biochemical and immunohistochemical studies have 
proposed that carboxymethyllysine (CML) modifications of proteins are predominant in AGEs 
that accumulate in vivo (Basta et al, 2004). 
1.7.1 Fluorescent cross-linked AGEs 
The fluorescent cross-linked AGEs are the minor AGE molecules, which account for only 1% 
or less of the total cross-linking molecules. Certain fluorescent cross-linked AGEs, for instance, 
pentosidine, vesperlysine A- B- C and crossline (Elosta et al, 2012), have been recognised 
under physiological conditions in vitro. Examples of these types of AGEs are shown in Figure 
1.6A. 
1.7.2 Non-fluorescent cross-linked AGEs 
Non-fluorescent cross-linked AGEs are believed to be major types of AGEs structures and 
possess a vital role in protein cross-linking in vivo. For instance, glyoxal-lysine dimers 
(GOLD)and methyl-glyoxal-lysine dimers (MOLD) are common types of non-fluorescent 
cross-linked AGEs (Ahmed, 2005; Elosta et al, 2012 ). Examples of non-fluorescent cross-
linked AGEs are illustrated in Figure 1.6B 
1.7.3  Fluorescent non-cross-linked AGEs 
Similarly to cross-linked AGEs which inhance the function and structure of proteins, a range 
of fluorescent non-cross-linked AGEs have been  discovered in the blood of diabetic patients. 
Furthermore, argpyrimidine is a typical example of AGEs structure belonging to this family of 
fluorescent non-cross-linked AGEs and are demonstrated in Figure 1.6C (Elosta et al, 2012; 
Mashilipa et al, 2011). 
1.7.4 Non-fluorescent non-cross-linked AGEs 
In addition to other types of AGEs there is another group of AGEs called non-fluorescent non-
cross-linked AGEs which arise from protein glycation under physiological conditions. 
Carboxymethyllysine (CML), carboxyethyllysine (CEL), pyrraline and imidazolone are the 
common types of this class of AGEs that are shown in Figure 1.6D ( Elosta et al, 2012). 
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Figure 1.6: Chemical structures of different types of AGEs: 
(A) Fluorescent cross-linked AGEs, (B) Non-fluorescent cross-linked AGEs 
(C) Fluorescent non-cross-linked AGEs, (D) Non-fluorescent non-cross-linked AGEs.  
 
1.8 Intercellular protein glycation and AGE formation 
The oxidation of Amadori products and lipid peroxidation lead to the generation of AGE 
molecules. Several studies have indicated that, along with glucose as a main precursor for AGE 
formation, other reducing sugars are involved as being more reactive than glucose (Ahmad et 
al, 2007). Moreover, the more reactive reducing sugars such methylglyoxal form via non-
oxidative glyceraldehyde-3-phosphate fragmentation and produce the most reactive AGEs in 
the intercellular compartment (Brownlee, 2005). In regard to these findings, further studies 
were carried out using the AGE inhibitors benfotiamine and thiamine. Benfotiamine is a lipid-
soluble thiamine precursor obtaining higher bioavailability than thiamine and, reduces the 
severity of the complications which are associated with diabetes such neuropathy, nephropathy, 
retinopathy and angiopathy by preventing the production of AGEs (Balakumar et al, 2010). 
Exposure of the endothelial cells to glucose for 7 days resulted in alleviating AGEs levels 14 
fold. This increase  most likely results from glycation by more highly reactive intercellular 
reducing sugars such as glucose-6-phosphate, methylglyoxal and fructose (Ahmed, 2005). 
12 
 
1.9 Major exogenous sources of AGEs formation 
One of the greatest exogenous sources of highly reactive AGEs is a complex diet that is rich in 
proteins, fatty substances and carbohydrates. Certain type of foods and dietary factors directly 
affect production of AGEs. Heating is an important factor in food processing, and plays a key 
role in increasing the formation of AGEs. In addition, the production of AGEs in food during 
cooking depends particularly on other factors, for instance the ingredients, temperature and the 
duration of heat application. Hence, foods containing high levels of fat and prepared at high 
temperature under dry conditions form high levels of AGEs (Goldberg et al, 2004; Vlassara et 
al, 2008). It has been reported that tobacco smoking is recognised as a serious, worldwide 
public health concern and is accounted as a major exogenous source of AGE production. 
Previous studies have demonstrated that consequential increases in serum concentrations of 
AGEs have been detected in diabetic smokers as compared with non-smokers, irrespective of 
diabetes (Fujioka & Shibamoto, 2006). Tobacco leaves naturally contain a variety of chemical 
substances and sugars such as glucose, fructose and sucrose. Cigarette smoke produces highly 
toxic materials such as glycotoxins, which are absorbed from the lungs into blood vessels and 
accelerate the production of AGEs.  In addition, high concentrations of glyoxal and 
methylglyoxal are produced from burning cigarettes. Methylglyoxal forms as a result of the 
thermal decomposition of saccharides, which are considered as essential precursors of 
smoking-associated AGEs (Talhout et al, 2006). 
1.10 Biological effects of AGEs 
The modification and aggregation of different proteins may generate several pathological 
processes, which lead directly to tissue damage. Thus, accelerated AGE formation or decreased 
degradation causes the accumulation of AGEs in tissues (Bohlender et al, 2005). AGEs cause 
tissue injury which comes from a variety of mechanisms such as aggregation and precipitation 
of proteins, cross-link production of AGEs, prevention of particular functions of proteins, the 
formation of free radical molecules, interaction with specific cellular receptors called RAGE 
(receptors for glycation end products), and intercellular glycation of proteins  (Rojas & 
Morales, 2004).  
1.11 Receptor for advanced glycation endproducts 
The receptor for advanced glycated endproducts known as (RAGE), belongs to an 
immunoglobulin super family, and possesses a mass of 45-kDa. A number of researchers have 
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reported that the RAGE gene is situated on chromosome six and is located between class II and 
III of the histocompatibility complex genes (Hudson & Schmidt, 2004; Srikanth et al, 2011). 
RAGE is a transmembrane receptor consisting of 394 amino acids, with a single hydrophobic 
transmembrane domain of 19 amino acids, and a short cytoplasmic tail of 43 amino acids. The 
extracellular part of RAGE contains of one the V-type of immunoglobulin domains, followed 
by two C-type immunoglobulin domains. Furthermore, structure function studies have 
illustrated that the V-domain is vital for ligand binding. On the contrary, the cytosolic tail is 
critical for RAGE-mediated intercellular signalling (Srikanth et al, 2011). There is another 
form of RAGE receptor, not of full length,  lacks the cystolic tail located inside the membrane  
is a dominant-negative form called DN-RAGE, and not essential in RAGE–mediated 
intercellular signalling as shown in Figure 1.7 (Hallam et al, 2010). RAGE is highly conserved 
in all species, present in a wide variety of tissues, particularly in the heart, lung, and skeletal 
muscle. A considerable number of studies have investigated AGE-binding protein receptors. 
These studies have identified several AGE receptors, including lactoferrin, oligosaccharyl 
transferase complex protein 48 (AGE-R1), 80K-H protein (AGE-R2), galectine-3 (AGE-3), 
lysozyme, SRA, CD-36 and receptors for AGE (RAGE), which are the most important signal 
transducers for AGEs (Bohlender et al, 2005; Hudson & Schmidt, 2004). Moreover, RAGE is 
localised in different cell types, including endothelial cells, macrophages, smooth muscle cells, 
mesangial cells and epithelial cells, lymphocytes, monocytes, neurons and was originally 
extracted from bovine lung endothelium for its ability to bind AGE molecules (Basta, 2008).  
 
14 
 
 
Figure 1.7: Structure of RAGE. The extracellular part of RAGE contains of one the V-type 
of immunoglobulin domains, followed by two C-type immunoglobulin domains,  the cystolic 
tail located inside the membrane  is a dominant-negative form called DN-RAGE ( Hallam et 
al, 2010 . 
1.12 Diabetic mellitus and oxidative-stress signalling pathways  
A considerable amount of evidence reported that hyperglycaemia causes production of AGE, 
which play a vital role in generation of ROS, ultimately leading to elevated oxidative stress in 
several tissues (Elosta et al, 2012). ROS causes injury to cell components such as proteins, 
lipids and nucleic acids (DNA and RNA). Thus, natural endogenous antioxidant enzymes such 
as Catalase (CAT), Superoxide dismutase (SOD) and Glutathione peroxidase (GPx) are 
available within cells to engulf ROS and these defences systems are vital for maintaining 
normal cellular functions. When the endogenous antioxidant system fails to provide proper 
response to restore cellular redox balance, oxidative-stress ensures. The major result is the 
generation of gene products that lead cellular injury and are significantly responsible for the 
complications of diabetes mellitus (Stefanie et al, 2012). 
 AGE-RAGE interaction leads to the generation of a variety of biological effects such as 
elevated secretion of cytokinase, tumour necrosis factor-α (TNF-α), interleukin-1α (1L-1α) and 
interleukin-6 (IL-6α) (Bierhaus et al, 2005; Elosta et al, 2012). The most important biological 
effects of AGEs binding to RAGE is the formation of intercellular ROS. The first step of ROS 
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production is triggered by the activation of NADPH-oxidase system (NOX family including 
NOX1, 2, 3, 4, 5 and DOX1 and DOX2) (Frey et al, 2009). Nevertheless, glucose-metabolising 
pathway consisting the enzymes aldose reductase and sorbitol dehydrogenase that is discovered 
in organs that develop diabetic complications.  Many studies have indicated that production of 
ROS and the increase in oxidative stress are significant factors in generating signal transduction 
and changes in gene expression (Cho et al, 2013). Furthermore, the transcription factor NF-κB 
is accounted as a major intercellular target of hyperglycaemia and oxidative stress (Nigel et al, 
2009).  
In addition, AGE generation is improved in the presence of hyperglycaemia and oxidative 
stress. AGE-RAGE interaction stimulates a various number of signal transduction pathways 
including p21 ras, mitogen activated protein kinasen (MAPK) such as p38, extracellular 
regulated (ERK)-1/2 and c-Jun N-terminal kinase (JNK), Cdc42/rac, and Jak/Stat pathways as 
demonstrated in Figure 1.8 (Cho et al, 2013). The consequence is the generation of gene 
products, such as vascular endothelial growth factor (VEGF), Vascular cell adhesion molecule-
1 (VCAM-1) and others, which cause cellular injury and are significantly responsible for the 
long term complications associated with diabetic mellitus (Basta et al, 2004; Hudson & 
Schmidt, 2004). ROS is an important component in oxidative stress and plays a key role in 
diabetic complications (Rojas & Morales, 2004).  
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Figure 1.8: Signal transduction pathways activated by AGE-RAGE interaction. 
Activation of extracellular and cystolic domains of RAGE by AGEs mediates increased the 
production of ROS by different signalling pathways (Nigel et al, 2009).  
1.13 Glycation and oxidative stress 
The adverse effects of oxidative stress on human health have received serious attention. There 
is a strong relation between the formation of AGEs and oxidative stress ( Miguel, 2010). The 
most important chemical reactions occurring in every cell are the oxidation and reduction of 
molecules. The results of these reactions are the formation of free radicals, such as superoxide 
anion radicals (O2
•
-), hydroxyl radicals (OH
•),  singlet oxygen (1O2), hypochlorous acid 
(HOCl), peroxyl radicals (ROO•), alkoxyl radicals (RO•) and non-free radical molecules such 
as hydrogen peroxide (H2O2) which are able to react with cell components such as proteins, 
lipids, and nucleic acids (Rains et al, 2013). Eventually, these interactions lead to changes in 
the structure and function of the cells, create oxidative stress, and may cause several chronic 
diseases such as atherosclerosis, Alzheimer’s disease, chronic inflammation and diabetes 
(Nigel et al, 2009) . Glycated proteins play a vital role in the enhancement of oxidative stress 
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in diabetes and form approximately 50-fold more free radicals than non-glycated proteins 
(Pandey et al, 2010). Both ROS and reactive nitrogen species (RNS) are classed as free radicals. 
They are formed as a consequence of normal cellular reactions. Hence, free radicals are not 
only produced as a result of normal metabolism, but also form as a consequence of exposure 
to toxic agents, environmental pollutants, drugs, radiation, natural food constituents, smoking 
and inflammatory disease (Jones et al, 2008).  
1.14 Antioxidant enzymes and oxidative stress 
ROS are considered a major factor of oxidative stress, which exist in all cells in balance with 
antioxidant compounds. In a normal cell, there is an appropriate pro-oxidant–antioxidant 
balance. Oxidative stress occurs when this balance is disrupted due to the reduction of 
antioxidants or elevated accumulation of ROS or both (Pandey & Rizvi, 2010). The biological 
effects are controlled in vivo by different enzymatic and non-enzymatic antioxidant defence 
systems. Antioxidant enzymes such as superoxide dismutase (SOD), glutathione peroxidase 
(GPx) and catalase, and non-enzyme antioxidants including ascorbic acid (vitamin C), α-
tocopherol (vitamin E), glutathione, uric acid, carotenoids, flavonoids, catechins and ferritin 
are important components of the antioxidant system against oxidative stress (Krishnaiah et al, 
2011). Furthermore, any chemical compound capable of forming potentially toxic oxygen 
species are also known as pro-oxidants. Antioxidants consist of enzymes and molecules that 
may act as potent physical barriers to inhibit ROS production or ROS transfer to vital biological 
sites of action such as the cell membrane. Therefore, they act as  chemical traps that engulf 
energy and electrons, quenching ROS activity (Miguel, 2010).  
1.15 Diabetic complications and AGEs 
Macrovascular and microvascular are recognised as main types of diabetic complications. 
Despite a considerable amount of literature on this topic, it is still unclear what the exact cause 
of most diabetic complications is. However, chronic exposure to hyperglycaemia via elevated 
formation and accumulation of AGEs plays a key role in the progress of diabetic complications. 
Similarly, reduced AGE formation through  intensive glycaemic management may decrease 
the risk vascular complications in diabetic patients (Ahmed & Thornalley, 2007; O'Sullivan & 
Dinneen, 2009). 
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1.15.1 AGEs and microvascular complications 
Generally, microvascular complications can be defined as dysfunctional alterations occurring 
in the microvascular bed. However, retinopathy, neuropathy and nephropathy are the most 
common type of microangiopathy (Peppa & Vlassara, 2005), and it takes 10-15 years to 
develop such complications in patients suffering from diabetes. Additionally, microangiopathy 
is characterised by increased vascular permeability and a prothrombotic state, the thickening 
of basement membranes and decreasing blood flow (Huebschmann et al, 2006). Notably, there 
is no effective therapy for  microangiopathy complications associated with diabetes mellitus ( 
Ahmed & Thornalley, 2007). 
1.15.1.1 Diabetic retinopathy 
Diabetic retinopathy is one of the commonest microangiopathy complications in diabetes 
mellitus and it can cause loss of vision on a worldwide scale. The occurrence of retinopathy 
increases with the length of existence of diabetes mellitus. After 20 years of diabetes, nearly 
all patients with type I diabetes and more than 60% of patients with type II diabetes prove to 
have some degree of retinopathy. A large number of in vivo and in vitro longitudinal studies 
involving diabetic retinopathy have illustrated that increased intercellular and extracellular 
AGEs during diabetes can play a key role in diabetic retinopathy development and progression 
(Anitha et al, 2008; Sato et al, 2006). Furthermore, the elevated AGE production can generate 
abnormal proliferative reactions in retinal microvascular endothelial cells, and subsequently 
cause abnormal expression of endothelial nitric oxide synthase (eNOS)  (Giacco & Brownlee, 
2010). Additionally, AGE production displays an inhibitory response on pericyte growth, 
thereby causing a loss of pericytes, which is the earliest histological hallmark of diabetic 
retinopathy. This, in turn, causes basement membrane thickening which significantly 
contributes to the breakdown of the inner blood-retinal barrier (Stitt & Curtis, 2005). Neural 
dysfunction and depletion may occur in diabetic retinopathy as a result of the production and 
accumulation of AGEs (Anitha et al, 2003). It has been reported that growth factors, for 
example VEGF, growth hormone and transforming growth factor beta have also been (Fowler, 
2008). In recent years, there has been a study in animal models that reported that suppression 
of VEGF formation is accompanied by decreased progression of retinopathy (Fowler, 2011). 
postulated to play a pivotal role in the progression of diabetic retinopathy. Increases in the 
production of VEGF in diabetic neuropathy may be related to the response to hypoxia  
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1.15.1.2 Diabetic cataract 
Hyperglycaemia and the duration of diabetes are considered main risk factors for the 
development of cataracts; diabetic patients suffer from cataracts 10 years earlier than the 
healthy individual (Gul et al, 2008). AGEs precursors such methylglyoxal, play a pivotal role 
in cataract formation. Long-lived proteins such as lens crystallins, are more likely to be prone 
to glycation (Fowler  et al, 2011). Glycation of lens crystallins may result in protein cross-
linking, oxidation and the production of the high molecular weight aggregates responsible for 
cataracts (Cheng et al, 2006; Linetsky et al, 2008). Moreover, glycation of channel proteins 
and the sodium potassium pump (Na/K-ATPase) may significantly contribute towards cataract 
production in diabetes (Gallicchio & Bach, 2010).  
1.15.1.3 Diabetic nephropathy 
Diabetic nephropathy is the main cause of end stage renal disease, where a three-fold elevation 
in the accumulation of AGEs is indicated, and is responsible for a significantly increased 
morbidity and mortality in patients with diabetic mellitus (Makita et al, 1991; Yamagishi et al, 
2007). It occurs in 40-50% of all diabetic patients (Wolf, 2004). Diabetic nephropathy is 
associated with complications such as coagulation of glomerular and tubular basement 
membranes, thickening and mesangial matrix expansion, which eventually leads to vascular 
occlusion, microvascular impairment and fibrotic conversion, thus resulting in 
glomerulosclerosis (Coughlan et al, 2005). The kidney is a key target for AGEs-mediated 
damage, and also is a major site of clearance of AGEs (Goh & Cooper, 2008). In addition, 
diabetic nephropathy involves large concentrations of AGEs and these can be related to reduced 
clearance in the kidney rather than elevated formation by glycation of proteins ( Monnier et al, 
2005). Recently, in vivo studies have shown that higher levels of pentosdine and CML  are 
detected in diabetic patients’ renal tissues with or without end-stage renal disorder 
(Beisswenger et al, 2013; Hashimoto et al, 2010). 
1.15.1.4 Diabetic neuropathy 
More than 50% of all patients with diabetes suffer from neuropathy complications, which are 
the cause of significant morbidity and mortality (Duby et al, 2004). Diabetic neuropathy results 
in continuous damage to the peripheral sensory and autonomic nervous system (Beisswenger 
et al, 2013). The production of AGEs is an important biochemical pathway which contributes 
to diabetic neuropathy (Fowler, 2008). Recent evidence has suggested that AGEs-modified 
peripheral nerve myelin is vulnerable to phagocytosis by macrophages, which results in 
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segmental demyelination. Consequently, the alteration of main axonal cytoskeletal proteins, 
for instance tubulin, neurofilaments  and actin by AGEs, leads to axonal degeneration and 
damaged axonal transport in diabetic neuropathy (Sugimoto et al, 2008). Furthermore, AGEs 
alter the expression levels of the inducible form of nitric oxide synthase (iNOS), and in turn, 
this may reduce nerve blood flow and cause hypoxia in the peripheral nerves (Wada & 
Yagihashi, 2005). Previous research has indicated that interactions between AGEs and RAGE 
contribute to endoneural vascular dysfunction, resulting in microangiopathy in the peripheral 
nerves, although their precise role remains unknown (Huijberts et al, 2008). 
1.15.2 AGEs and macrovascular complications 
Macrovascular complications are associated with a series of pathological alterations 
influencing major blood vessels and resulting in structural and functional abnormalities. It has 
been reported that the glycation of wall structures and functional alterations generates 
endothelial dysfunction and thickening of artery walls or reduces vascular compliance. This 
results in structural amendments. Moreover, atherosclerosis is counted as the greatest  risk 
factor leading to diabetic macrovascular complications such as stroke, myocardial infarction 
and peripheral vascular disorders (Rahman et al, 2007). 
1.15.2.1 Diabetic atherosclerosis 
Atherosclerosis appears to be a multifactorial disorder in origin, resulting from excessive 
accumulation of lipids in the vascular wall, which limits blood flow. Currently, it is the root 
cause of the biggest killer worldwide. Several studies thus far have linked AGE production 
with atherosclerosis development in diabetic patients (Huijberts et al, 2008; Mallika et al, 
2007). Conversely, AGE-RAGE interaction may also cause increased endothelial impairment, 
elevated plaque destabilisation, neointimal proliferation and delayed wound healing (Guo & 
DiPietro, 2010; Hallam et al, 2010). Moreover, AGEs provoke vasoconstriction via quenching 
of NO (Basta et al, 2004; Pandolfi & De Filippis, 2007). It has been suggested that AGE–
RAGE interaction may play a central role in the development of atherosclerosis in diabetic 
patients (Jandeleit-Dahm & Cooper, 2008; Soro-Paavonen et al, 2008). Additionally, activation 
of NF-kB and activator protein-1 transcription factors in vascular wall cells by AGEs leads to 
the elevated expression of a multiple of atherosclerosis-related genes, including endothelin-1, 
VCAM-1, inflammatory cytokines and PAL-1( Laakso, 2010). 
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1.16 Measurement of AGEs 
AGEs are recognised as complex  molecules in nature and their detection in tissue and serum 
has been difficult (Smit & Lutgers, 2004). To date, AGEs measurement is limited to investigate 
laboratories, and there is no universal accepted assay for measuring AGEs. Several assays have 
been used qualitatively and quantitatively to examine the level of AGEs. Fluorescence 
spectroscopy is reckoned to be a main method for detection of fluorescent AGEs in vitro and 
in vivo (Vigneshwaran et al, 2005). The fluorescence measurement of AGEs was used because 
of the easy to reproduce data by incubating proteins and reducing sugar such as glucose in 
order to explore its occurrence in diabetes (Monner et al, 2005). However, this technique has 
limitations because it is only an indicator of the trend of AGEs and does not provide any 
information to recognise the AGEs structurally (Giardino et al, 1994). The use of matrix–
assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF-MS) has 
successfully been utilized to examine AGEs (Lapolla et al, 2005). This is a rapid and cost 
effective method with benefits of soft ionisation, excellent sensitivity; high resolution and 
minimum sample work up. MALDI-TOF-MS, peptide mapping is an important technique to 
measure specific protein glycation products in vitro and in vivo (Ahmed & Thornalley, 2007; 
Kislinger et al, 2004; Niwa, 2006). Nevertheless, separation assay methods, for example SDS-
PAGE, are utilised during the course of glycation research (Ahmad et al, 2007; Xie et al, 2011). 
This is a common and cost effective technique which easily detects oligomerisation of glycated 
protein.  Moreover, immunochemical techniques such as ELISA using polyclonal and 
monoclonal antibodies specific to defined AGEs structures, allow highly sensitive and 
quantitative estimations of AGEs (Elosta et al, 2012).  
1.17 Medicinal plants and diabetes mellitus 
The World Health Organization (WHO) has estimated that 80% of the earth’s inhabitants rely 
on traditional medicine for their primary health care needs, and most of this therapy involves 
the use of plant extracts and their active components (WHO, 2013). Traditional medicines have 
been used for treating chronic disorders such diabetes since ancient times; they are derived 
mainly from medicinal plants, minerals and organic matter. According to the WHO, 
approximately 150 species out of 21,000 plants are commercially available for medicinal 
purposes in the world (Joseph & Jini, 2013). A recent report has indicated that approximately 
30% of patients with diabetes mellitus use traditional medicines (Raman et al, 2012). A large 
amount of medicinal plants are currently under extensive study and analysis in vivo, but only a 
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small portion of these studies have successfully entered clinical trials. Nevertheless, none of 
these plant extracts have so far been approved for clinical use. Recently, a considerable number 
of studies have identified that complimentary medicine in combination with antiglycation and 
antioxidant nutrients is believed to be a safe and simple complement to traditional medicines 
and it is hoped they may prevent and target diabetic complications (Ahmad et al, 2007; Babu 
et al, 2006). For example, tomato paste showed strong inhibitory activity against glycation 
(Kiho et al, 2004) and autoxidative reactions (Cervantes-Laurean et al, 2006). In addition, other 
medicinal plants containing polyphenolic molecules such as in soy sauces (Mashilipa et al, 
2011), Luobuma tea (Yokozawa & Nakagawa, 2004), garcinol from Garacina indica 
(Yamaguchi et al, 2000) and crisilineol from Thymus vulgaris (Roby et al, 2013) have been 
identified to be potent inhibitors of AGE production. Nevertheless, a range of other antioxidant 
compounds has been shown to have antiglycation properties in vitro. For instance, the extract 
of green tea, is composed of a large portion of tannins (flavonoidas) (Babu et al, 2007), garlic 
(Allium sativum), which contains large amounts of S-allyl cysteine (Ahmad et al, 2007) as is 
curcumin isolated from turmeric (Curcuma longa) (Qadir et al, 2016). A considerable  number 
of natural compounds such as caffeic acid, chlorogenic acid, epigallocatechin-3-gallate, 
capsaicin and hesperidin, have shown AGEs inhibitory effects (Popova et al, 2010).  
1.18 Description of Momordica charantia 
Momordica charantia also known as Karela or bitter melon, is characterised by a slender 
flowering annual vine, and belongs to the Cucurbitaceae family. I Momordica charantia is 
amongst the popular medicinal plants currently used for alleviating diabetes worldwide. It is 
often referred to as food medicine, and its use is supported by modern scientific evidence  
(Joseph & Jini, 2013). MC is counted as a rich source of natural antioxidants, which are safe, 
inexpensive and are bioactive.t is a green vegetable, widely grown in all tropical areas of the 
world. This plant can grow up to 4-5 m in length, and bears a fruit with a warty surface. The 
immature, emerald green fruit changes to orange-yellow when ripe as demonstrated in Figure 
1.9. MC possesses bitter-tasting fruit, stems, leaves and seeds (Joseph & Jini, 2013). 
Furthermore, MC possesses medicinal properties such as antimicrobial, antihelminthic, 
anticancerous, antimutagenic, abortifacient, antifertility and antidiabetic properties. Different 
parts of MC have different calorific values, for example, leaves  produce 213.26  kcal/100g, 
fruit  241.66  kcal/100g  and  seeds 176.61 kcal/100g, respectively  (Bakare et al, 2010). 
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Figure 1.9: Momordica charantia plant. 
A- Immature green fruit and flower of (Joseph & Jini, 2013) 
B- Fully ripe fruit and seeds (Cao et al, 2014) 
 
In scientific terms, the plant is to referred as: 
a- Kingdom:                Plantae 
b- Division:                 Plantae 
c- Order (family):       Cucurbitales 
d- Genus:                    Momordica 
e- Species:                  M. charantia L 
f- Duration:                Annual 
g- Synonyms: Momordica chinenus, Momordica elegans, Momordica indica, Momordica 
operculata, Momordica sinenuns and Silyos fauriei. 
1.19 Phytochemical constituents of Momordica charantia. 
MC possesses about 230 compounds as shown in Table 1.1. The most important property of 
this plant for humans and animals is its antioxidant activity. This antioxidant property of MC 
is related to the mixture of steroidal saponins named charantins, insulin-like peptides, 
triterpene, steroids, lipids, phenolics and alkaloids which are present mainly in the fruit of MC. 
Subsequently, the fruit of the plant has shown the most effective anti-hyperglycaemic 
properties (Paul & Raychaudhuri, 2010). However, MC fruits contain high amounts of different 
vitamins such as vitamin C, vitamin E, vitamins B1, B2, B3 and B9 (folate) and also a high 
density of minerals including potassium, calcium, zinc, magnesium and iron. It also contains 
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large amounts of dietary fibre. Conversely, several glycosides separated from the fruit and stem 
of MC are classified under the genera of cucurbitane triterpenoids. Subsequently, the possible 
anti-hyperglycaemic mechanism of MC is related to four different triterpenoids that have 
AMP-activated protein kinase activity (Joseph & Jini, 2013). Nonetheless, the potent 
antioxidant activity of MC is partially due to phenolics, flavonoids, flavones, terpenes, 
anthraquinones and glucosinolates, which all possess a bitter taste (Joseph & Jini, 2013; Snee 
et al, 2011). Polyphenolic compounds, which have been shown to be more effective 
antioxidants in vitro than others, are synthetic antioxidants such as tocopherols and ascorbate. 
This property of polyphenolics is related to their free radical scavenging activity. The 
antioxidant abilities of these active compounds is derived from three different properties. 
Firstly, they possess high reactivity as hydrogen or electron donors. Secondly, polyphenol-
derived radicals stabilise and delocalise unpaired electrons. Thirdly, they chelate transition 
metal ions (Tupe et al, 2014). Antidiabetic effects of MC have been examined in cell culture, 
animal models and human studies (Hui et al, 2009). 
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Table 1.1: The major phytochemicals and constituents in different parts, body, leaves, 
fruits and seeds, respectively of Momordica charantia. 
 
Plant source Phytochemicals present References 
Plant body 
 
Momorcharins, momordenol, 
momordicilin,  
momordicins, momordicinin, momordin, 
momordolol, charantin, charine,  
cryptoxanthin, cucurbitins, 
cucurbitacins,  
cucurbitanes, cycloartenols, diosgenin, 
elaeostearic acids, erythrodiol, 
galacturonic acids, gentisic acid, 
goyaglycosides, goyasaponins and 
multiflorenol  
 
(Orlovskaya & 
Chelombitko, 2007;  
Manoharan et al, 
2014) 
Plant leaves Glycosides, saponins, alkaloids, fixed oils, 
triterpenes, proteins and steroids  
(Hui et al, 2009) 
Plant fruit Momorcharins, momordicine, charantin, 
polypeptide- p insulin, ascorbigee, amino 
acids, aspartic acid, serine, glutamic acid, 
threonine, glutamic acid, threonine, alanine 
and g-amino butyric acid. Other 
constituents include pipecolic acid, luteolin 
and a number of fatty acids such as lauric, 
myristic, palmitic, palmitoleic, stearic, 
oleic, linoleic, linolenic acid  
 
(Manoharan et al, 
2014) 
Plant seeds Urease, amino acids: valine, threonine 
methionine, isoleucine, lectin, leucine, 
phenylalanine, vicine.  
 
(Leung et al, 2009; 
Orlovskaya & 
Chelombitko, 2007) 
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1.20 Possible pharmacological actions of Momordica charantia. 
Antiglycation and antioxidant properties of MC are derived from its phytochemical 
constituents. This activity could be exerted via different physiological and biochemical 
processes as shown Figure 1.10. Briefly, MC has some activity in the regulation of glucose and 
lipid metabolism, which has been tested in diabetic animals and diabetic patients. The mode of 
action is not yet fully understood. MC can be utilised as an alternative medicine for the 
management of diabetic complications. Moreover, the therapeutic efficacy of MC requires it 
to be evaluated in  clinical trials with a large sample size (Cefalu et al, 2008). 
 
Figure 1.10: Possible mechanism of Momordica charantia in the reduction of blood 
Glucose (Prabhakar & Mukesh, 2011) 
1.21 Toxicity of Momordica charantia. 
It has been reported that MC is safe, with no signs and symptoms of nephrotoxicity, 
hepatotoxicity, any adverse reaction on food intake, growth organ weights or haematological 
parameters  in vivo when it given orally in low doses up to 60 days (Joseph et al, 2013).  
Nevertheless, large numbers of clinical trials have indicated decreased toxicity of all parts of 
MC when administrated orally (Kumar et al, 2010). On the contrary, toxicity and even death, 
in laboratory animals has been reported when the extract was administered in high doses in 
other ways rather than orally ( Joseph et al, 2013). Vicine is an active chemical compound 
contained within the seeds of MC. It can trigger symptoms in susceptible individuals with 
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glucose-6-phosphate dehydrogenase deficiency (Leung et al, 2009). Previous research has 
reported that vicine could causes hypoglycaemic coma and convulsions in children, decreased 
fertility in mice, a favism-like syndrome, elevations in gamma-glutamyltransferase and 
alkaline phosphatase levels in animals, and headache (Kumar et al, 2010). MC can sometimes 
cause heartburn and ulcers and should not be taken during pregnancy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
1.22 Aims 
 To determine whether MC can inhibit the formation of AGEs in vitro . 
 To determine the antioxidant properties of MC and its active ingredients in vitro. 
 To determine whether MC can inhibit oxidative stress in endothelial cells by studying 
oxidative stress-related transcription factor parameters and their expression.  
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Chapter 2. Materials and methods                               
2.1 Materials 
 24-well, 48-welland 96-well plates (Scientific Laboratory Supplies, UK)  
 2-Mercaptoethanol (Sigma, UK)  
 Acetic acid (Fisher, UK) 
 Acrylamide/Bis solution 40% (Bio-Rad Laboratories, Germany).  
 Aminoguanidine (Sigma, UK)  
 Ammonium persulphate  (Sigma, UK) 
 Antibiotics: Penicillin and Streptomycin solution containing L-glutamine (PSG) in 
0.9% NaCl (Sigma, UK)  
 Ascorbic acid (Sigma, UK) 
 Blotting papers (Schleicher and Schuell, Germany)  
 Bovine aortic endothelial cells, secondary cell line (Cell and Molecular Biology 
Research Laboratory, Manchester Metropolitan University, UK)  
 Bovine serum albumin (Sigma, UK) 
 Bromophenol blue (Serva, Germany) 
 Chloroform (Sigma, UK) 
 ColorBurst™ Electrophoresis Marker for SDS-PAGE (Sigma, UK)  
 Coomassie brilliant blue (Sigma, UK) 
 Copper sulphate (Fluka, UK) 
 Cryotubes (Scientific Laboratory Supplies, UK)  
 Detoxi-gel endotoxin removal columns (Thermo Scientific, USA)  
 D-glucose (BDH, UK)  
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 Dialysis tube (Visking, UK)  
 2′,7′-Dichlorodihydrofluorescein diacetate (Sigma, UK) 
 Dulbecco’s modified Eagle’s medium (Lonza SPRL, Belgium)  
 ECL1 and ECL2 kits (Amersham Biosciences, UK).  
 Eppendorf tubes (Scientific Laboratory Supplies, UK)  
 Ethanol (Fisher, UK) 
 E-toxate kit for endotoxin measurement (Sigma, UK)  
 Ferric chloride (Fe Cl3) (Sigma- Aldrich, UK) 
 Ferrous chloride (Fe Cl2) (Sigma- Aldrich, UK) 
 Ferrous sulphate (Fe SO4) (Sigma- Aldrich, UK) 
 Fibroblast growth factor-basic (R & D Systems, USA)  
 Foetal bovine serum (Lonza, Belgium)    
 Gallic acid (Sigma- Aldrich, UK) 
 Glacial acetic acid (Fisher, UK) 
 Glycine (BDH, UK) 
 Glycerol (BDH, UK) 
 Hydrochloric acid (Sigma, UK) 
 Isopropanol (Sigma, UK) 
 Lysozyme (Sigma, UK) 
 Mannitol (Sigma, UK)  
 2-Mercaptoethanol (Sigma, UK) 
 Methanol (Fisher, UK) 
 Methylglyoxal (Sigma, UK)  
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 Momordica charantia – bitter melon (Local market, Manchester-UK)  
 Muslin cloth (Local cloth shop, Chorlton, Manchester, UK) 
 N, N, N′, N′-tetramethylethylenediamine (TEMED) (Sigma, UK) 
 Nitrocellulose membrane (Scientific Laboratory Supplies, UK) 
 Quinine sulphate (Sigma- Aldrich, UK) 
 Parafilm (UK) 
 Phosphate buffer saline (Lonza, UK)  
 Plate sealers (R & D Systems, USA)  
 Potassium ferricyanide (Fluka, UK) 
 Potassium persulphate (Sigma, UK) 
 Potassium phosphate mono- and di-basic anhydrous (Sigma, UK) 
 Protein molecular weight marker for SDS-PAGE (Sigma, UK) 
 Razor blades (Kratos Analytical, UK)  
 Ribose (BDH, UK) 
 Skimmed milk powder (Local store, Manchester, UK)  
 Sodium acetate (Fluka, UK) 
 Sodium azide (Sigma, UK) 
 Sodium bicarbonate (Sigma, UK) 
 Sodium chloride (Sigma, UK)  
 Sodium cyanoborohydride (Fluka, UK) 
 Sodium dodecyl sulphate (BDH, UK) 
 Sulphuric acid (Sigma-Aldrich, UK) 
 Tissue culture flasks (T-25, and T-75 ) (Scientific Laboratory Supplies, UK)  
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 Trichloroacetic acid (Sigma, UK) 
 Tris (hydroxymethyl) methylamine (BDH, UK) 
 Trypsin-10X (Sigma, UK)  
 Tween 20 solution (Sigma, UK)  
 Trolox, (Fluka, UK) 
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2.2 Equipment and software 
 Adobe illustrator CS4  
 Adobe Photoshop 7.0  
 Analytical balance (Sartorius Machatronics Ltd, UK)  
 Automated cell counter (Bio-Rad, UK)  
 Autovortex mixer SA1 (Stuart Scientific Co, UK) 
 Analytical balance (Sartorius Machatronics Ltd, UK) 
 Blender (Kenwood Limited, UK) 
 Centrifuge S415D (Eppendorf, Germany) 
 Class II microbiological safety cabinet (Walker Safety Cabinet Ltd, UK)  
 CO2 incubator for cell culture use (Lab Impex Research, UK)  
 Cross power 500 for electrophoresis (Atto, Japan). 
 Digital multi channel pipettes (Eppendorf, Germany) 
 Dual gel casting electrophoresis chambers (Atto, Japan) 
 Eppendorf Centrifuges 5415 D (Eppendorf, Germany) 
 Fuji S2 Pro camera  
 G Box Chem HR 16 (gel documentation and analysis system) (Syngene, UK)  
 Gene tool image analyzer (Syngene, UK) 
 Grant-bio shaker POS-300 (Grant Instruments, UK) 
 Ice maker (P & S Refrigeration, UK) 
 Image J software analyser (free on line software) 
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 Inverted phase contrast microscope (Nikon TMS, Japan  
 Laboratory freezer (Scientific Laboratory Supplies, UK) 
 Laboratory fridge (Scientific Laboratory, UK) 
 Laboratory pH/mV/temperature meter AGB-75 (Medical Scientific Instruments, 
England). 
 LTE IP 30 incubator for glycation samples (Scientific Laboratory Supplier, UK)  
 Luminescence spectrometer model LS 30 (Perkin Elmer LAS Ltd, UK).  
 Magnetic stirrer hotplate (Stuart Scientific Co, UK) 
 Microplate reader,  96-well (Spectramax, Finland)  
 Microsoft office Excel 2003 (Microsoft, USA) 
 Rotator shaker R100 (Luckman Ltd, UK) 
 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis tank (mini-Protean® 3 
apparatus) (Bio-Rad Laboratories, Germany).  
 Statistical Package for the Social Sciences 16.0 for Windows (SPSS) (SPSS Inc., 
Chicago, USA) 
 Syngene G Box (Bio-imaging system) (Syngene, UK) 
 G Box Chem HR 16 (gel documentation and analysis system) (Syngene, UK) 
 Trans-blot SD semi-dry transfer cell (Bio-Rad Laboratories, Germany). 
 Ultrospec 2000 UV–VIS spectrophotometer (Pharmacia Biotech Ltd, UK) 
 Water bath (Grant Instruments Ltd, UK) 
 Water de-ionizer (Millipore, UK)  
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 2.3 Solutions 
 Solution A: Acrylamide (29.2 g) and N, N´-methylene-bis-acrylamide (0.8 g) were 
dissolved in 100 ml of distilled water.  
 Solution D: ammonium persulphate (100 mg) was dissolved in 1ml of distilled water. 
the solution was freshly prepared  before use. 
 BSA (1 mg/ml) standard solution for the Bradford protein assay: Bovine serum 
albumin (20 mg) was dissolved in 20 ml of distilled water. Freshly made, 30 minutes 
prior the experiment. 
 Blocking buffer (1% BSA-TBST): BSA (1g) was dissolved in 100 ml of Tris-buffered 
saline and tween-20 (TBST). The pH was adjusted to 7.4.  
 Destaining solution for SDS-PAGE analysis: Methanol (250 ml) was dissolved in 70 
ml of acetic acid and the volume was made up to 1 L with distilled water.  
 Developing solution for Western blotting membrane: ECL1 solution (1 ml) was mixed 
with (1 ml) of ECL2 solution and the mixture was applied to the membrane.  
                                                
 Electrode buffer (running buffer) for SDS-PAGE and Western blotting analysis: Tris-
base (12.02 g), SDS (4 g) and 57.68 g of glycine were dissolved in 2 L of distilled water. 
The buffer was stored at room temperature. 
 
 Blocking buffer 5% milk as used in Western blotting analysis: Skimmed milk (5 g) was 
dissolved in 100 ml of TBST buffer. The pH was adjusted to 7.4. 
 
 Sample buffer for used in Western blotting: Tris-base (1.51 g), 20 ml of glycerol, 4 g 
of SDS, 10 ml of 2-mercaptoethanol and 0.004 g of bromophenol blue were dissolved 
in 100 ml of distilled water. The solution was filtered and the pH adjusted to 6.8 and 
stored at -20°C.  
 
 Running buffer: Tris-base (1.5 g), glycine (7.2 g) and 0.5g of SDS were dissolved in 
500 ml of distilled water. 
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 Solution C: Tris-HCl buffer 0.5 M, pH 6.8; Tris-hydroxymethyl aminomethane (6.1 g), 
0.4 g of SDS and 4.2 ml of HCl were dissolved in distilled water, made up to 100 ml. 
The pH was adjusted to 6.8 and the solution bottle was covered with aluminium foil 
and stored in a fridge.  
 Solution B: Tris-HCl buffer (1.5 M), pH 8.8; Tris (Tris-hydroxymethyl amino methane) 
(18.2 g), 0.4 g of SDS and 2 ml of HCl were dissolved in distilled water. The pH was 
adjusted to 8.8 and the solution was stored in a room temperature. 
 Sample treatment buffer: Sodium dodecyl sulphate (0.1 g), and 0.1 ml of 2-
mercaptoethanol were added to 1 ml of solution C and 2 ml of glycerine and the volume 
was made up to 10 ml with distilled water. The sample treatment buffer was stored at 
room temperature. 
 Separation gel (12.5%) for Western blotting analysis: Separating solution (2.5 ml) was 
added to 4.2 ml of distilled water and mixed with 3.3 ml of 40% cold acrylamide 
solution. Then, 100 µl of ammonium persulphate (10%) was added to the mixture. Gel 
polymerization was initiated by adding 10 µl of TEMED and allowed to polymerize for 
10 – 15 minutes. 
 
 0.1 M and 0.2 M sodium phosphate buffer solution (pH 7.4): the acid component of 
the buffer (sodium dihydrogen phosphate) and the basic component (sodium 
hydroxide) were weighed out in a certain ratio according to the Henderson Hasselbalch 
equation. The desired volume was then accordingly adjusted with distilled water and 
the solution was mixed. The pH meter was calibrated at pH 7.0 and the pH of the buffer 
was adjusted to 7.4. Sodium azide (3 mM) was added to the mixture to prevent any 
bacterial growth. The buffer was stored at 4 °C. 
 Stacking solution used for Western blotting analysis: Tris-base (15 g) and 1 g of SDS 
were dissolved in distilled water. The pH was adjusted to 6.8 with HCl. The final 
volume of the buffer was made up to 250 ml with distilled water. 
 Staining solution for SDS-PAGE analysis: Coomassie brilliant blue (2.5 g) was 
dissolved in 500 ml of methanol and 100ml of acetic acid. The volume was made up 
to 1 L with distilled water and then filtered. The staining solution was stored at room 
temperature. 
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 TBST buffer: Tris-base (2.422 g), 16.36 g of NaCl, and 2 ml of Tween 20 were 
dissolved in 2 L of distilled water. The pH was adjusted to 7.4 with HCl. 
  Towbin buffer used for Western blotting analysis: Tris-base (1.51 g), 7.2 g of glycine 
and 0.167 g of SDS were dissolved in 400 ml distilled water and 75 ml of methanol. 
The pH was adjusted to 8.3. The final volume of the buffer was made up to 500 ml with 
distilled water.  
 Tracking dye solution for SDS-PAGE analysis: Bromophenol blue (1 mg) was added 
to 0.1 ml of glycerine and mixed with 0.9 ml of distilled water. 
 Reconstitution of FGF-2: Sterile phosphate- buffered saline was added to the vial in 
order to prepare a working stock solution (≥ 100 g/ml). The carrier-free protein was 
immediately used upon reconstitution to avoid loss in activity. FGF-2 was stored at -20 
°C. 
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 2.4 Methods 
2.4.1 Preparation of Momordica charantia extracts 
The fresh plant MC was purchased from a local Asian market (Manchester, England) in 
February 2013. The extraction method in this study was based on a method used previously  
(Manoharan et al, 2014). Briefly, whole plant (fruit pulp and seed) were used in this extraction. 
The whole plant was washed thoroughly with deionized water. Approximately 100 g of the 
clean plant was weighed and then cut into small pieces and mixed with 100 ml of deionized 
water, then blended for 5 minutes at low speed, and blended again for another 5 minutes at high 
speed. The green supernatant made up to 200 ml with deionized water then blended again for 
a few seconds. Firstly, 100 ml of the sample was sonicated at 35°C for 25 minutes, and then 
the solution filtered by muslin cloth, followed by centrifugation for 30 minutes at 9000 x g. 
After that, the supernatant was transferred into a 250 conical flask, and then evaporated under 
air pressure until the supernatant become a very thick substance (concentrated) that was for 
CWE of MC. The preparation for HWE in addition to above steps, 100 ml 100 ml of the sample 
was incubated for two hours at 67°C, then sonicated at 35°C for 25 minutes and filtered by 
muslin cloth (Manoharan et al, 2014). Both samples of concentrated extracts were freeze dried 
and kept at -80ºC for future use.  
2.4.2 Glycation of proteins in vitro 
The detection of glycated proteins was based on the methods described previously (Ahmad et 
al, 2007). In short, either BSA or lysozyme (10 mg/ml) were incubated with different 
concentrations of sugars (glucose, ribose or methylglyoxal) in 0.1 M Na phosphate buffer 
containing 3mM sodium azide, pH 7.4 at 37 °C ± different concentration of Momordica 
charantia extracts for a defined period of time. Control sample were incubated under the same 
conditions without the addition of sugars or extracts. After the incubation period all samples 
were kept at -20ºC for future use. 
2.4.3 Protein dialysis  
Samples were dialyzed to remove unbound sugars, prior to protein estimation. A 10 cm length 
of dialysis tubing was boiled for two minutes in distilled H2O with a few drops of chloroform 
to prevent microbial contamination. The tube was removed from the boiling water, and then 
washed with distilled water. The glycated protein samples were defrosted to room temperature 
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and loaded into dialysis tubing, and then dialyzed against 4 L of distilled water at 4°C with 4-
5 changes for two days; the dialysis was carried out by stirring the tube samples with frequent 
changes of the buffer until the equilibrium was reached. The samples were then removed from 
the dialysis tube and stored at -20ºC for future use. 
2.4.4 Endotoxin removal  
The Detoxi-gel resin column underwent regeneration through wash cycles with five resin-bed 
volumes of 1% sodium deoxycholate, and subsequently by 3-5 resin-bed volumes of basal DMEM. 
Bovine serum albumin-AGEs were diluted in DMEM containing red phenol (used a tracking dye) 
and added to the column. The flow ceased when the samples filled the resin-bed from top to bottom. 
The column was for 60 minutes at room temperature prior to samples being collected. In order to 
achieve greater efficiency with a gravity-flow column, the samples emerging from the column after 
the void volume were collected.  
 
2.4.5 Measurement of endotoxin content  
Glycated proteins (BSA-AGEs) were examined for endotoxin content using E-toxate kit. A 
100 μl of MC extracts, water and endotoxin standards were added to the bottom of test tubes. 
Consequently, 100 μl of E-toxate working solution was added to each tube by inserting a pipette 
to just above the contents, and the lysate was then allowed to flow down the inside of the tube. 
The tubes were mixed gently and covered with foil or parafilm, and incubated for 1 hour at 37 
°C. Following incubation, the tubes were gently inverted to observe evidence of gelation. The 
formation of a hard gel was considered to be a positive test. All other result including soft gels, 
turbidity, and increase in viscosity or clear liquid were considered to be negative tests. Notably, 
the amount of endotoxin level (EU/ml) was calculated using the following equation: 
Endotoxin (EU/ml) = 1/ H x L 
Where L is the lowest concentration of endotoxin standared found positive and H is the highest 
dilution of sample (+ ve).  
                                  
2.4.6 Determination of protein concentration by Bio-Rad protein assay. 
BSA (1 mg/ml) stock solution was diluted with distilled water to obtain the concentrations of 
0, 5, 10, 20, 40, 60, 80 and 100 μg/ml for standards. Different sample extracts were prepared 
in a ratio of (1:10) where 10 µl of each sample diluted with 90 µl of distilled water. Bio-Rad 
solution was used as a dye reagent in a ratio of 1:5 in distilled water, then 2 ml of this solution 
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was added to each extract and standarsd. The absorbance of the protein solutions were 
measured at 570 nm and a standard curve generated. All values were expressed as μg/ml. An 
example of standard curve established for protein estimation is shown in Figure 2.1) 
 
Figure 2.1: Calibration graph for protein estimation using the Bio-Rad method. Each 
value illustrates the mean ± SD (n=3).  
2.4.7 Measurement of cross-linked AGEs by SDS-PAGE  
Cross-linking of glycated proteins was determined by the extent of dimer and polymer 
formation in protein samples removed from cross-linking assays carried out in the presence 
MC extracts. This was assessed by SDS-PAGE using 10% polyacrylamide gels for lysozyme 
according to an established method (Xie et al, 2011). The glass plate sandwiches were 
assembled with a gaskets and clips in place. The separating gel consisting of 10% w/v for BSA 
and 15% w/v for lysozyme separation was introduced and left to polymerise for 1 hour at room 
temperature. Then the stacking gel (4.5 % w/v) was introduced, combs quickly inserted and 
allowed to polymerise for up to 30 minutes. 5μl of ColorBurst® electrophoresis marker was 
loaded in the first well of each gel and 3μl of tracking dye loaded in the rest of the wells. Then 
10μl of appropriate control was loaded in the second well and 10μl of treated samples loaded 
in each of the remaining wells. Electrophoresis was carried out at 75V until the blue band 
reached the separating gel (approximately after 45 minutes). Then voltage was increased to 
150V and left for approximately 60 minutes. The gels were stained with coomassie brilliant 
blue for 90-120 minutes. This was followed by a series of distaining washes on an orbital shaker 
until the background cleared and was ready for photographs to be taken. The gel images were 
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analysed using G Box Chem HR16. Bands were compared within the same gel. Integrated 
Density (I.D) of bands was measured and analysed and the percentage inhibition of cross-
linked AGEs was calculated using the following formula: 
% inhibition = (I.D without inhibitor – I.D with inhibitor) / I.D without inhibitor x 100 
2.4.8 Measurements of fluorescent AGEs 
The formation of AGEs was assessed by their characteristic fluorescence emission spectra at 
420 nm after excitation at 350 nm. Glycated samples were thawed at room temperature and 0.2 
ml of each sample was diluted in 1.8 ml of distilled water to give a solution with a final 
concentration of 1 mg/ml. Fluorescent measurements were carried out on a fluorimeter. 
Fluorescence intensity standards were used to calibrate and monitor the performance of the 
instrument and calibrated against quinine sulphate (1 ng/ml) in H2SO4. Fluorescence of AGEs 
was expressed in arbitrary units (AU) per mg of protein.  
2.4.9 Detection of AGEs using ELISA  
Cell Bio labs AGEs ELISA Kit was used for the detection and quantitation of AGEs protein 
adducts. AGE-BSA was obtained by incubating BSA(10 mg / ml) at 37 °C with ribose (0.5 M) 
in sodium phosphate buffer (0.1M, pH 7.4) containing 3 mM sodium azide for defined period 
of time (Mashilip et al, 2013). Dialysis and protein estimation of the AGE-BSA product was 
obtained. The glycated samples were diluted to a final concentration of 10 µg/ml. 100 µl of 
each sample was incubated for two hours at 37°C. Each glycated sample and AGE-BSA 
standards were assayed in duplicate or triplicate. After  incubation 250 µl of PBS buffer was 
used twice for washing the 96-well plate to remove the protein samples. A 200 μl of assay 
diluents (blocking solution) was used to block the remaining protein binding sites in each 
coated well then incubated for 24 hours at 4°C on an orbital shaker. The plate was washed 
twice with  (0.1M, pH 7.4) 250 µl of washing buffer. 100 μl of diluted secondary antibody-
HRP conjugate was then added to each well and incubated for 1 hour at 37°C on an orbital 
shaker, followed by washing the wells, five times with washing buffer. A volume of 100 μl 
substrate solution, warmed to room temperature, was added to each well and incubated at 37°C 
for half an hour. The enzymatic reaction was stopped by adding 100 μl of stop solution to each 
well. The absorbance at 450 nm was measured immediately using a microplate reader.  
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2.4.10 Measurement of total phenolic compounds  
The amount of total phenolic compounds in MC extracts were measured based on the method 
reported by Miliauskas et al, 2004 using Folin-Ciocalteu reagent with little modification. 
Briefly, 1 ml aliquots of the ethanolic HWE and CWE of MC (10 g/l) were mixed with 5 ml of 
Folin-Ciocalteau reagent (diluted 10-fold), then, 5 ml of 10 % Na2CO3 solution was added, and 
allowed to stand for 1 hour at room temperature. The standard curve was prepared using 0–0.3 
mg/ml ethanolic gallic acid solutions. The absorbance detected at 760 nm and the results were 
expressed as mg/ml of gallic acid equivalents. Calibration standard is shown in Figure 2.2. A 
phenolic content in MC extracts in gallic acid equivalents was calculated as described below: 
C= c* v/m 
Where: C total content of phenolic compounds, mg/g plant extracts, in GAE 
c: the concentration of gallic acid established from the calibration curve (mg/ml) 
v: the volume of extracts (ml) 
m: the weight of pure plant extracts (g) 
 
Figure 2.2: Standard curve using ethanolic gallic acid solution. Gallic acid (0-0.3 mg/ml) 
was used as a standard solution for phenolic contents. Each value represents the mean ± SD 
(n=3). 
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2.4.11 Measurement of ferric ion reducing power  
The antioxidant activity of MC extracts was tested  by a ferric ion reducing antioxidant power 
assay (FRAP) as described previously (Thaipong et al, 2006). 1 ml of different concentrations 
of  MC extracts were mixed with 1 ml of methanol (50%), followed by 2.5 ml of phosphate 
buffer and  2.5 ml of 1%  potassium ferricyanide K3Fe (CN)6. The mixture was incubated at 50 
ºC for 30 minutes. Then, 2.5 ml of 10% trichloroacetic acid (TCA) was added to the mixture 
and the samples were centrifuged at 2900 x g for 10 minutes, after which 2.5 ml of the upper 
layer of supernatant was taken from each sample tube, and mixed with 2.5 ml of deionised 
water and 0.5 ml of 0.1% ferric chloride solution (FeCl3). The absorbance was measured at 700 
nm. Distilled water (dH2O) mixed with FRAP reagents was used as a blank. In addition, 
different concentrations of vitamin C (ascorbic acid) were used as a positive control. All the 
analyses were carried out in triplicates and mean values were taken.  
2.4.12  Measurement of cupric ion reducing/antioxidant capacity  
The cupric ions (Cu2+) reducing ability of MC extract was measured according to modified 
method described before (Apak et al, 2007). 1ml of different concentrations of HWE or CWE 
of MC were mixed with 1 ml CuCl2 solution (0.01M), 1 ml ethanoic neocuproine solution 
(0.0075 M), 1 ml CH3COONH4 buffer (1M), and  0.6 ml of distilled was made up to a final 
volume of 4.6 ml in each tube. The tubes were kept at room temperature for 30 minutes, then 
the absorbance was measured at 450nm. Distilled water (dH2O) mixed with CUPRAC reagents 
was used as a blank instead of the extracts. Different concentrations of vitamin C (ascorbic 
acid) were used as a positive control. All the analyses were carried out in triplicates and average 
values were taken.  
2.4.13 Measuring superoxide dismutase activity  
Superoxide dismutase enzyme activity of the sample was calculated using superoxide 
dismutase assay kit from (Cayman chemical) according to the manufacturer’s instructions. 
BAEC (3 x 105/ml) were seeded into a 6-well plate, in 2 ml of complete culture medium (10% 
FBS) DEME. When they were confluent (80-90%), medium was discarded, and cells were 
washed with PBS. Fresh complete culture medium (10% FBS) was added to each well. 
Combination of HWE and CWE of MC (90 ug/ml) with BSA-AGE (10 µg/ml), methylglyoxal 
(5 mM), glucose (25 mM), were added to the flasks, Trolox (10 mM) was  used as positive 
control. Control wells treated with DMEM supplemented with 10% FBS were included in the 
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experiments. The contents of the plate were gently mixed to avoid possible dislodging of cells 
and incubated in a humidified atmosphere of 95% air and 5% CO2, at a temperature of 37°C 
for a further 24 hours. After the incubation, cells were washed three times with PBS. Cell lysis 
buffer (0.4 ml) was added to each wells and kept on ice. Gently the plate were shaken gently 
on ice for a few minutes, cells were scraped using a cell scraper. The total cells lysates were 
transferred to cold Eppendorf tubes on ice, sonicated for two seconds and stored at -80 ºC until 
used.  
The equation below, which obtained from the linear regression of the standard curve 
substituting the linearized rate (LR) for each samples. One unit is defined as the amount of 
enzyme required to display 50% dismutation of the superoxide radical.  
SOD (U/ml) = [(sample LR – intercept / slope) x 0.23ml / 0.01ml ] x sample dilution 
2.4.14 Measuring catalase activity  
Catalase enzyme activity of the sample was calculated using catalase assay kit from (Cayman 
chemical) according to the manufacturer’s instructions. BAEC (3 x 105/ml) were seeded into a 
6-well plate, in 2 ml of complete culture medium (10% FBS) DEME. When they were 
confluent (80-90%), medium was discarded, and cells were washed with PBS. Fresh complete 
culture medium (10% FBS) was added to each well. Combination of MC extracts (90 µg/ml) 
with BSA-AGE (10 µg/ml), methylglyoxal (5 mM), glucose (25 mM), were added to the flasks, 
Trolox (10 mM) was used as positive control. Control wells treated with DMEM supplemented 
with 10% FBS were included in the experiments. The contents of the plate were gently mixed 
to avoid possible disloding of cells and incubated in a humidified atmosphere of 95% air and 
5% CO2, at a temperature of 37°C for a further 24 hours. After incubation, cells were washed 
three times with PBS. Cell lysis buffer (0.4 ml) was added to each wells and kept on ice. The 
plate was shaken gently on ice for a few minutes, cells were scraped using a cell scraper. The 
total cells lysates were transferred to cold Eppendorf tubes on ice, sonicated and stored at -80 
ºC until used.  
Notably, to calculate formaldehyde concentration of the samples the equation obtained from 
the linear regression of the standard curve was used by substituting corrected absorbance values 
for each sample.  
Formaldehyde (µM) = [sample absorbance – (y- intercept) / slope ] x 0.17 ml / 0.02 ml ] 
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Conversely, the CAT activity of the samples was obtained by using the following equation. 
One unit is defined as the amount of enzyme that will lead to the production of 1.0 nmol of 
formaldehyde per minutes at 25 ºC. 
CAT Activity = µM of sample / 20 min. x Sample dilution = nmol/min/ml 
 
Figure 2.3: Standard curve using formaldehyde solution. 
2.4.15 Measuring reactive oxygen species  
Antioxidant capacity of MC extracts against reactive oxygen species was tested  according to 
the method previously (Brimson & Tencomnao, 2011). Prior to the experiment the dye 2′,7′-
Dichlorodihydrofluorescei diacetate (H2DCF-DA) stock solution was prepared by dissolving 
100 mg of the dye powder into anhydrous DMSO. Later this stock solution was further diluted 
to a final concentration of 0.5 mM and kept as 100 µl aliquots in a – 20 ºC freezer. To avoid 
dye degradation by light and air, the stock solution and aliquots were prepared in the dark. For 
each experiment, a new aliquot was used. BAEC (3 x 105/ml) were seeded into a 6-well plate, 
in 2 ml of complete culture medium (10% FBS) DEME. When they were confluent (80-90%), 
medium was discarded, and cells were washed with PBS. Fresh complete culture medium (10% 
FBS) was added to each well. Combination of HWE and CWE of MC (90 µg/ml) with BSA-
AGE (10 µg/ml), methylglyoxal (5 mM), glucose (25 mM), were added to the flasks, Trolox 
(10 mM) were used as positive control. Control wells treated with DMEM supplemented with 
10% FBS were included. The contents of the plate were gently mixed to avoid possible 
dislodging of cells and incubated in a humidified atmosphere of 95% air and 5% CO2, at a 
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temperature of 37°C for a further 24 hours. After the incubation time, cells were washed three 
times with PBS. Cell lysis buffer 0.4 ml was added to each wells and kept on ice. Gently the 
plate was shaken gently on ice for a few minutes, cells were scraped using a cell scraper. The 
total cells lysates were transferred to cold Eppendorf tubes on ice, sonicated for two seconds 
and stored at -80 ºC until used.  
2.4.16 Thawing of cells 
Frozen cell cryotubes were taken from liquid nitrogen, and were accordingly cleaned with 70% 
ethanol. Inside the tubes, there was a build-up of pressure, which was released inside a laminar 
flow hood. Subsequently, the frozen cells were gently defrosted at a temperature of 37°C. The 
cell suspension was transferred to a universal tube containing a pre-warmed complete medium. 
The suspension was centrifuged at 1300 rpm for 5 minutes, after that the supernatant was 
discarded and the cell pellet re-immersed in 1 ml of fresh, (10% FBS) DEME. Subsequently, 
cells were seeded in T-75 flasks and incubated at 37°C. 
2.4.17 Heat inactivation of foetal bovine serum  
Frozen FBS was incubated in a water bath (at a temperature of 37°C) until the serum was 
thawed, and subsequently incubaed for 30-45 minutes in a 56°C water bath. Notably, every 10 
minutes, the bottle would be turned. Following this period, the bottle was taken out of the water 
and allowed to settle until it reached room temperature. The heat-inactivated serum was 
aliquoted into 50 ml Falcon tubes and stored at - 20°C.  
2.4.18 Cell culture of BAEC 
Bovine aortic endothelial cells (BAEC) were generously provided by Dr. Donghui Liu 
(Manchester Metropolitan University’s Cell and Molecular Biology Research Laboratory). The 
endothelial cells were characterised by the presence of the von Willebrand factor. Bovine aortic 
endothelial cells were cultured routinely in T-75 flasks; these containers had been previously 
coated with 0.1% gelatine. On a weekly basis, cells were sub-cultured using DMEM contains 
5.1 mM glucose; this was further complemented with 15% FBS, 200 mM L-glutamine, 10,000 
U/ml penicillin and 10 mg/ml streptomycin. During this period, the culture flasks were 
incubated in a humidified atmosphere of 95% air and 5% CO2, at a temperature of 37°C.  After 
confluence had been achieved, the BAEC culture was increased; this was achieved by taking 
part of the freezing cells, as well as by increasing the flask number (sub-culture). Passage levels 
6–14 was used throughout the final experiments. For sub-culturing of cells the seeding of 
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bovine aortic endothelial cells (1.5 x 105 – 5 x 105) was carried out using of 12 ml of 15% 
DMEM in T-75 flasks. Incubation was implemented in a CO2 incubator for a period of 24 
hours. After 24-hours, it was replaced with a fresh complete medium. Trypsinization of cells 
was started when the cell density reached confluence state by removing the medium and 
discarding it. Using 10 ml of sterile PBS, the cells were washed in triplicate, and incubated 
with 5–10 ml of 1 X trypsin solution for 2-5 minutes. When cell detachment was achieved, 5 
ml of complete medium was added to the flask to counteract the function trypsin. The cell 
suspension was centrifuged at 1300 rpm for 5 minutes. Upon discarding the supernatant, the 
pellet was re-immersed in the fresh medium (1ml) on ice, and then the number of cells per ml 
was counted. Freezing medium was prepared using of 90% FBS and 10% DMSO. Cold FBS 
(9 ml) was taken, to which 1 ml of DMSO was added. Freezing medium was mixed and stored 
at a temperature of 4°C. Fresh freezing medium was prepared when required for use. Freezing 
of cells was achieved by using two cryotubes with an estimated 3.5 x 105 cells per cryotubes. 
They were taken from the same confluent flask and stored at –20°C for a period of half an hour. 
Subsequently, they were either stored overnight at –80°C. The cells were subsequently moved 
into liquid nitrogen for long-term storage. 
2.4.19 Cell counting 
Cells were counted using a Coulter counter. Isotonic solution (10 ml) was mixed with 50 µl of 
cell suspension in a counting chamber, and counted in triplicate. During this stage of counting, 
there was also the calculation of the dilution factor. Suspended cells were frozen in liquid 
nitrogen or otherwise sub-cultured. Importantly, when noting a cell concentration in 1ml, this 
is calculated as follows: 
Cell concentration / ml = cell count x dilution factor  
2.4.20 Assessment of cell proliferation using the Coulter counter  
BAECs (2.5x104 cells/ml) in 0.5 ml of culture medium (15% FBS) were seeded in 24-well 
plates and allowed to adhere for approximately 4 hours. The complete medium was discarded 
and the cells were washed gently three times with PBS. Fresh media supplemented with 2.5% 
FBS was added to each well. BSA-AGE (10 µg/ml), sugars such as glucose (25, 50, 75 and 
100 mM ), methylglyoxal (1, 2, 4 and 5 mM), and MC extracts at low concentrations of (15, 
30, 60 and 90 µl /ml), and at high concentrations of (0.1, 0.2, 0.4, 0.6, 0.8 and 1 mg /ml ) were 
added to the wells. Growth factors such as FGF-2 (25 ng/ml) were used as positive control. 
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Control wells treated with DMEM supplemented with 10% FBS were included. The contents 
of the plate were gently mixed to avoid possible dislodging of cells and incubated in a 
humidified atmosphere of 95% air and 5% CO2, at a temperature of 37°C for a further 48 hours. 
Cells were washed three times with PBS and trypsinized. The number of cells was counted 
using a Coulter counter. Each experiment was carried out in triplicate, and repeated at least 
three times independently.  
2.4.21 Assessment of cell viability using automated cell counter  
BAECs (2.5x104 cells/ml) in 0.5 ml of culture medium (10% FBS) were seeded in 24-well 
plates and allowed to adhere for approximately 4 hours. The complete medium was discarded 
and the cells were washed gently with PBS three times. Fresh media supplemented with 2.5% 
FBS was added to each well. BSA-AGE, sugars and MC extracts at various concentrations 
were added to the wells. Growth factors such as FGF-2 (25 ng/ml) was used as a positive 
control. Control wells treated with DMEM supplemented with 15% FBS were also included. 
The contents of the plate were gently mixed to avoid possible dislodging of cells and incubated 
in a humidified atmosphere of 95% air and 5% CO2, at a temperature of 37°C for a further 72 
hours. Cells were washed three times with PBS and trypsinized. Cells (10 µl) were mixed with 
10 µl of trypan blue. The number of cells was counted using the automated cell counter. Each 
experiment was carried out in triplicate, and repeated at least three times independently. 
2.4.22 Cell lysis for Western blot 
 BAECs (3 x 105/ml) were seeded into a 6-well plate, in 2 ml of complete culture medium (10% 
FBS) DEME. When they were confluent (80-90%), medium was discarded, and cells were 
washed with PBS. Fresh complete culture medium (10% FBS) was added to each well. MC 
extracts (90 µg/ml) with BSA-AGE (10 µg/ml) or with  methylglygoxal (5 mM) or with glucose 
(25 mM) were added to the flasks, respectively. Control wells treated with DMEM 
supplemented with 10% FBS were included in the experiments. The contents of the plate were 
gently mixed to avoid possible dislodging of cells and incubated in a humidified atmosphere 
of 95% air and 5% CO2, at a temperature of 37°C for a further 24 hours. After the incubation 
time, cells were washed three times with PBS. Cell lysis buffer 0.4 ml was added to each wells 
and kept on ice. Gently the plate was shaken on ice for a few minutes, cells were scraped using 
a cell scraper. The total cells lysates were transferred to cold Eppendorf tubes on ice, sonicated 
for two seconds and stored at -80 ºC until used 
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2.4.23 Western blot 
The acrylamide gel was prepared by mixing 3.3 ml of 40% bis-acrylamide with 4.2 ml distilled 
water and 2.5 ml separating buffer in a universal tube. 100 μl of 10% ammonium persulphate 
solution was added followed by 10 μl TEMED solutions and the gel left to polymerise for 20 
minutes. A few drops of isopropanol were added on top of the gel. Isopropanol was removed 
after 15 minutes and rinsed with plenty of distilled water. As much as possible, distilled water 
was removed by filter paper and then the stacking solution was prepared in a second universal 
tube, by combining 1.45 ml of 40% bis-acrylamide with 6.1 ml distilled water, and 2.5 ml 
stacking buffer. As before, 100 μl APS was added followed by 10 μl TEMED solution and the 
gel left to polymerise for a minimum of 20 minutes. Slowly the combs, clamps, and gaskets 
were then removed taking care not to damage the wells and the gel plates inserted into the 
electrophoresis chamber. The chamber was subsequently filled with reservoir buffer (25 mM 
Tris, 192 mM glycine, 0.1% SDS, pH 8.3). A total of 500 ml-electrode buffer was used to fill 
the tank, in the space between the two sets of glass plates. Protein samples, sample buffer and 
molecular weight marker were taken out from the freezer and warmed to room temperature. 
The protein concentration of each sample was determined by Bio-Rad protein assay to facilitate 
equal protein loading/well. Equal amounts of protein sample and sample buffer were mixed in 
Eppendorf tube and boiled for 10 minutes, then sample buffer (20 μl), molecular weight marker 
(8 μl) and the protein sample from plaques (20 μl) were gently loaded. Sample buffer was 
added to the first and last well and in the second well molecular weight marker was added. 
Samples containing 15 μg protein up to 20 μl solution, along with pre-stained molecular weight 
markers, were separated by SDS-PAGE (10% w/v) for 45 minutes at 60V (when samples were 
in stacking gel) and switched to 200V for separation until the dye, bromophenol blue, reached 
the bottom of the separation gel. 
2.4.24 Blotting the gel  
Two nitrocellulose membranes and 12 pieces of blotting paper were soaking for two minutes 
in towbin’s buffer. Stacking gels were removed from the separation gels and discarded. The 
gels were sandwiched separately. The sandwich was assembled in an electro blotter for each 
gel as follows: Three pieces of blotting paper, nitrocellulose membranes, gel and at the top 
three pieces of blotting papers. Any bubbles within the sandwiches were removed by rolling a 
clean 5 ml tip over the sandwich. Proteins were transferred to the membrane at 40 mA/gel for 
one hour. 
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2.4.25 Blocking the nitrocellulose membranes 
Membranes were blocked with 1% BSA-TBS tween (pH 7.4) for 1 hour at room temperature 
on a rotating shaker. The blocking buffer was discarded and membranes were incubated 
separately in 12 ml of primary antibody solution (1:1000) dilution such as rabbit polyclonal 
anti-actin, p21, pJAK-2, NOX4, NOX5, RAGE and goat polyclonal antibodies to total JAK at 
40C. After overnight incubation on a rotating shaker, primary antibody solutions were 
discarded and membranes were washed five times in TBS-tween buffered saline and tween-20 
(TBS-tween) for 8 minutes each at room temperature on a rotating shaker. Membranes were 
incubated for 1 hour at room temperature in 12 ml of goat anti-rabbit or rabbit anti-goat 
horseradish peroxidase-conjugated secondary antibody diluted in TBS-tween containing 5% 
(w/v) de-fatted milk (1:1000) for actin, NOX4, NOX5, p.JAK-2, total JAK, p21, and RAGE, 
respectively. After incubation, secondary antibody solutions were discarded and membranes 
were washed five times in TBS-tween for 8 minutes each at room temperature on a rotating 
shaker. 
2.4.26 Developing the nitrocellulose membranes 
In a dark room, membranes were immersed in enhanced chemiluminescence (ECL) solution. 
To prepare the ECL solution, 1ml of (Lominol enhancer) solution was added to 1ml of 
(Peroxide) solution  and kept in the dark room for five minutes. Once the ECL solution was 
prepared it was then poured on to the membranes for one minute, left in the dark room and 
excess reagent was drained off, and membranes were quickly wrapped in cellophane films and 
kept in a box. The box was taken to the G-Box and the sample was measured as a 
chemiluminescent sample, the intensities of bands on the membranes were quantified by image 
J analysis software. The results were semi-quantitative and compared to the control. 
2.4.27 RNA extraction 
BAEC (5x105 cells/ml) in 10 ml of culture medium (10% FBS) were seeded in T.75 (60 mm) 
flask, and allowed to adhere for approximately 24 hours. The complete medium was discarded 
and the cells were washed gently three times with PBS. Fresh complete medium 10% FBS was 
added to each each flask. Combination of BSA-AGE (10 µg/ml), HWE and CWE of MC (90 
µg/ml) were added to the flasks. Control wells treated with DMEM supplemented with 10% 
FBS were included in the experiments. The contents of the plate were gently mixed to avoid 
possible dislodging of cells and incubated in a humidified atmosphere of 95% air and 5% CO2, 
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at a temperature of 37°C for a further 48 hours. Cells were washed three times with PBS. The 
cells were kept in -80 ºC for later use. Each experiment was carried out in triplicate, and 
repeated at least three times independently. Cells were removed from the freezer, placed in 
RNA extraction cabinet, allowed to thaw for two minutes in room temperature, then 4ml 
TRIzol reagent was added directly to the cells in the culture flask. The homogenized samples 
were incubated for 5 minutes at room temperature.  1 ml of the homogenise sample was 
transferred into Eppendorf tube, and 0.2 ml of chloroform added into each tube. Tubes were 
shaken vigorously by hand for 15-20 seconds, incubated for 2-3 minutes at room temperature. 
Samples were centrifuged at 12,000 x g for 15 minutes at 15 ºC, after the mixture separated 
into a lower red phenol-chloroform phase, an interphase, and a colorless upper aqueous phase. 
Notably, RNA remained exclusively in the aqueous phase, which accounted for 50% of total 
volume. The aqueous phase of the samples were removed from the tube by angling the tube at 
45º and pipetting the solution out, caution was taken to avoid drowning any of the interphase 
or organic layer into the pipette when the aqueous phase was removed. The aqueous phase was 
transferred into a new tube. A volume of 0.5 ml of 100% of isopropanol was added to the 
aqueous phase, the mixture was incubated at room temperature for 10 minutes, and centrifuged 
at 12,000 x g for 10 minutes at 4 ºC. RNA extracts appeared as a gel-like pellet on the side and 
bottom of the tube. The pellet was washed in 1 ml of 75% ethanol, and was vortexed briefly, 
centrifuged at 7500 x g for 5 minutes at 4 ºC , then discarded the solution. The RNA pellet was 
air dried for 5-10 minutes, and resuspended in  15 ul of RNase-free water by passing the 
solution up and down several times through a pipette tip. The solution was stored at -70 ºC. 
2.4.28 RNA quantification 
The concentration of RNA was determined using NanoDrop 2000. RNA purity was measured 
using the ratio of the absorbance at 260 nm and 280 nm. A value between 1.8 and 2.0 was 
considered as pure RNA.        
2.4.29 Complementary DNA Synthesis  
Extracted RNA was reverse transcribed into cDNA using ImProm-IITM Reverse Transcription 
system (Promega, UK) according to manufacturer’s instructions.  In brief, 1µg of total RNA, 
1 µl oligo (dT)15 primer (0.5 U/µl), 4 µl of 25 mM MgCl2, 4 µl of 5 X reaction buffer (pH 8.5), 
1µl of 10 mM dNTP mix, 0.5 µl of 2500 U/ml recombinant ribonuclease inhibitor (Rnasin) and 
1µl of 50 U/ml reverse transcriptase were combined in nuclease-free water to a final volume 
of 20 µl per reaction.  The reaction programme included denaturing at 70 ºC for 5 min 
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(primers/template was denatured), followed by annealing at 25ºC for 5 min, extension at 42 ºC 
for 1 h, and incubation at 70 ºC for 15 min (to inactivate reverse transcriptase)  in a thermal 
cycler.  The synthesized cDNA was stored at -20 ºC. 
2.4.30 Primer design  
The primers were designed using software Primer3. All sequences of primers were compared 
with GeneBank® using the Basic Local Alignment Search Tool (BLAST) program, which is 
available at the National Centre for Biotechnology Information (NCBI). Table 2.1 shows the 
sequences of primers used for RT-PCR. 
Table 2.1: The sequence of primers used for RT-PCR analysis 
Gene 
symbol 
Forward Primer (5’ → 3’) Revers Primer (5’ → 3’) 
ACTB 5’-TAGTTTCGTGAATGCCGCAG-3’ 5’-CAAAGTTCTGCATCGCCACT-3’ 
GPx 5’-CAAGGAGATCGAAGGCTTGC-3’ 5’-CGTAGTTGACAGCAGGCATC-3’ 
HOX B13 5’-GCATCCCTTTACCCTGACCT-3’ 5’-GGAACTGGCGAATACTGCTG-3’ 
NOX1 5’-TGCTTATCTGGCTCTCCCTG-3’ 5’-GCATCTCGTGGAGGTAGTGA-3’ 
NOX4 5’-TGCCCAAGGAGAAGCTAGAC-3’ 5’-ATCTCGGAGCTCCTCGAAAG-3’ 
NOX5 5’-CAAGAAGCCGAGTGAGGAGG-3’ 5’-TTGAGGTTCTGGTCACACGA-3’ 
P22 phox 5’-CGCACCTCCTCAACTTCTTC-3’ 5’-CAGCGTTGTTCTTGCCATCT-3’ 
P47 phox 5’-CAGGGACGCTTACAGATTGC-3’ 5’-CATGCTCCCACACGTCAATC-3’ 
CAT 5’-CAGTGGTCAGGACATCAGGT-3’ 5’-CATTCTTCCAGTCAACCGGG-3’ 
Mn-SOD 5’-CATGCTCCCACACGTCAATC-3’ 
 
5’-CCCTGGAGAAGAGCTACGAG-3’ 
 
 
 
2.4.31 Statistical analysis 
Statistical analysis was performed using Microsoft Office Excel 2009. The results of each 
experiment are expressed as mean ± standard deviation. Data were analysed for statistical 
significance using Student t-test for comparison between two groups and one way ANOVA for 
more than two groups. All analysis were performed using PRISM software.  Variations with p 
values ≤ 0.05 were considered statistically significant.  
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Chapter 3. Antiglycation properties of Momordica charantia extracts 
3.1 Introduction 
Reducing sugars such as glucose can react non-enzymatically with the free amino residues of 
proteins, fatty acids and nucleic acids via a series of reactions generating reversible Schiff base 
dicarbonyl compounds (Huang et al, 2008). The products of this reaction undergo further 
reactions to become irreversibly cross-linked, heterogeneous fluorescent compounds called 
AGEs (Chang et al, 2011). AGEs are a complex class of molecules generated from protein 
glycation under the potent influence of oxidative or carbonyl stress (Smit & Lutgers, 2004). 
High levels of glucose in the body cause more AGE production (Hsu & Zimmer, 2010). 
Dicarbonyl compounds such methylglyoxal are generated such as an intermediate of protein 
glycation and is a potent precursor of AGE production and  found at high levels in blood or 
tissues from diabetic subjects (Marchitti P, 2009). Furthermore, prolonged exposure to 
hyperglycaemia, impaired glucose metabolism and oxidative stress leads to accumulation of 
methylglyoxal, hence this induce serious toxic effects to varieties of cells such as endothelial, 
epithelial, macrophage and  neuronal cells (de Arriba et al, 2007). Glycation of protein is a 
spontaneous process depending in vivo on the degree and duration of hyperglycemia (Schmitt 
et al, 2005). AGEs accumulate gradually and can permanently change protein formation and 
function (Elosta et al, 2012). AGEs accumulate in great extents in proteins with long half live 
like extracellular collagen, lens crystalline, laminin and fibronectin, hence this leads to 
changing protein forms and bio-chemical properties (Thornalley et al, 1999; Verzelloni et al, 
2011). The production and accumulation of AGEs has been demonstrated to play a central role 
in the pathogenesis of diabetic complications (Jack & Wright, 2012). Conversely, in order to 
inhibit diabetic complications, inhibitors of AGE production have an essential role in future 
therapy. It has been suggested that the metal catalysed oxidation reactions play a key role in 
stimulating the rate of AGEs generation (Chen et al, 2011). Therefore, compounds with 
antiglycation and antioxidant activities may delay the process of AGE production by inhibiting 
further oxidation of metal-catalyzed glucose oxidation (Chen et al, 2011; Mukherjee et al, 
2012). 
Beside synthetic agents, recent attention has focused on the advantages of medicinal plants 
with both antiglycation and antioxidant activities.  Synthetic compounds and medicinal plants 
have been estimated as inhibitors against the production of AGEs, since the synthetic AGEs 
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inhibitors may be divided into three groups which are carbonyl trapping compounds which 
attenuate carbonyl stress, metal ion chelators , which reduce glycation and cross-link breakers 
that reverse AGE cross-linking (Reddy & Beyaz, 2006). Medicinal plants have been recognised 
to be relatively safe for human use and many plant products have been examined for their 
ability to inhibit AGEs. In this respect, medicinal plants with wide broad properties could be 
promising tools with at least disadvantage effects and as superior alternative to synthetic 
medicines.  
Momordica charantia also known as bitter melon is one of the world’s ancient medicinal plants 
especially in tropical countries, which has been used for the management of several conditions 
such as ulcers and diabetes. A considerable number of studies have investigated the anti-
hyperglycaemic properties  (Joseph & Jini, 2013), and anti-diabetic properties of MC (Singh 
et al, 2011). Animal and human studies suggest that the plant extracts of MC possess 
antihyperglycaemic effects. The active compounds within MC are either fat-soluble or water-
soluble compounds, since lectin, vicine and insulin-like polypeptide and glycoside are water 
soluble, and are more soluble in HWE than in CWE of MC extracts (Dans et al, 2007). Water 
has been used in this study to extracts active ingredients from MC, since the solvent is safe, 
cheap and affordable and for its bioavailability (kumar et al, 2010).  
Advantage of hot water over cold extract is hot water increases the solubility of the MC 
compounds affected by the increase of the extraction temperature, hence increasing in mass 
transfer. Under these environments, water viscosity is decreased, resulting a better penetration 
of the solvent extract in the matrix of the plant cells, subsequently increasing the extracting rate 
(Budrat & Shotipruk, 2009). In contrast with other methods of extraction hot water was 
regarded to possess good extraction efficiency and precision (Ong et al, 2006). Antiglycation 
activity of medicinal plants may be related to their polyphenolic content (Ardestani & 
Yazdanparast, 2007; Ho et al, 2010; Hsieh et al, 2007). However, MC extracts may express 
their antiglycation activity through inhibition of the post-Amadori phase, where free radical 
such as superoxide anion and metal ions are involved. Chelating and free radical species 
scavenging activities are important for inhibition of AGEs. Previous study has  indicated that 
MC extract inhibit AGEs formation in diabetic rats (Chaturvedi & George, 2010). However, 
comparative studies between HWE and CWE of MC on cross-linked AGEs have not been 
reported before. 
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3.2 Aim and objectives 
The aim of this study was to investigate and compare the effects of MC extracts on the 
production of AGEs in vitro. 
The objectives were: 
 To assess and compare the effects of different concentrations of reducing sugars and 
different times of incubations on fluorescent and cross-linked AGEs in vitro.  
 To examine and compare the ability of MC extracts to inhibit the production cross-
linked AGEs in vitro. 
 To study and validate the effect of MC extracts on the production of AGEs in vitro 
using ELISA techniques. 
 
 
3.3 Methods 
Lysozyme was glycated by incubating with different concentrations of sugars with / or without 
MC extracts as described in section 2.4.2. Crosslinked AGEs were examined as described in 
section 2.4.7. The production of fluorescent AGEs were investigated by their characteristic 
fluorescence as mentioned in section 2.4.8. AGEs was detected using ELISA as mentioned in 
section 2.4.9. 
 
 
 
 
 
.  
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3.4 Results  
3.4.1 Effect of different glucose concentrations on the formation of AGEs in vitro. 
Glucose was incubated with lysozyme, cross-linked AGEs were formed that caused production 
of dimers having a molecular weight of approximately 28.7 kDa as indicated by molecular 
weight markers as shown in Figure 3.1, lane a. The effect of glucose on cross-linked AGEs 
formation are clearly visible by their ability to reduce electrophoretic mobility and increase the 
intensity of the dimer bands in a dose-dependent manner as shown in Figure 3.1, lane c to h. 
 
Figure 3.1: Gel showing the effect of different glucose concentrations on the formation of 
AGE. SDS-PAGE gel showing lysozyme (10 mg/ml) incubated alone (lane b) or in the 
presence of (c) 0.1 , (d) 0.2 , (e) 0.4 , (f) 0.6 , (g) 0.8  and (h) 1 M glucose in 0.1 M sodium 
phosphate buffer (pH 7.4) at 37 °C for 35 days. The result is a representative figure of three 
independent experiments.  
Incubation with glucose showed a significant (p< 0.05) increase in cross-linked AGEs in 
comparison with the control as shown in Figure 3.2. This effect also depended on the dose of 
glucose. The cross-linked AGE production was more than 27-fold greater when lysozyme was 
incubated for 35 days with 1 M glucose as compared to the control and 9 -fold greater when 
0.1 M glucose was used. 
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Figure 3.2: Effect of different glucose concentrations on the formation of AGE. The scan 
of  SDS-PAGE gel shows the effect of different concentrations of glucose on formation of AGE 
in 0.1 M sodium phosphate buffer pH 7.4 at 37 °C for 35 days. Each value represents the mean 
± SD (n = 3), where (n.s =non-significant), ** p < 0.001 and *** p < 0.0001 v.s control 
(Lysozyme). 
3.4.2 Effect of period of incubation of glucose on the formation of AGE in vitro. 
An increasing quantity of cross-linked AGEs were produced when lysozyme was allowed to 
react with glucose for different incubation periods. The control sample contained lysozyme 
only Figure 3.3, lane a. Decreased electrophoretic mobility with higher Mr and increased dimer 
and trimer intensity as compared to control was observed with varying incubation periods of 
glucose as demonstrated in Figure 3.3, lane b to i. 
57 
 
 
Figure 3.3: Gel showing the effect of different incubation times of glucose on AGE 
formation. SDS-PAGE gel showing lysozyme (10 mg/ml) incubated alone (lane a) or in 
glucose (0.5 M) for different incubation time (b) 0 , (c) 7 , (d) 14 , (e) 21 , (f) 28 , (g) 35 , (h) 
42  and (i) 49 days in 0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 49 days. The result 
is a representative figure of at least three independent experiments. 
Formation of cross-linked AGEs was significantly (p < 0.05) increased in comparison with the 
control sample and this effect depends on time of incubation. The production of cross-linked 
AGEs was more than 60 fold greater when lysozyme was incubated with glucose for 49 days 
as compared to control, and 4.7 fold greater than when incubated for 0 days as shown in Figure 
3.4 
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Figure 3.4: Effect of different incubation times of glucose on the formation of AGE. The 
scan of SDS-PAGE gel shows the effect of lysozyme (10 mg/ml) with different incubation 
times in 0.1 M sodium phosphate buffer,  pH 7.4 at 37 °C for 7 weeks. Each value represents 
the mean ± SD (n=3), * p < 0.05, * * p < 0.001 and *** p < 0.0001 v.s control (lysozyme). 
3.4.3 Effect of HWE of Momordica charantia on glucose-induced AGEs 
Lysozyme incubated in the presence of glucose produces sufficient cross-linked AGEs. The 
effect HWE of MC on cross-linked AGEs formation are clearly visible by their ability to reduce 
electrophoretic mobility and the intensity of the dimer bands in a dose-dependent manner as 
shown in Figure 3.5. 
  
59 
 
 
Figure 3.5: Gel showing the effect of HWE of MC on glucose-induced AGEs. SDS-PAGE 
gel showing Lysozyme (10 mg/ml) incubated without glucose  (lane a) or in the presence of 
0.5 M glucose (lane b) in 0.1 M sodium phosphate buffer pH 7.4 at 37 °C for 35 days. The 
inhibition of dimer production of glucose-lysozyme AGEs was determined using different 
concentrations of HWE of MC lane (c) 7, (d) 14, (e) 30, (f) 45, (g) 60, (h) 75 and (i) 90 mg/ml. 
The result is a represent of at least three independent experiments.  
Production of cross-linked AGEs in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as maximum (77%) inhibition was observed in the sample with 90 mg/ml of 
MC extracts as in Figure 3.6. 
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Figure 3.6: Effect of HWE of MC on AGE formation. The scan of SDS-PAGE gel shows 
the effect of lysozyme (10mg/ml) incubated in the presence of glucose (0.5 M) produces cross-
linked AGEs. The glycation mixture was incubated with different concentration of HWE of 
MC for 35 days and percentage inhibition of glucose-induced AGE production. Each value 
represented the mean ± SD (n=3), ** p < 0.001, *** p < 0.001 v.s control.  
3.4.4 Effect of CWE of Momordica charantia on glucose-induced AGEs. 
Lysozyme incubated in the presence of glucose produces sufficient cross-linked AGEs. The 
effect of CWE of MC on cross-linked AGEs formation are clearly visible by their ability to 
decrease intensity of the dimer bands in a dose-dependent manner as illustrated in Figure 3.7. 
These results showed that inhibition of cross-linked AGEs formation by CWE of MC was dose-
dependent.  
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Figure 3.7: Gel showing the effect of CWE of MC on glucose-induced AGEs. SDS-PAGE 
gel showing lysozyme (10 mg/ml) incubated without glucose  (lane a) or in the presence of 0.5 
M glucose (lane b) in 0.1 M sodium phosphate buffer pH 7.4 at 37 °C for 35 days. The 
inhibition of dimer formation was determined using different concentrations of CWE of MC 
lane (c) 7, (d) 14, (e) 30, (f) 45, (g) 60, (h) 75 and (i) 90 mg/ml. The result is a representative 
figure of at least three independent experiments. 
Production  of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as maximum (41%) inhibition was observed in the sample with 90 mg/ml of 
MC extracts as in Figure 3.8 
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Figure 3.8: Effect of CWE of MC on glucose-induced AGE formation. The scan of SDS-
PAGE gel shows the effect lysozyme (10mg/ml) incubated in the presence of glucose (0.5 M) 
produces cross-linked AGEs. The glycation mixture was incubated with different concentration 
of CWE of MC for 35 days. The percentage inhibition of AGE production was investigated 
utilizing different concentration of CWE of MC. Each value represented the mean ± SD (n=3), 
where n.s = non-significant , * * p < 0.001 and *** p < 0.0001 v.s control. 
3.4.5 Effect of HWE of Momordica charantia on methylglyoxal-induced AGEs. 
The reaction between methylglyoxal and lysozyme results in formation of cross-linked AGEs 
after 7 days of incubation. The monomers, dimers, trimers and tetramers of the cross-linked 
AGEs were inhibited substantially depending on the concentration of HWE of MC as shown 
in Figure 3.9. The reduced electrophoretic mobility of cross-linked AGEs with higher 
molecular weights were demonstrated in lanes b-i compared to the control lane a. The effect of 
different concentrations of HWE of MC clearly showed a reduction in the intensity of the dimer 
bands, which was used to measure the percentage of inhibition. 
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Figure 3.9: Gel showing the effect of HWE of MC on methylglyoxal-induced AGEs. SDS-
PAGE gel showing lysozyme  (10 mg/ml) incubated alone (lane a) or in the presence of 0.1 M 
methylglyoxal (lane b) and the effect of different concentrations (c) 7, (d) 14, (e) 30, (f) 45, (g) 
60, (h) 75 and (i) 90 mg/ml of HWE of MC in 0.1 M sodium phosphate buffer pH 7.4 at 37 °C 
for 7 days. The result is a representative figure of at least three independent experiments. 
Production  of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as maximum (73%) inhibition was observed in the sample with 90 mg/ml of 
MC extracts as in Figure 3.10 
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Figure 3.10: Effect of HWE of MC on methylglyoxal-induced AGE formation. The scan 
of SDS-PAGE gel shows the effect lysozyme (10mg/ml) incubated in the presence of 
methylglyoxal (0.1 M) produces cross-linked AGEs. The glycation mixture was incubated with 
different concentration of HWE of MC for 7 days. Each value represented the mean ± SD (n = 
3), where n.s = non-significant , * p < 0.05 and *** p < 0.0001 v.s control. 
3.4.6 Effect of CWE of Momordica charantia on methylglyoxal-induced AGEs. 
The reaction between methylglyoxal and lysozyme results in formation of cross-linked AGEs 
after 7 days of incubation. The monomers, dimers, trimers and tetramers of the cross-linked 
AGEs were inhibited substantially depending on the concentration of CWE of MC as shown 
in Figure 3.11. The reduced electrophoretic mobility of cross-linked AGEs with higher 
molecular weights were demonstrated in lanes c-i compared to the control lane a. The effect of 
different concentrations of CWE of MC clearly showed a reduction in the intensity of the dimer 
bands, which was used to measure the percentage of inhibition. 
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Figure 3.11: Gel showing the effect of CWE of MC on methylglyoxal-induced AGEs. SDS-
PAGE gel showing lysozyme (10 mg/ml) incubated alone (lane a) or in the presence of 0.1 M 
methylglyoxal (lane b) and the effect of different concentrations (c) 7, (d) 14, (e) 30, (f) 45, (g) 
60, (h) 75 and (i) 90 mg/ml of CWE of MC in 0.1 M sodium phosphate buffer pH 7.4 at 37 °C 
for 7 days. The result is a representative figure of at least three independent experiments. 
Production  of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as optimum (62%) inhibition was observed in the sample with 90 mg/ml of 
CWE of MC extracts as shown in Figure 3.12. 
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Figure 3.12: Effect of CWE of MC on methylglyoxal-induced AGE formation. The scan 
of SDS-PAGE gel shows the effect of lysozyme (10 mg/ml) incubated in the presence of 
methylglyoxal (0.1 M) produces cross-linked AGEs. The glycation mixture was incubated with 
different concentration of CWE of MC for 7 days. Each value represented the mean ± SD (n = 
3), where n.s = non-significant , * * p < 0.001 and *** p < 0.0001 v.s control. 
3.4.7 Effect of different glucose concentrations on fluorescent AGE formation  in vitro 
Figure 3.13 demonstrates the effect of different concentrations of glucose on the fluorescence 
AGE production over 35 days. Subsequent analysis was made by using 1 M glucose. In contrast 
with the control, the intensity of the fluorescence of lysozyme incubated with glucose showed 
a significant increase (p < 0.01). The effect determined for lysozyme being incubated for 35 
days with 1 M glucose was more than 11.2 fold greater as compared to control and 5 fold 
greater than the effect observed in case of 0.1 M glucose.  
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Figure 3.13: Effect of different glucose concentrations on the formation of fluorescent 
AGE. The graph shows effect of different concentrations of glucose on fluorescent AGEs 
formation. Lysozyme (10 mg/ml) was incubated with different concentrations of glucose in 0.1 
M sodium phosphate buffer pH 7.4 at 37 °C for 35 days. Each value represents the mean ± SD 
(n = 3), * p < 0.05, * * p < 0.001 and *** p < 0.0001 v.s control (lysozyme). 
3.4.8 Effect of different incubation time of glucose on the formation of fluorescent AGE 
in vitro. 
Lysozyme incubated with glucose for 35 days showed a significantly (p<0.01) higher 
fluorescence level than that detected within the control sample without glucose. Formation of 
fluorescent AGEs is time-dependent. Fluorescence obtained in case of lysozyme incubated 
with glucose for 35 days was 6.8 fold greater  compared to control and 3.7 fold greater than the 
starting time of incubation as shown in Figure 3.14     
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Figure 3.14: Effect of incubation time of glucose on the formation of fluorescent AGE. 
The graph shows the effect of different incubation times on fluorescent AGEs formation. 
Lysozyme (10 mg/ml) was incubated with 1 M glucose in 0.1 M sodium phosphate buffer pH 
7.4 at 37 °C for 35 days. Each value represents the mean ± SD (n = 3), *p< 0.05 **p< 0.001 
***p< 0.0001 v.s control (lysozyme). 
3.4.9 Effect of low concentration of HWE of Momordica charantia on glucose-induced 
AGEs 
The effects HWE of  MC on cross-linked AGEs formation are clearly visible by their ability to 
decrease electrophoretic mobility and intensity of the dimer bands as shown in Figure 3.15. 
These results showed that the inhibition of cross-linked AGEs production by HWE of MC was 
dose dependent in manner. 
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Figure 3.15: Gel showing the effect of low concentration of HWE of MC on the formation 
of AGEs. SDS-PAGE gel showing lysozyme (10 mg/ml) incubated alone (lane a) or in the 
presence of 50m M glucose (lane b) and the effect of different concentrations (c) 1, (d) 2, (e) 
3, (f) 4, (g) 5, and (h) 7.5 mg/ml of HWE of MC in 0.1 M sodium phosphate buffer pH 7.4 at 
37 °C for 12 weeks. 
Formation  of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC 
extracts as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as optimum (58.54%) inhibition was observed in the sample with 7.5 mg/ml 
of HWE of MC extracts as in Figure 3.16. 
 
 
 
 
70 
 
Co
nt
ro
l 1 2 3 4 5
7.
5
0
20
40
60
80
*** 
*** 
*** 
n .s  
*  
n .s  
Momordica charantia (mg/ml)
In
h
ib
ti
o
n
 o
f 
c
ro
s
s
lin
k
e
d
 A
G
E
s
 (
%
)
 
Figure 3.16: Effect of low concentration of HWE of MC on the formation of AGEs. The 
scan of SDS-PAGE gel shows the effect of different concentrations of HWE of MC on 
fluorescent AGE formation. Lysozyme (10 mg/ml) was incubated with 50 mM glucose alone 
or in presence of different concentrations of HWE of MC in 0.1 M sodium phosphate buffer 
pH 7.4 at 37 °C for 12 weeks. Each value represents the mean ± SD (n = 3), where n.s =(non-
significant), *p < 0.05, ***p < 0.0001 v. control (lysozyme + glucose). 
3.4.10 Effect of low concentration of CWE of Momordica charantia on glucose-induced 
AGEs. 
The effects CWE of  MC on cross-linked AGEs formation are clearly visible by their ability to 
decrease electrophoretic mobility and intensity of the dimer bands as demonstrated in Figure 
3.17. These results showed that the inhibition of cross-linked AGEs production by HWE of 
MC was dose dependent in manner. 
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Figure 3.17: Gel showing the effect of low concentration of CWE of MC on the formation 
of AGE. SDS-PAGE gel showing lysozyme (10 mg/ml) incubated alone (lane a) or in the 
presence of 50m M glucose (lane b) and the effect of different concentrations (c) 1, (d) 2, (e) 
3, (f) 4, (g) 5, and (h) 7.5 mg/ml of CWE of MC in 0.1 M sodium phosphate buffer pH 7.4 at 
37 °C for 12 weeks. 
Formation of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as optimum (29.54%) inhibition was observed in the sample with 7.5 mg/ml of 
HWE of MC extracts as shown in Figure 3.18 
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Figure 3.18: Effect of low concentration of CWE of MC on the formation of AGE. The 
scan of SDS-PAGE gel shows the effect of different concentrations of CWE of MC on 
fluorescent AGEs formation. Lysozyme (10 mg/ml) was incubated with 50 mM glucose alone 
or in presence of different concentrations of CWE of MC in 0.1 M sodium phosphate buffer 
pH 7.4 at 37 °C for 12 weeks. Each value represents the mean ± SD (n = 3), where n.s = (non-
significant), *p < 0.05 and ***p < 0.0001 v.control (lysozyme +glucose). 
3.4.11 Effect of low concentration of HWE of Momordica charantia on the formation of 
fluorescent AGE in vitro. 
The glycation mixture was incubated with different concentrations of  HWE of MC for 12 
weeks. The results showed that inhibition of fluorescent cross-linked AGEs formation by CWE 
of MC was dose-dependent in manner. 
Formation of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as optimum (40 %) inhibition was observed in the sample with 7.5 mg/ml of 
HWE of MC extracts as shown in Figure 3.19 
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Figure 3.19: Effect of low concentration of HWE of MC on the formation of fluorescent 
AGE. The graph shows the effect of different concentrations of HWE of MC on fluorescent 
AGEs formation. Lysozyme (10 mg/ml) was incubated with 50 mM glucose alone or in the 
presence of different concentrations of HWE of MC in 0.1 M sodium phosphate buffer pH 7.4 
at 37 °C for 12 weeks. Each value represents the mean ± SD (n = 3), *p < 0.05, **p < 0.001 
and ***p < 0.0001  v.s control ( lysozyme + glucose). 
3.4.12 Effect of low concentration of CWE of Momordica charantia on the formation of 
fluorescent AGE in vitro. 
The glycation mixture was incubated with different concentrations of CWE of MC for 12 
weeks. The results showed that inhibition of fluorescent cross-linked AGEs formation by CWE 
of MC was dose-dependent in manner. 
Formation  of cross-linked AGE in vitro was significantly (p < 0.05) inhibited by MC extracts 
as compared to the control sample and this inhibition was dependent on MC extract 
concentrations as optimum (35%) inhibition was observed in the sample with 7.5 mg/ml of 
CWE of MC extracts as in Figure 3.20 
74 
 
Co
nt
ro
l 1 2 3 4 5
7.
5
0
10
20
30
40
n .s  
*** 
*** 
*** 
** n .s  
Momordica charantia (mg/ml)
In
h
ib
ti
o
n
 (
%
)
 
Figure 3.20: Effect of low concentration of CWE of MC on the formation of fluorescent 
AGE. The graph shows the effect of different concentrations of CWE of MC on fluorescent 
AGEs formation. Lysozyme (10 mg/ml) was incubated with 50 mM glucose alone or in the 
presence of different concentrations of CWE of MC in  0.1 M sodium phosphate buffer pH 7.4 
at 37 °C for 12 weeks. Each value represents the mean ± SD (n = 3), where n.s = (non-
significant), **p < 0.001 and ***p < 0.0001 v.s control (lysozyme + glucose). 
3.4.13 Effect of Momordica charantia extracts on AGEs levels using ELISA 
The glycated product was obtained by incubating BSA (10 mg /ml) with ribose (0.5 M). In 
contrast with the control containing BSA-AGE, significant inhibition (p < 0.001) was 
illustrated by both MC extracts with the maximum inhibition by the HWE of MC. Furthermore, 
the inhibitory effects of MC extracts on AGEs level was shown to be in a dose-dependent 
manner as shown in Figure 3.21. There was a gradual decrease of the level of AGEs after 
incubation with both MC extracts, where, at the maximum concentration (90 mg/ml), the AGEs 
production was  reduced to 64 %  for HWE of MC and 53 % CWE of MC (p < 0.01). 
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Figure 3.21: Effect of HWE and CWE of MC on AGE formation as measured by an 
ELISA technique. The graph demonstrates the inhibitory effect of MC extracts on AGEs 
levels that were determined in the presence of different concentrations of HWE and CWE of 
MC. Each value represents the mean ± SD (n=3), **p < 0.01 v.s control (BSA + AGE). 
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3.5 Discussion 
AGEs can be generated from the amino residues of proteins, lipids and DNA through several 
different mechanisms, including non-enzymatic glycation by glucose and reactions with 
metabolic intermediates and reactive dicarbonyl intermediates (methylglyoxal and glyoxal). 
Consequently, these reactions not only alter the form and structure of the proteins, but also lead 
to intramolecular and intermolecular cross-link production. The accumulation of cross-linked 
AGEs in biological compartments such as tissues and plasma  plays a vital role in long-term 
complications associated with diabetes mellitus (Wu et al, 2009). The rate of formation and 
accumulation of tissue AGEs is faster in diabetic tissue (Mashilipa et al, 2011). A number of 
studies have examined the benefits of using plant extracts for inhibiting AGEs production, and 
may also provide protection to diminish the development of such complications (Leung et al, 
2009; Tripathi & Chandra, 2009; Verzelloni et al, 2011). Diabetes mellitus is accounted as the 
major chronic disorder worldwide. It has been demonstrated that more than a third of the total 
of diabetic patients use medicinal plants. MC is one of the most common  medicinal plants 
used as an anti-diabetic remedy (Joseph & Jini, 2013). In the current study, glycation of 
proteins was examined in vitro by incubation of proteins with different reducing sugars 
(glucose and methylglyoxal) at physiological pH for different time intervals. Furthermore, non-
physiological concentrations of reducing sugars were also used to elevate the rate of production 
of AGEs in a short period. ****Lysozyme is a popular protein for the detection of cross-linked 
AGEs production, as oligomerisation occurs readily and is easily measurable by SDS-PAGE 
techniques. A number of researchers have examined the glycation of lysozyme in vitro 
(Kislinger et al, 2004). Lysozyme consist 6 lysine and 11 arginine per molecules and 
modifications of these residues can be achieved by both glucose and methylglyoxal. The results 
illustrated that elevated cross-linked AGEs formation correlated with glucose concentration 
and the period of incubation, this is in agreement with previous study (Mashilipa et al, 2011). 
The detection of fluorescence to study the effects of different glucose concentrations and 
different times of incubation on AGEs production also confirmed the previous findings with 
SDS-PAGE techniques. The dicarbonyl reducing sugar methylglyoxal was used because it is 
more reactive than the other reducing sugars, and consists of the carbonyl compounds 
(aldehyde and ketone). Moreover, the other important features of methylglyoxal are its ability 
to bind with sulfhydryl, amino, lysine and arginine functional groups in protein molecules 
(Goldin et al, 2006). In this respect, methylglyoxal induced generation of AGEs have been 
contributed in the progression and development of diabetic microvascular complications such 
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neuropathy, retinopathy and atherosclerosis (Chang et al, 2011) and the concentration of 
methylglyoxal is elevated during diabetes (Ahmed, 2005).  Moreover, methylglyoxal is 
recognised as a toxic agent, and its toxicity is mainly associated in cell apoptosis. Several 
studies in vitro have demonstrated that methylglyoxal-induced apoptosis in varieties cells for 
endothelial cells , epithelial cells, human leukaemia cells, Schwaan cells, osteoblasts and rat 
hippocampal cells (Chan et al, 2007; Huang et al, 2008; Ota et al, 2007). ELISA assay 
experiments have shown that the incubation of lysozyme with methylglyoxal resulted in 
elevated generation of AGEs. However, the inhibitory effects of MC extracts were almost 
similar as determined by SDS-PAGE and fluorescence assays. This activity of MC extracts 
against AGEs production may be related to the ability to chelate transition metals thus 
inhibiting autoxidative glycation and glycoxidation reactions, and the antioxidant activity may 
due to the properties against free radicals activity. It was assumed that MC extracts would 
compete with protein, and thereby block the modification of lysine residues in the protein. 
Sugars that exist in open (acyclic) form, obtain a higher rate of reaction than those of the same 
sugar in the closed (cyclic) form. Acyclic sugars have a higher rate of producing Schiff base 
and this rate is directly proportional to the concentration of the acyclic form. In addition to that, 
glucose is most abundant reducing sugar in the blood and naturally exists in the cyclic form, 
but when dissolved in the solution changes to acyclic form, this process of changing from cyclic 
form to acyclic form is named mutoratation (Mashilipa et al. 2011). In contrast, methylglyoxal 
is reported to obtain a higher rate of reaction and is reported to be more reactive than glucose 
(Gul et al, 2009). This reactivity is justified because methylglyoxal exists all in the acyclic 
form. The reactivity of sugars is dependent on the existence of the-open chain carbonyl form 
(Ahmed, 2005). This study illustrates for the first time that high and low concentrations of 
HWE and CWE of MC have significant inhibitory effects on cross-linked and fluorescence 
AGEs in a dose-dependent manner in vitro. Several types of AGEs are produced by oxidation 
reactions and protein glycation (Ahmed, 2005; Mashilipa et al, 2011).  
In this study, the potential benefits of utilizing MC extracts as medicinal plants were 
investigated in lysozyme-glucose system in vitro. The formation of cross-linked AGEs was 
induced by incubation of lysozyme, this is in agreement with previous study (Elosta et al, 
2012).  In addition, low concentrations of the reducing sugar glucose and MC extracts were 
used in lysozyme-glucose system in vitro. This is to investigate whether the extract inhibit AGE 
production in relevant diabetic condition   in vitro.  This study illustrates for the first time that 
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high and low concentrations of HWE and CWE of MC have significant inhibitory effects on 
cross-linked and fluorescence AGEs in a dose-dependent manner in vitro. The results from this 
study have shown that AGE formation is inhibited by HWE and CWE of MC with the HWE 
of MC possessing the more potent effect. This result may suggests that MC contains of varieties 
of amino acid molecules that can reduce the production of AGEs by engulfing carbonyl 
molecules (Mahomoodally et al, 2012; Orlovskaya & Chelombitko, 2007). Moreover, MC 
consists of a large number of antioxidant compounds, they are therefore able to scavenge the 
free radicals thereby, reducing the level of AGEs (Leung et al, 2009; Shan et al, 2012). It has 
been found that MC extracts have ability to chelate Cu2+ ions and protect against LDL oxidation 
reactions (Hsieh et al, 2005). The inhibition of methylglyoxal-induced AGEs by MC extracts 
may occur through blocking the conversion of dicarbonyl intermediates to AGEs. The results 
indicate that HWE of MC shows potent antioxidant activity, thus prevent the production of 
AGEs. The results suggest that the other active compounds under influence of temperature may 
be present in HWE of MC in addition to those compounds presents in CWE of MC, which 
provides its antiglycation property, however these compounds have not yet established.  In this 
respect, other methods required to be utilized in order to determine active constituents of MC 
extracts and study their effects on formation of cross-linked AGEs. In this study, MC extracts 
inhibited AGE-induced cross-links, as found by its effect on inhibiting glucose- and 
methylglyoxal-induced lysozyme polymerisation in vitro. The results obtained from this study 
suggest that MC extracts has the ability to break pre-formed AGEs cross-linked in vitro and 
therefore further in vivo investigations are needed in order to examine its role in the inhibition 
of diabetic complications.  
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Chapter 4. Antioxidant properties of Momordica charantia extracts 
4.1 Introduction 
It has been well established that ROS such as free radical species play a pivotal role in the 
progression and enhancement of tissue injury and pathological events in living organism (  
(Tabatabaei-Malazy et al, 2013). Therefore, oxidative stress occurs when there is an imbalance 
between antioxidant compounds and oxidant species and causes damage in all kinds of 
biomolecules such as protein, lipids, DNA and RNA, thus, the balance between ROS and 
antioxidants is an important aspect for maintaining biological systems (Sharma & Vig, 2013). 
Oxidative stress is the most important factor and plays a central role in the progression of 
diabetic complications, at both microvascular and macrovascular levels (Giacco & Brownlee, 
2010). Previous studies have shown that oxidative stress is elevated in insulin-dependent 
(type1) and non-insulin-dependent (type 2) diabetes (Rahimi et al, 2005; Soufi et al, 2012). 
The primary antioxidant enzymes that protect cells from injury mediated by ROS are SOD, 
CAT and GPx (Chiang et al, 2006). Their role as protective enzymes are well established and 
have been extensively examined in vivo and in vitro in model systems (Semiz & Sen, 2007). 
SOD plays a central role in defence system combating oxidative stresses  by catalysing ROS 
to hydrogen peroxide which is subsequently changed to water by CAT (Zhang et al, 2011). In 
this respect, natural antioxidants, particularly those presented in medicinal plant extracts such 
as phenolics, flavonoids, tannins and anthocyanins, are affordable, safe and are also bioactive 
(Mohsen & Ammar, 2009). Medicinal plants could be an important sources of natural 
antioxidant compounds (Ahmad & Ahmed, 2006). The antioxidant properties of these 
compounds derive from their ability to scavenge free radical species, chelate ion metals and 
improve antioxidant enzymes activity (Fraga et al, 2010). Moreover, the medicinal plants either 
in the form of supplementary medicine or food products are widely utilized to improve health 
and inhibit oxidative stress-induced chronic conditions like diabetic mellitus (Kalim et al, 
2010). 
Natural compounds and medicinal plants have become an increasingly attractive option to 
alleviate diabetic complications and other chronic conditions, because there is growing 
evidence that these nutritional compounds provide potential adjunctive therapeutic effects on 
different disorders including diabetes (Amornrit & Santiyanont, 2015). A large number of 
studies have reported that plant extracts of MC contain different active compounds against 
oxidative stress (Budrat & Shotipruk, 2009; Mahomoodally et al, 2012). Several in vitro 
80 
 
antioxidant assays were employed to evaluate the activity of different MC extracts (Semiz & 
Sen, 2007). Moreover, reports on the in vivo antioxidant activity of MC extracts have outlined 
the elevated efficacy of naturally occurring human antioxidant enzymes such as SOD and CAT 
(Sathishsekar & Subramanian, 2005). Moreover, previous study has reported that MC extract 
lower systemic oxidative stress in diabetic rats (Nerurkar et al, 2011). In this chapter, the 
antioxidant property of MC extracts was analysed during this research via a number of in vitro 
antioxidant assays. Determination of phenolic compounds in MC extracts was executed in vitro 
leading to an elaboration of the link between anti-oxidative and antiglycation properties of MC.  
4.2 Aim and objectives 
The aim of the current study was to investigate and compare the antioxidant activities of HWE 
and CWE of MC in vitro. 
The objectives of this study are: 
 To investigate and compare the total phenolic content of Momordica charantia extracts. 
 To examine the ferric ion reducing power of Momordica charantia extracts. 
 To examine the cupric ion reducing antioxidant capacity of Momordica charantia 
extracts 
 To investigate the effect of MC extracts on SOD enzyme activity in BAEC exposed to 
glucose, methylglyoxal and AGEs 
 To examine the effect of MC extracts on CAT enzyme activity in BAEC exposed to 
glucose, methylglyoxal and AGEs 
 To investigate the effects of MC extracts on ROS formation in BAEC exposed to 
glucose, methylglyoxal and AGEs 
4.3 Methods 
Total phenolic compounds in MC extracts were measured as defined in section 2.4.10, FRAP 
antioxidant activity of MC was assessed as in section 2.4.11, CUPRAC was measured as in 
section 2.4.12, SOD enzyme activity of MC extracts  in BAEC were measured as in section 
2.4.13, CAT enzyme activity of HWE and CWE of MC in BAEC were assessed as defined in 
section 2.4.14, ROS enzyme activity of HWE and CWE of MC in BAEC was also measured 
as in section 2.4.15. 
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4.4 Results 
4.4.1 Total phenolic content of Momordica charantia extracts 
The amount of phenolic compounds (mg/g) in MC extracts were represented as gallic acid 
equivalents (GAE). The phenolic amounts in HWE and CWE varied considerably as shown 
in Table 4.1. The highest amount was found in HWE with a value of 169.7 ± 2.25 mg/g 
whereas for CWE it was 123.43 ± 1.14 mg/g. 
Table 4.1: Total amount of phenolic compounds in Momordica charantia extracts. Each value 
represents the mean ± SD (n = 3) from at least three independent experiments. 
Momordica charantia extracts Total phenolic content (mg GAE/g extract) 
HWE 169.7 ± 2.25 
CWE 123.43 ± 1.14 
 
4.4.2 Effect of ferric ion reducing power in Momordica charantia  
The results show that the increasing concentrations of HWE of MC possess high reducing 
power of 13.68, 16.84, 30.82 and 32.46 with fold inhibitions, respectively. CWE of MC has 
lower reducing power activity of 10.82, 15.74, 27.28 and 28.63 with fold inhibitions, 
respectively, at the test concentrations. The lowest reducing activity was found in ascorbic acid 
of 1.20, 2.58, 7.32 and 11.61 with fold inhibitions, respectively, when tested at the same the 
concentrations. HWE and CWE of MC possess high reducing power activity compared to the 
positive control (ascorbic acid). The reducing power of HWE, CWE of MC and ascorbic acid 
increases with increases in the amount of sample and control concentrations as shown in Figure 
4.1  
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Figure 4.1: Reducing power of HWE and CWE of MC. The effects of different 
concentrations of HWE and CWE of MC on reducing power. Ascorbic acid was used as a 
positive control. Results are presented as mean ± SD, n=3. *p < 0.05   
4.4.3 Effect of cupric ion reducing antioxidant capacity of Momordica charantia  
The results show that the increasing concentrations of HWE of MC possess high reducing 
power of 8.24, 8.93, 11.85 and 13.16 with fold inhibitions, respectively. Ascorbic acid has 
lower reducing power activity of 3.19, 4.86, 10.16 and 10.98 with fold inhibitions, respectively, 
at the test concentrations. The lowest reducing activety was shown in CWE of MC of 2.14, 
2.57, 2.67 and 3.75 with fold inhibitions, respectively, when tested at the same the 
concentrations. HWE of MC showed the highest reducing power activity compared to ascorbic 
acid. In contrast, the lowest reducing power activity was found in CWE of MC as demonstrated 
in Figure 4.2  
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Figure 4.2: Reducing activity of HWE and CWE of MC. The effects of different 
concentration of HWE and CWE of MC on reducing activity. Ascorbic acid was used as a 
positive control. Results are presented as mean ± SD, n=3 and **p < 0.01.   
4.4.4 Effects of Momordica charantia on SOD activity in BAEC exposed to glucose 
The results show that Trolox induced a significant increase in SOD activity by 1.94 fold       (p 
= 0.003), compared to untreated control cells, whereas, CWE of MC induced no significant 
increase in SOD activity, and  HWE of MC induced a significant increase in SOD activity by 
1.68 fold (p = 0.0001) compared to glucose-treated cells. Moreover, glucose-treated cells 
induced a non-significant increase in SOD activity compared with untreated cells. HWE of MC 
possess a more potent SOD activity than the CWE of MC as demonstrated in Figure 4.3 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.5 3 6 9
A
b
so
rb
a
n
ce
 (
4
5
0
 n
m
)
Momordica charantia concentration (µg /ml)
Ascorbic acid CWE HWE
 
 
** 
 
 ** 
** 
 
 ** 
 
 
84 
 
Tr
ol
ox
C
on
tr
ol
 
G
lu
co
se
C
W
E+
G
lu
co
se
H
W
E+
G
lu
co
se
0
5
10
15 *** 
n.s 
n.s 
*** 
S
u
p
e
ro
x
id
e
 d
is
m
u
ta
s
e
 (
U
/m
g
)
 
Figure 4.3: Effect of MC extracts on SOD activity in BAEC exposed to glucose. The graph 
illustrates the effect of 25 mM glucose alone or with 90 mg/ml of MC extracts in BAEC 
medium cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are mean ± 
SD, n= 3. (n.s. = non-significant, ***p< 0.001). 
4.4.5 Effects of Momordica charantia on SOD activity in BAEC exposed to 
methylglyoxal 
The results show that Trolox induced a significant increase in SOD activity by 1.94 fold (p = 
0.0003) compared to untreated control cells, whereas, CWE of MC induced a non-significant 
increase in SOD activity compared to methylglyoxal-treated cells. On the other hand, the HWE 
of MC induced a significant increase in SOD activity by 1.53 fold (p = 0.0033) compared to 
methylglyoxal-treated cells. Moreover, methylglyoxal-treated cells induced a non-significant 
increase in SOD activity compared with untreated cells. HWE of MC possess a more potent 
SOD activity than the CWE of MC as shown in Figure 4.4 
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Figure 4.4: Effect of MC extracts on SOD activity in BAEC exposed to methylglyoxal. 
The graph illustrates the effect of 5 mM M methyglyoxal alone or with 90 mg/ml of MC 
extracts in BAEC medium cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. 
Data are mean ± SD, n= 3 (n.s. = non-significant, **p< 0.01, ***p> 0.001). 
4.4.6 Effects of Momordica charantia on SOD activity in BAEC exposed to AGEs  
Figure 4.5 showed that Trolox induced a significant increase in SOD activity by 1.94 fold       (p 
= 0.0003), compared to untreated control cells, whereas, CWE of MC induced a significant 
increase in SOD activity by 1.32 fold (p = 0.0003) compared to AGEs-treated cells. Similarly, 
the HWE of MC induced a significant increase in SOD activity by 1.94 fold         (p = 0.0001) 
compared to AGEs-treated cells. Moreover, AGEs- treated cells had no  significant effect in 
SOD activity compared with control cells. HWE of MC possess a more potent SOD activity 
than the CWE of MC. 
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Figure 4.5 Effect of MC extracts on SOD activity in BAEC exposed to AGEs. The graph 
illustrates the effect of 10 µg/ml AGE alone or with 90 mg/ml of MC extracts in BAEC medium 
cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are mean ± SD, n= 
3 (n.s. = non-significant, ***p < 0.001). 
4.4.7 Effects of Momordica charantia on CAT activity in BAEC exposed to glucose 
 The results show that Trolox induced a significant increase in CAT activity by 2.94 fold      (p 
= 0.0001), compared to untreated control cells. However, HWE and CWE of MC induced a 
significant increase in CAT activity by 2.15 fold (p = 0.0001), and by 2.73 fold                  (p = 
0.0001) respectively compared to glucose-treated cells. However, glucose-treated cells had no 
effect on CAT activity compared with untreated cells as shown in Figure 4.6 
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Figure 4.6:  Effect of MC extracts on CAT activity in BAEC exposed to glucose. The 
graph demonstrates the effect of 25 mM glucose alone or with 90 mg/ml of MC extracts in 
BAEC medium cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are 
mean ± SD, n= 3. (n.s. = non- significant, ***p < 0.001). 
4.4.8 Effects of Momordica charantia on CAT activity in BAEC exposed to   
methylglyoxal 
The results show that Trolox induced a significant increase in CAT activity by 2.94 fold        (p 
= 0.0001), compared to untreated control cells, whereas, CWE and HWE of MC induced a 
significant increase in CAT activity by 1.65 fold (p = 0.0001), 2.23 fold (p = 0.0001) compared 
to methylglyoxal-treated cells, respectively. Moreover, methylglyoxal-treated cells had no 
effect on CAT activity compared with untreated cells. HWE of MC possesses a more potent 
CAT activity than the CWE of MC as shown in Figure 4.7 
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Figure 4.7: Effect of MC extracts on CAT activity in BAEC exposed to methylglyoxal. 
The graph illustrates the effect of 5 mM methylglyoxal alone or with 90 mg/ml of MC extracts 
in BAEC medium cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data 
are mean ± SD, n= 3. (n.s. = non- significant, ***p < 0.001). 
4.4.9 Effects of Momordica charantia on CAT activity in BAEC exposed to AGEs 
The results shown that Trolox induced a significant increase in CAT activity by 2.94 fold      (p 
= 0.0001), compared to untreated control cells, whereas, CWE of MC induced a significant 
increase in CAT activity by 2.02 fold (p = 0.0001), and HWE of MC induced a significant 
increase in CAT activity by (p = 0.0001) compared to AGEs-treated cells. Moreover, AGEs-
treated cells also induced a significant decrease in CAT activity by 1.44 fold (p = 0.0002) 
compared with untreated cells. HWE of MC possess a more potent CAT activity than the CWE 
of MC as shown in Figure 4.8 
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Figure 4.8: Effect of MC extracts on CAT activity in BAEC exposed to AGEs. The graph 
shows the effect of 10 µg/ml AGE alone or with 90 mg/ml of MC extracts in BAEC medium 
cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are mean ± SD,   n= 
3, ***p < 0.001  
4.4.10 Effects of Momordica charantia on glucose–induced oxidative stress in BAEC 
The results show that Trolox did not increase ROS levels, compared to untreated control cells, 
whereas CWE of MC had no effect on ROS compared to glucose-treated cells. In contrast, the 
HWE of MC induced a significant decreased in ROS levels by 0.78 fold  (p = 0.0034) compared 
to glucose-treated cells. Moreover, glucose-treated cells also induced a significant increase in 
ROS levels by 0.89 fold (p = 0.0075) compared to untreated cells as shown in Figure 4.9 
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Figure 4.9 Effect of MC extracts on glucose-induced oxidative stress in BAEC.  The graph 
shows the effect of 25 mM glucose alone or with 90 mg/ml of MC extracts in BAEC medium 
cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are mean ± SD, n= 
3, (n.s. = non-significant, **p < 0.001). 
4.4.11 Effects of Momordica charantia on methylglyoxal–induced oxidative stress in 
BAEC  
The results show that Trolox did not increase ROS levels compared to untreated control cells, 
whereas, CWE and HWE of MC induced a significant decrease in ROS levels by 1.20 fold    
`(p = 0.0002), 1.08 fold (p = 0.0004), respectively compared to methylglyoxal-treated cells. 
Moreover, methylglyoxal-treated cells also induced a significant increase in ROS levels 1.10 
fold (p = 0.0003) compared to untreated cells as demonstrated in Figure 4.10 
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Figure 4.10 Effect of MC extracts on methylglyoxal-induced oxidative stress in BAEC. 
The graph shows the effect of 5 mM methylglyoxal alone or with 90 mg/ml of MC extracts in 
BAEC medium cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are 
mean ± SD, n=3, n.s = non-significant, ***p< 0.001. 
4.4.12  Effects of Momordica charantia on AGE–induced oxidative stress in BAEC 
Figure 4.11 showed that Trolox did not increase ROS levels compared to untreated control 
cells, whereas CWE and HWE of MC induced a significant decrease in the oxidative stress 
level by 0.95 fold (p = 0.0001), 0.98 fold (p = 0.0001) compared to AGEs-treated cells. 
Moreover, AGEs-treated cells also induced a significant increase in ROS levels 1.38 fold       (p 
= 0.0001) compared to untreated cells. 
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Figure 4.11 Effect of MC extracts on AGEs-induced oxidative stress in BAEC.  The graph 
shows the effect of 10 µg/ml AGE alone or with 90mg/ml of MC extracts in BAEC medium 
cells at 37 ºC for 24 hours. Trolox was used as standard antioxidant. Data are mean ± SD, n= 
3, n.s. = non-significant,  **p< 0.01 and ***p< 0.001. 
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4.5 Discussion 
In past two decades, it has become obvious that nearly all age-related diseases such as diabetic 
mellitus are associated with reactive oxygen species (ROS) such as superoxide anion radicals, 
hydroxyl radicals and hydrogen peroxide (Zahin et al, 2013). Oxidative stress occurs from 
either elevated free radical generation, a reduction in endogenous antioxidant compounds, or 
both (Chen et al, 2011). Previous studies have indicated that the phenolic molecules which are 
found in plant materials have potent antioxidant properties (Dhar et al, 2012). Phenolic 
compounds are essential plant components with antioxidant abilities that contribute directly to 
their redox activities, which demonstrate their importance in scavenging free radical molecules 
(Wang & Ballington, 2007).  
At present, the most frequently used assay for determining antioxidant properties is FRAP and 
CUPRAC. In  FRAP assay, an important effect of all inhibitors is to donate an electron was 
examined, where an increase in blue colour of the reaction indicates a higher ferric reducing 
power (Zheng et al, 2008). The results obtained from this study indicate that HWE of MC 
reduces a ferricyanide complex to ferrous ions more effectively than the CWE of MC. This 
results matches with the similar study  (Krishnaiah et al, 2011). Similarly, the CUPRAC 
reducing power assay demonstrated that HWE of MC reduces Cu2+ to Cu+ more strongly than 
the CWE of MC. The CUPRAC method that has been used in this study has shown responses 
in a dose-dependent manner to several antioxidant compounds such as vitamin C, flavonoids 
and phenolics (Apak et al, 2004). The CUPRAC findings correlated well with the results of 
FRAP, both being electron-transfer-based antioxidant capacity assays. It has been established 
that the reducing power it might be linked to the hydroxyl molecules in the aromatic rings of 
polyphenolic compounds, which were proven to apply antioxidant activities by donating 
hydrogen atom (Xing et al, 2005; Kubola & Siriamornpum, 2008). However, the reducing 
capacity of a compound may serve as an important indicator of its potential antioxidant activity.  
Momordica charantia extracts were found to have higher total phenolic contents in HWE than 
the CWE. These differences might be due to the extraction of MC in hot water, this findings 
similar to the results was reported previously (Kenny et al, 2013) who reported that MC extract 
with small amount of phenolic compound represent low antioxidant activity. The HWE of MC 
was found to contain the highest total phenolic compound levels and to be a potent, active 
extract in all in vitro antioxidant assays tested. The strong antioxidant properties of the plant 
extract are correlated with the high level of phenolic molecules (Hwang et al, 2013). 
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Momordica charantia extracts were studied for their antioxidant effects by investigating 
antioxidant enzymes as well as its protective effects on ROS damage in BAECs exposure to 
AGEs-induced oxidative stress were evaluated. AGEs are well known complex molecules 
cause endothelial cell dysfunction through the generation of reactive free radical species (Tupe 
et al, 2014). Antioxidant prevents the formation of ROS and play an important role in to 
inactivate them. Antioxidant activity of medicinal plants may be through inhibitory actions on 
formation of ROS or by direct scavenging of free radical species. Several studies further 
indicate that the antioxidant enzymes and antioxidant molecules can prevent free radical 
generation by chelating ion metals, decreasing concentrations of ROS and scavenging free 
radicals (Rolo et al, 2006). SOD and CAT are amongst the major antioxidant enzymes 
combating oxidative stress through scavenging free radical species that have shown to be down 
regulated in a number of pathophysiological conditions and diseases like diabetic mellitus (Li 
et al, 2013).  
In this study, we tested whether MC extracts could scavenger ROS and preserve the activities 
of antioxidant enzymes (SOD and CAT). The results of the present study show that the 
activities of SOD and CAT were higher and ROS was lower in BAECs treated with MC 
extracts. Furthermore, HWE of MC has better scavenger ROS and potent inducer SOD and 
CAT when compared with CWE of MC. These results suggest that MC extracts may attenuate 
oxidative stress by reducing ROS and increasing antioxidant enzyme activities in vitro. This 
finding was confirmed by a previous study which showed that in vitro and in vivo treatment 
with MC extracts enhances antioxidant enzymes such as SOD and CAT activities and lowers 
the concentration of free radical species (Semiz & Sen, 2007; Gong et al, 2015). It is more 
likely that a related synergistic mechanism may act against oxidative stress and carbonyl-
promoted cytotoxicity in in vitro models (Fenercioglu et al, 2010). BAECs were challenged by 
different oxidants including AGE, methylglyoxal and glucose. The results showed that HWE 
of MC potent than CWE of MC as compared to the control cells in all these assays. Hence, the 
activation of these antioxidant enzymes by the administration of MC extracts clearly 
demonstrates that MC extracts possess free radical scavenging property, which could provide 
beneficial effect against structural and functional alterations of cell components caused by the 
presence of free radical species such as superoxide and hydroxide radicals.  
These findings clearly show that the antioxidant activity of MC extracts in BAEC exposed to 
different oxidants-induced oxidative stress. In this study, we have shown for first time that 
HWE of MC contains high amount of phenolic compounds than the CWE of MC, which is a 
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promising source of antioxidant compounds that may be responsible for its antioxidant activity. 
In this context, further studies are required to isolate the active principles, as well as to define 
the role of several interacting active compounds in influencing therapeutic potential and 
efficacy in vivo. In addition, the present study supports the antioxidant potency of the plant 
extracts as proved by elevated level of these antioxidant enzymes in extract treated BAECs. 
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Chapter 5.  Inhibitory effect of Momordica charantia extracts on 
oxidative stress signalling pathways in BAEC. 
5.1 Introduction 
Oxidative stress occurs as a result of an increased production of ROS, and it is associated with 
a variety of chronic diseases including diabetes mellitus. Increased amounts of ROS are 
associated with endothelial cell death and apoptosis and. It is well established that oxidative 
stress increases the expression of certain genes in varieties of cells such as endothelial cells and 
smooth muscle cells (Chaturvedi et al, 2010). ROSs are produced from a variety of sources 
such as the mitochondrial transport system, xanthine oxidase, cytochrome p450, NADPH 
oxidase (NOX), uncoupled NO synthase (NOS), and the NOX family are the  main sources of 
ROS (oxidant signalling) in endothelial cells (Frey et al, 2009). The NOXs family consists of 
seven members (NOX1-5 and DUOX1 and 2) which differ in location and mechanism of 
activation.  NOX converts molecular oxygen (O2) to the superoxide anion  (O2•–), SOD then 
converts these products to hydrogen peroxide (H2O2), or to more reactive species such the 
hydroxyl radical (OH•⁻). Afterwards, they are converted to water (H2O) by CAT and GPx 
(Pinnell, 2003).  
A previous study has reported that direct exposure of endothelial cells to hyperglycemic 
concentration of reducing sugar such as glucose elevates the generation of ROS, thus activation 
of NADPH oxidase enzyme is directly associated in this process. AGEs exert their cellular 
effects by binding to particular receptors named RAGE. RAGE-mediated induction of cellular 
oxidant stress  triggers a cascade of intercellular signals involving p21ras (Lander et al, 1997). 
Interacting AGEs with RAGE generates cellular signals that activate NFkB, which leads to the 
transcription of diverse pro-oxidative stress genes (Stefanie et al, 2012). Moreover, ROS can 
be generated from activation of the growth-promoting enzyme Janus kinase 2 (JAK2) and its 
latent signal transducers and activators of transcription (STAT). Antioxidant compounds 
including enzymes and non-enzymes act as a free radical scavenging system and play a key 
role in first-line defence against ROS. In this regards, the most important action of a cell 
defence system is to counter oxidative stress is the induction of new gene expression in 
response to specific oxidative compounds. Some of the genes induced can be antioxidant 
enzymes such as SOD and CAT or pro-oxidative stress genes such p21(Simon et al, 1998). 
SOD and CAT are among antioxidant enzymes generate inside the human body to counter the 
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effects of ROS. Moreover, antioxidant can be obtain from external sources like medicinal 
plants (Snee et al, 2011). MC extracts contains natural antioxidants which can provide 
considerable activity against oxidative stress (Semiz & Sen, 2007).  
In this study we investigated the hypothesis that MC extracts have inhibitory effects on the 
activation of NADPH oxidase (NOX4, NOX5), p-JAK2, total JAK2, RAGE and P21 by AGE-
RAGE interaction. This interaction might attribute, at least in part, to formation of ROS and 
creating a series signalling pathways, which leading to altered gene expression in endothelial 
cells (Wautier et al, 2001). Excessive generation of ROS causes oxidative stress that contribute 
to protein oxidation, and subsequent dysfunction (Ulrich & Cerami, 2001). Hence, identifying 
the inhibitory effects of MC extracts on AGE-induced oxidative stress in BAECs in vitro is an 
essential step in investigating the vascular protective effect of MC extracts in diabetic vascular 
disease. 
5.2 Aim and objectives 
The aim of this work was to examine the effects of MC extracts on the oxidative stress 
signalling pathways in BAECs treated with AGEs in vitro.  
The objectives were: 
 To investigate the effect of different concentrations of MC extracts and AGEs on 
BAEC proliferation in vitro.  
 
 To determine the cytotoxic effects of AGEs, methylglyoxal, glucose alone or in 
combination with MC extracts on BAECs in vitro. 
 
 To investigate whether MC extracts can enhance antioxidant enzymes and inhibit 
oxidative stress expression genes in endothelial cells exposed to AGEs.  
 
 To examine the inhibitory effects of MC extracts on pro-oxidative stress proteins in 
endothelial cells exposed to AGEs. 
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5.2 Methods 
BAECs were used to determine the effect of MC extracts in the presence or absence of BSA-
AGEs on cell proliferation (2.4.20). Cell viability was examined as explained in section 
(2.4.21). The effects of MC extract on the oxidative stress gene expressions were investigated 
by qRT-PCR as mentioned in section (2.4.27). Furthermore, the effects of MC extract on AGE-
induced oxidative stress signalling pathways were investigated by western blotting as described 
in section (2.4.22)  
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5.3 Results 
5.3.1 Effects of Momordica charantia extracts, glucose, methylglyoxal and BSA-AGEs on 
BAEC proliferation  
Figures 5.1 -5.4 demonstrate the effects of different concentrations of MC extracts on BAEC 
proliferation after treatment for 24 hours. To check the cell response, FGF-2 was used as a 
positive control; and 25 ng/ml of FGF-2 induced a significant increase in the cell number by 
2.14-fold (p = 0.0002), compared to control cells. The addition of increasing concentrations 
(15, 30, 60, and 90 μg/ml) of MC extracts significantly improved BAEC proliferation in a dose-
dependent manner, with the greatest stimulation at 90 µg/ml (Figures 5.1 and 5.2). The 15, 30, 
60, and 90 μg/ml of HWE of MC elevated ( p< 0.0001) significantly BAEC proliferation by 
2.11 fold, 2.20 fold, 2.45 fold and 2.56-fold respectively, compared to untreated control cells 
(Figure 5.1). At the same concentrations of CWE also significantly ( p< 0.0001) increased 
BAEC proliferation by 2.04 fold 2.16 fold 2.41 fold and 2.48 fold respectively, compared to 
control cells as shown in Figure 5.2  
Figure 5.3 shows exposure of BAECs to 100, 200, 600 μg/ml of HWE of MC for 24 hours 
resulted in a significant increase of 1.73-fold  (p = 0.0002), 1.64-fold (p = 0.0006), 0.43- fold 
(p = 0.0013), 1.20- fold (p = 0.04) in BAEC proliferation compared with the control.  However,  
800 and 1000 μg/ml HWE of MC significantly inhibited BAEC proliferation by 0.71-fold (p< 
0.02), 0.48 (p< 0.02) compared with the control.  
Figure 5.4 shows exposure of BAECs to 100, 200, 400 μg/ml CWE of MC for 24 hours resulted 
in a significant increase of 1.65-fold  (p = 0.0004), 1.54-fold (p= 0.0006), 0.43- fold (p = 
0.0013) in BAEC proliferation compared with the control. 600 and 800 μg/ml CWE of MC 
resulted in non-significant change in BAEC proliferation compared to the control Whereas,  
1000 μg/ml CWE of MC significantly inhibited BAEC proliferation by 0.47-fold (p = 0.0016) 
compared with the control cells.  
Figure 5.5 shows at a concentration of 10.1 mM, glucose had no effect on BAEC proliferation 
compared with the control cells. Whereas, at 30.1, 55.1 and 105.1 mM, glucose significantly 
(p< 0.0001) inhibited BAEC proliferation compared to the control (5.1 mM).  The inhibitory 
effects on BAEC proliferation by glucose was dose-dependent. Similarly, methylglyoxal at 
concentrations of 1, 2, 4 and 5 mM, demonstrated significant (p< 0.001 ) decreasing effects  in 
BAEC proliferation compared to the control (Figure 5.6). This inhibition occurred in a dose-
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dependent manner. Moreover, BSA-AGEs at concentrations of 10, 50, 75 and 100 μg/ml 
showed significant (p< 0.001) inhibition of BAEC proliferation compared to the control cells. 
This inhibition occurred in a concentration–dependent manner as illustrated in Figure 5.7  
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Figure 5.1: Effect of different concentrations (15 to 90 μg/ml) of HWE of MC on BAEC 
proliferation. Bovine aortic endothelial cells (2 x 105 cells/ml) were seeded in 48-well plates 
and incubated with different concentrations of HWE of MC for 24 hours. Fibroblast growth 
factor 2 (25 ng/ml) was used as a positive control. Control is cells cultured under the same 
condition without any treatment. Results are presented as mean ± SD (n=3). *** p < 0.0001. 
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Figure 5.2: Effect of different concentrations (15 to 90 μg/ml) of CWE of MC on BAEC 
proliferation. Bovine aortic endothelial cells (2 x 105 cells/ml) were seeded in 48-well plates 
and incubated with different concentrations of CWE of MC for 24 hours. Fibroblast growth 
factor 2 (25 ng/ml) was used as a positive control. Control is cells cultured under the same 
condition without any treatment. Results are presented as mean ± SD (n=3). ***p < 0.0001. 
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Figure 5.3: Effect of higher concentrations (100 to 1000 μg/ml) of HWE of MC on BAEC 
proliferation. Bovine aortic endothelial cells (2x105 cells/well) were seeded in       48-well 
plates and incubated with different concentrations of HWE of MC for 24 hours. Fibroblast 
growth factor 2 (FGF-2) (25 ng/ml) was used as a positive control. Control is cells cultured 
under the same condition without any treatment. Results are represented as mean     ± SD (n=3). 
Where n.s. = non-significant, * p < 0.05  ** p < 0.001 and ***p < 0.0001. 
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Figure 5.4: Effect of higher concentrations (100 to 1000 μg/ml) of CWE of MC on BAEC 
proliferation. Bovine aortic endothelial cells (2x105cells/well) were seeded in 48-well plates 
and incubated with different concentrations of CWE of MC for 24 hours. Fibroblast growth 
factor-2 (25 ng/ml) was used as a positive control. Control is cells cultured under the same 
condition without any treatment. Results are represented as mean ± SD (n=3). Where n.s. = non-
significant, ** p < 0.001 and ***p < 0.0001. 
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Figure 5.5: Effect of different concentrations of glucose on BAEC proliferation. Bovine 
aortic endothelial cells (2 x 105 cells/ml) were seeded in 48-well plates and incubated with 
different concentrations of glucose for 24 hours. Fibroblast growth factor-2 (25 ng/ml) was 
used as a positive control. Control is cells cultured under the same condition without any 
treatment. Results are presented as mean ± SD (n=3). n.s = non-significant, *p < 0.05 and ** p 
< 0.001 and *** p < 0.0001. 
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Figure 5.6: Effect of different concentrations of methylglyoxal on BAEC proliferation. 
Bovine aortic endothelial cells (2 x 105 cells/ml) were seeded in 48-well plates and incubated 
with different concentrations of methylglyoxal for 24 hours. Fibroblast growth factor-2      (25 
ng/ml) was used as a positive control. Control is cells cultured under the same condition without 
any treatment. Results are presented as mean ± SD (n=3). ** p < 0.001, *** p < 0.0001. 
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Figure 5.7: Effect of different concentrations of BSA-AGEs on BAEC proliferation. 
Bovine aortic endothelial cells (2 x 105 cells/ml) were seeded in 48-well plates and incubated 
with different concentrations of BSA-AGEs for 24 hours. Fibroblast growth factor-2          (25 
ng/ml) was used as a positive control. Control is cells cultured under the same condition without 
any treatment. Results are presented as mean ± SD (n=3). * p < 0.05, ** p < 0.001 and *** p < 
0.0001. 
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5.3.2 Effects of Momordica charantia extracts on glucose, methylglyoxal and                  
AGEs-induced inhibition of endothelial cell proliferation 
Figure 5.8 shows that Glucose (30.1 mM) inhibited cell proliferation by 0.61 fold (p = 0.0139) 
when compared to untreated control cells (5.1mM). The addition of CWE of MC, reduced 
glucose’s inhibitory effect on the proliferation of BAEC by 1.11 fold (p = 0.013) and HWE did 
so by 1.32-fold (p = 0.0052). Similarly, MC extract reduced methylglyoxal’s (1 mM) inhibitory 
effect on the proliferation of BAEC by 1.24-fold (p = 0.0001) with the addition of CWE, and 
by 1.54-fold (p = 0.0004) with the addition of HWE (Figure 5.9). At 10 μg/ml, BSA-glucose-
AGEs inhibited cell proliferation by 0.48-fold (p = 0.0038) when compared to the control cells. 
The addition of MC extract reduced BSA-AGEs inhibitory effect on the proliferation of BAEC 
by 1.69-fold (p = 0.0001) with CWE and by 1.86-fold (p = 0.0004) with the addition of HWE 
as shown in Figure 5.10  
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 Figure 5.8:  Effect of MC extracts on glucose-induced inhibition of endothelial cell 
proliferation. Bovine aortic endothelial (2 x 105 cells/ml) were cultured in 48-well plates and 
incubated with glucose 30.1 mM alone or in presences of 90 μg/ml of HWE or CWE of MC 
respectively for 24 hours. FGF-2 (25 ng/ml) was used as a positive control. Control is cells 
cultured under the same condition without any treatment. Results are presented as mean ± SD 
(n=3). * p < 0.05 and ** p < 0.001. 
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Figure 5.9: Effect of MC extracts on methylglyoxal-induced inhibition of endothelial cell 
proliferation. Bovine aortic endothelial cells (2 x 105 cells/ml) were cultured in 48-well plates 
and incubated with methylglyoxal 1 mM alone or in presences of 90 μg/ml of HWE or CWE 
of MC respectively for 24 hours. FGF-2 (25 ng/ml) was used as a positive control. Control is 
cells cultured under the same condition without any treatment. Results are presented as mean ± 
SD (n=3). * p < 0.05 and ** p < 0.001. 
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Figure 5.10: Effect of MC extracts on BSA-glucose-AGEs-induced inhibition of 
endothelial cell proliferation. Bovine aortic endothelial cells (2 x 105 cells/ml) were cultured 
in 48-well plates and incubated with 10 μg/ml BSA-glucose-AGEs alone or in presences of 90 
μg/ml of HWE or CWE of MC respectively for 24 hours. FGF-2 (25 ng/ml) was used as a 
positive control. Control is cells cultured under the same condition without any treatment. Results 
are presented as mean ± SD (n=3). ** p < 0.01 and *** p < 0.001. 
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5.3.3 Effects of Momordica charantia extracts, glucose, methylglyoxal, BSA-AGEs on 
BAEC cell viability  
Figures 5.11 and 5.12 show that HWE and CWE of MC  at concentrations of 15 to 90 μg/ml 
had no cytotoxic effects on the viability of BAEC, compared to the control. Glucose at 10.1 
mM had no cytotoxic effects on BAEC cell, whereas at 30.1, 55.1 and 105.1 mM, it 
significantly reduced BAEC viability by 7 %. 26 %, and 28 % , respectively, compared with 
untreated control cells as demonstrated in Figure 5.13. Figure 5.14 shows the BAEC viabilities 
were  significantly reduced by 8 %, 17 %, 22.3 % and 23 % , following the treatment of 1, 2, 4 
and 5 mM methylglyoxal for 24 hours respectively, compared to the control. At the 
concentrations of 10, 50, 75 and 100 ug/ml, BSA-AGEs slightly reduced BAEC viabilities by 
6 %, 7.5 %, 10 % and 21 % , respectively, compared with untreated control cells. This inhibition 
was dose-dependent as shown in Figure 5.15  
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Figure 5.11: Effect of HWE of MC on BAEC viability. Bovine aortic endothelial cells      (2 
x 105 cells/ml) were seeded in 48-well plates and incubated with different concentrations of 
HWE of MC extracts for 24 hours. Results are expressed as mean ± SD (n = 3) and                       
n.s = non-significant. 
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Figure 5.12: Effect of CWE of MC extracts on BAEC viability. Bovine aortic endothelial 
cells (2 x 105 cell/well) were seeded in 48-well plates and incubated with different 
concentrations of CWE of MC extracts after 24 hours. Results are expressed as mean ± SD     
(n = 3) and  n.s = non-significant. 
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Figure 5.13: Effect of glucose on BAEC viability. Bovine aortic endothelial cells (2 x 105 
cells/ml) were seeded in 48-well plates and incubated with different concentrations of glucose 
after 24 hours. Results are expressed as mean ± SD (n = 3). ** p < 0.01, *** p < 0.001 and    
n.s = non-significant.  
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Figure 5.14: Effect of methylglyoxal on BAEC viability. Bovine aortic endothelial cells   (2 
x 105 cells/ml) were seeded in 48-well plates and incubated with different concentrations of 
methylglyoxal for 24 hours. Results are expressed as mean ± SD (n = 3). * p < 0.05 **,  p < 
0.01 and *** p < 0.001.  
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Figure 5.15: Effect of BSA-AGEs on BAEC viability. Bovine aortic endothelial cells        (2 
x 105 cells/ml) were seeded in 48-well plates and incubated with different concentrations of 
BSA-AGEs for 24 hours. Results are expressed as mean ± SD (n = 3).* p < 0.05 ** p < 0.01 
and *** p < 0.001. 
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5.3.4 Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis 
of selected oxidative stress gene expression in BAECs 
Figure 5.16 illustrates the relative mRNA expression of CAT, SOD2, HOX 1, p47 phox, NOX5, 
NOX4, p22phox, and GPx genes in BAECs in response to HWE or CWE of MC plus AGEs 
treatment compared to the cells treated with AGEs alone for 24 hours by qRT-PCR. The results 
show that expression of CAT and SOD2 in AGEs-induced oxidative stress in BAECs increases 
significantly by3.36-fold (p< 0.03), 3.31-fold (p< 0.04) respectively, following 24 hours 
treatment with 10 µg/ml of AGEs and 90 µg/ml of HWE of MC. Similar effects of CWE plus 
AGEs on the expressions of CAT and SOD2 were observed in BAECs with upregulations by 
2.06-fold (p< 0.005), and 2.81-fold (p< 0.0043) respectively, following 24 hours treatment.  In 
contrast, the expressions of HOX1,  NOX5, NOX4, p22phox and GPx in AGEs-induced oxidative 
stress in BAEC decreases by by 0.20-fold (p< 0.047), 0.23-fold (p< 0.036), 0.26-fold (p< 
0.044), 0.27-fold (p< 0.049) and 0.29-fold (p< 0.037) respectively, following 24 hours 
treatment with HWE and AGEs. Similarly, HOX1, NOX5, NOX4, p22phox and GPx in AGEs-
induced oxidative stress in BAEC decreases by 0.14-fold (p< 0.037), 0.18-fold (p< 0.02), 0.23-
fold (p< 0.043, 0.20-fold (p< 0.023) and 0.25-fold (p< 0.012) respectively, following 24 hours 
treatment with CWE and AGEs. Only the expression of p47phox did not change (p>0.05) 
following the treatment of HWE+AGEs or CWE+AGEs compared to treatment with AGEs 
alone. 
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Figure 5.16 Effects of HWE or CWE of MC on mRNA expression of CAT, SOD2,              
p47 phox, NOX5, NOX4, p22 phox and GPx in BAEC. The relative gene expression in cells 
treated with HWE or CWE of MC plus AGEs were compared to the cells treated with AGEs 
alone (used as control, value=1) and normalised to the housekeeping gene ACTB expression.  
Columns represent mean ± SD (n=3). * p < 0.05, ** p < 0.001. 
5.3.5  Effects of Momordica charantia extracts on AGE-induced oxidative stress 
signalling pathways in BAEC. 
To optimise the incubation time corresponding to the maximal inhibitory effects of MC extracts 
on the oxidative stress cell signalling induced by BSA-glucose-AGEs, the expression of RAGE 
and p-JAK2 in BAECs treated with 10 μg/ml AGEs alone or AGEs with 90 μg/ml MC extracts 
were investigated at 10 minutes, 1, 6 and 24 hours of incubation times. After 10 minutes 
incubation, the cells treated with AGEs alone significantly increased the level of 
phosphorylated JAK-2 (p-JAK2) and RAGE compared to the basal level of p-JAK2 and RAGE 
expressed in untreated control cells. The expressions of p-JAK2 and RAGE were reduced in 
the cells treated with HWC of MC and AGEs compared to their expressions in cells treated 
with AGEs alone (p< 0.001). The highest inhibitory effect was shown after 24-hours treatment 
as demonstrated in Figures 5.17 and 5.18 
The effects of different concentrations of HWE or CWE of MC on the protein expressions of 
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p21 and RAGE in BAECs after 24 hours treatment were investigated and demonstrated in 
Figures 5.19 to 5.30. Figure 5.19 shows that AGEs significantly induced the expression of 
NOX4 by 1.61 fold (p< 0.0001), compared to the basal level of NOX4 in control cells. 
However, the inhibitory effects of 15, 30, 60 μg/ml HWE on the expression of NOX4 induced 
by AGEs were not significant after 24 hours incubation (p > 0.05), compared to cells treated 
with AGEs alone. The addition of 90 μg/ml of HWE of MC significantly (p< 0.0001) reduced 
NOX4 expression by 0.37 fold, compared to cells treated with AGEs alone. The CWE shows 
greater inhibitory effects on NOX4 expression than HWE. The addition of 15, 30, 60, or 90 
μg/ml of CWE of MC significantly (p< 0.001) reduced NOX4 expression by 5.7-fold, 6-fold, 
8.1-fold, 8.2-fold respectively, compared to cells treated with AGEs alone as shown in Figure 
5.20  
AGEs significantly (p< 0.0001) induced NOX5 expression by 1.59-fold, compared to the basal 
level of NOX5 in untreated control cells. The addition of 15, 30, 60 and 90 μg/ml of HWE of 
MC as shown in Figure 5.21 significantly (p< 0.001) decreased NOX5 by 0.33, 0.39, 0.44 and 
0.57 fold, at same concentration CWE  as demonstrated in Figure 5.22 significantly (p<0.001) 
reduced NOX5 by 0.36, 0.48, 0.49 and 0.59 fold, compared to cells treated with AGEs alone. 
Moreover, AGEs significantly (p< 0.001) induced p-JAK2 expression by 2.53-fold, compared 
to the basal level of p-JAK2 in untreated control cells. The addition of 15, 30, 60 and 90 μg/ml 
of HWE of MC as demonstrated in Figure 5.23 significantly (p< 0.001) reduced p-JAK2 
overexpression by 0.35-fold, 0.40-fold, 0.45-fold and 0.72-fold, compared to cells treated with 
AGEs alone. However, the inhibitory effects of 15μg/ml of CWE on the expression of p-JAK2 
induced by AGEs was not significant after 24 hours incubation (p >0.05), compared to cells 
treated with AGEs alone. The addition of 30, 60 and 90 μg/ml of CWE of MC as demonstrated 
in Figure 5.24 significantly (p< 0.01) reduced p-JAK2 expression by 0.33-fold, 0.38-fold, and 
0.48-fold, compared to cells treated with AGEs alone. 
Figures 5.25 and 5.26 show AGEs significantly (p< 0.001) induced total JAK2 overexpression 
by 1.68- fold, compared to the basal level of total JAK2 in untreated control cells.  The 
inhibitory effects of 15, 30 and 60 μg/ml of HWE of MC on expression of total JAK2 induced 
by AGEs were not significant (p> 0.05),  compared to cells treated with AGEs alone. Whereas, 
the addition of 90 μg/ml of HWE of MC significantly (p< 0.001) reduced total JAK2 expression 
by 0.65-fold, compared to cells treated with AGEs alone. The inhibitory effects of 15μg/ml of 
CWE on the expression of total JAK2 induced by AGEs was not significant (p> 0.05) compared 
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to cells treated with AGEs alone.  In contrast, the addition of 30μg/ml of CWE of MC 
significantly (p< 0.05) reduced total JAK2 overexpression by 0.49-fold, compared to cells 
treated with AGEs alone. Furthermore, the addition of 60 and 90 μg/ml of CWE of MC 
significantly (p< 0.001) reduced total JAK2 overexpression by 0.69-fold and 0.77-fold 
respectively, compared to cells treated with AGEs alone. 
AGEs significantly (p< 0.001) induced p21 overexpression by 1.52 fold, compared to the basal 
level of p21 in untreated control cells. The addition of 15, 30, 60 and 90 μg/ml of HWE of MC 
significantly (p< 0.0001) reduced p21 overexpression by 0.25, 0.36, 0.40 and 0.65 fold 
respectively, compared to cells treated with AGEs alone as shown in Figure 5.27. The 
inhibitory effects of 15 μg/ml of CWE of MC on expression of p21induced by AGEs was not 
significant (p> 0.05), compared to cells treated with AGEs alone. Whereas, the addition of 30, 
60 and 90 μg/ml of CWE of MC significantly reduced p21expression by 0.07-fold (p< 0.05), 
0.11-fold (p< 0.001) and 0.57-fold (p< 0.0001) respectively, compared to cells treated with 
AGEs alone as shown in Figure 5.28  
Figure 5.29 shows AGEs significantly (p< 0.001) induced RAGE overexpression by 1.55-fold 
increase, compared to the basal level of RAGE in untreated control cells. The addition of 15, 
30 60 and  90 μg/ml of HWE of MC significantly reduced p21 overexpression by 0.42-fold (p< 
0.01), 0.52-fold (p< 0.001), 0.56-fold (p< 0.001) and 0.58-fold (p< 0.001) respectively, 
compared to cells treated with AGEs alone. The inhibitory effects of 15 μg/ml of CWE of MC 
on expression of RAGE induced by AGEs was not significant (p> 0.05), compared to cells 
treated with AGEs alone. In the contrary, the addition of 30, 60 and 90 μg/ml of CWE of MC 
significantly (p< 0.001) reduced RAGE overexpression by 0.21-fold   (p< 0.01), 0.25-fold (p< 
0.001) and 0.37-fold (p< 0.001) respectively, compared to cells treated with AGEs alone as 
shown in Figure 5.30 
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Figure 5.17: Time-course of p-JAK2 protein expression in BAECs treated with AGEs 
and MC extracts. (A) A representative Western blot analysis showing the effect of 90 µg/ml 
HWE of MC on p-JAK2 expression in BAECs after incubation with 10µg/ml AGEs for 10 
minutes, 1, 6, or 24 hours, compared with cells treated with AGEs alone or untreated control 
cells. (B) Bar graph showing the relative expression of p.JAK2, which were normalized to 
actin expression. Actin was employed as loading control. Results are presented as mean ± SD 
(n = 3). ** p < 0.001 and *** p < 0.0001 
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Figure 5.18: Time-course of RAGE protein expression in BAECs treated with AGEs and 
MC extracts. (A) A representative Western blot analysis showing the effect of 90 µg/ml HWE 
of MC on RAGE expression in BAECs after incubation with 10 µg/ml AGEs for 10 minutes, 
1, 6, or 24 hours, compared with cells treated with AGEs alone or untreated control cells. (B) 
Bar graph showing the relative expression of RAGE, which were normalized to actin 
expression. Actin was employed as loading control. Results are presented as mean ± SD (n = 
3). ** p < 0.001 and *** p < 0.0001 
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Figure 5.19: Effect of different concentrations of HWE of MC on NOX4 expression in 
BAECs . (A) A representative western blot showing the expression of NOX4 in BAECs after 
treatment with different concentrations of HWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of NOX4 in control cells, or in cells treated 
with AGEs (10 µg/ml) alone or AGEs plus HWE at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean    ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin.         ***p < 
0.0001 and n.s. = non-significant. 
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Figure 5.20: Effect of different concentrations of CWE of MC on NOX4 expression in 
BAECs. (A) A representative western blot showing the expression of NOX4 in BAECs after 
treatment with different concentrations of CWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of NOX4 in control cells, or in cells treated 
with AGEs (10 µg/ml) alone or AGEs plus CWE at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean    ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin.            **p 
< 0.001 and ***p < 0.0001. 
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Figure 5.21: Effect of different concentrations of HWE of MC on NOX5 expression in 
BAECs. (A) A representative western blot showing the expression of NOX5 in BAECs after 
treatment with different concentrations of HWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar graph shows the relative expression of NOX5 in control cells, or in cells 
treated with AGEs (10 µg/ml) alone or AGEs plus HWE at different concentrations for 24 
hours. To check the equal loading of proteins, actin was employed as loading control. Data are 
mean ± SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin. **p 
< 0.001 and ***p < 0.0001 
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Figure 5.22: Effect of different concentrations of CWE of MC on NOX5 expression in 
BAECs . (A) A representative western blot showing the expression of NOX5 in BAECs after 
treatment with different concentrations of CWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of NOX5 in control cells, or in cells treated 
with AGEs (10 µg/ml) alone or AGEs plus CWE at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin. **p < 0.001 
and ***p < 0.0001 
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Figure 5.23: Effect of different concentrations of HWE of MC on p.JAK2 expression in 
BAECs. (A) A representative western blot showing the expression of p.JAK2 in BAECs after 
treatment with different concentrations of HWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of p.JAK2 in control cells, or in cells treated 
with AGEs (10 µg/ml) alone or AGEs plus HWE at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin. **p < 0.001 
and ***p < 0.0001. 
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Figure 5.24: Effect of different concentrations of CWE of MC on p.JAK2 expression in 
BAECs. (A) A representative western blot showing the expression of p.JAK2 in BAECs after 
treatment with different concentrations of CWE of MC plus AGEs (10µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of p.JAK2 in control cells, or in cells treated 
with AGEs (10µg/ml) alone or AGEs plus CWE at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin. **p < 0.001, 
***p < 0.0001, and n.s. = non-significant. 
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Figure 5.25: Effect of different concentrations of HWE of MC on total JAK2 expression 
in BAECs. (A) A representative western blot showing the expression of total JAK2 in BAECs 
after treatment with different concentrations of HWE of MC plus AGEs (10 µg/ml), or with 
AGEs alone. (B) The bar shows the relative expression of total JAK2 in control cells, or in 
cells treated with AGEs (10 µg/ml) alone or AGEs plus HWE at different concentrations for 
24 hours. To check the equal loading of proteins, actin was employed as loading control. Data 
are mean ± SD, n=3. All values were compared to AGEs (value=1) and normalised to  ß-actin. 
**p < 0.001, ***p < 0.0001 and n.s. = non-significant. 
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Figure 5.26: Effect of different concentrations of CWE of MC on total JAK2 expression 
in BAECs. (A) A representative western blot showing the expression of total JAK2 in BAECs 
after treatment with different concentrations of CWE of MC plus AGEs (10 µg/ml), or with 
AGEs alone. (B) The bar shows the relative expression of total JAK2 in control cells, or in 
cells treated with AGEs (10 µg/ml) alone or AGEs plus CWE at different concentrations for 
24 hours. To check the equal loading of proteins, actin was employed as loading control. Data 
are mean ± SD, n=3. All values were compared to AGEs (value=1) and normalised to   ß-actin. 
*p < 0.05, *p < 0.001, **p < 0.001 and n.s. = non-significant. 
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Figure 5.27: Effect of different concentrations of HWE of MC on p21 expression in 
BAECs. (A) A representative western blot showing the expression of p21 in BAECs after 
treatment with different concentrations of HWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of p21 in control cells, or in cells treated with 
AGEs (10 µg/ml) alone or AGEs plus MC extracts at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin. ***p < 
0.0001. 
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Figure 5.28: Effect of different concentrations of MC extract on p21 expression in 24 
hours. (A) A representative Western blot demonstrating the expression of p21induced by    10 
µg/ml AGEs alone or in the presence of MC extracts at different concentrations. (B) The effects 
of AGEs 10 µg/ml alone or with MC extracts at different concentrations in 24 hours on p21 
expression. To check the equal loading of proteins, actin was employed as loading control. 
Data are mean ± SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-
actin. *p < 0.05, **p < 0.001, ***p < 0.0001 and n.s = non-significant. 
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Figure 5.29: Effect of different concentrations of HWE of MC on RAGE in BAECs. (A) 
A representative western blot showing the expression of RAGE in BAECs after treatment with 
different concentrations of HWE of MC plus AGEs (10 µg/ml), or with AGEs alone.   (B) The 
bar shows the relative expression of RAGE in control cells, or in cells treated with AGEs (10 
µg/ml) alone or AGEs plus HWE at different concentrations for 24 hours. To check the equal 
loading of proteins, actin was employed as loading control. Data are mean    ± SD, n=3. All 
values were compared to AGEs (value=1) and normalised to ß-actin.           **p < 0.001 and 
**p < 0.0001. 
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Figure 5.30: Effect of different concentrations of CWE of MC on RAGE expression in 
BAECs. (A) A representative western blot showing the expression of RAGE in BAECs after 
treatment with different concentrations of CWE of MC plus AGEs (10 µg/ml), or with AGEs 
alone. (B) The bar shows the relative expression of RAGE in control cells, or in cells treated 
with AGEs (10 µg/ml) alone or AGEs plus CWE at different concentrations for 24 hours. To 
check the equal loading of proteins, actin was employed as loading control. Data are mean ± 
SD, n=3. All values were compared to AGEs (value=1) and normalised to ß-actin. **p < 0.001, 
***p < 0.0001 and n.s. = non-significant. 
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5.4 Discussion 
Long-term exposure to hyperglycaemia cause formation of AGEs which plays a central role in 
the pathogenesis of diabetic complications such as retinopathy, nephropathy, neuropathy and 
delayed wound healing (Ahmed, 2005). Furthermore, it has been reported that the 
hyperglycemia decreases endothelial cell proliferation, migration and growth blood vessels 
formation in vitro, hence results in to damage angiogenesis (Stitt & Curtis, 2005). However, 
estimation of AGEs is great important for clinicians and researchers concerned with the 
management and prevention of diabetic complications and the pathological role of AGEs has 
encouraged the research for inhibitors of AGEs.  
This study reported that both HWE and CWE of MC increased cell proliferation in BAEC 
expouserd to glucose, methylglyoxal and AGEs-induced oxidative stress. Figures 5.1 and 5.2 
show that MC extracts ranging from 15 to 90 μg/ml increased endothelial cell proliferation in 
a dose-dependent manner. The stimulation effects on BAEC cell proliferation by 90 μg/ml MC 
extracts were even stronger than by 25 ng/ml FGF-2. FGF-2 is a potent mitogen that induces 
cell proliferation, migration, blood vessel growth, and plays a pivotal role in tissue reformation 
and stimulate wound healing (Mashilipa et al, 2011). FGF2 at a concentration of 25 ng/ml 
showed significant elevate BAEC proliferation (Hussain et al, 2009).  The results obtained 
from this study indicate that like FGF2, 15 to 90 μg/ml MC extract might have angiogenic 
property. Proliferation study proposed that HWE of MC consist more-insulin-like proteins or 
other stimulating molecules than CWE of MC. It has been reported that MC extracts contain 
varieties of chemical compounds, among them insulin-like molecules, which act as pro-
angiogenic growth factors by the activation of tyrosine kinase via binding to insulin receptors 
(Kim & Kim, 2011). Previous research has reported that topical insulin effectively improves 
skin wound-healing in diabetic rats (Lima et al, 2012). Cytotoxicity studies as demonstrated 
that MC extracts had no effects on BAEC viability at low concentrations of 15, 30, 60 and 90 
µg/ml, but high concentrations of 100 to 1000 μg/ml of HWE and CWE of MC decreased cell 
viability indicating the characteristic pattern of BAEC cell death as shown in Figure 5.3 and 
5.4, respectively. Moreover, MC extracts (2-100 μg/ml) was not affected cell viability in ß-
cells (Kim & Kim, 2011). 
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It is well established that in DM, hyperglycaemia usually ranges from 6 to 30 mM glucose and 
in severe condition the levels may reach 55 mM glucose (Facchiano et al, 2006). To examine 
the effect of high glucose concentration in vivo, BAECs were cultured in medium containing 
10.6, 30.6, 55.6 and 105.6 mM glucose to mimic different physiological conditions. The results 
have shown that high concentrations of glucose inhibit BAEC proliferation as shown in Figure 
5.5, which is in accordance with previous studies reported that high glucose concentration 
inhibited cell proliferation of BAEC in vitro (Jiaojun et al, 2004). The results suggest                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
that glucose may had mitogenic effect on BAECs cultured at 30.6 mM glucose compared to 
control; this effect may be related to the elevation of nutrients in the growth medium before 
starting to cause cellular toxicity. At the higher concentration of glucose 30.6. 55.6 and        
105.6 mM cell growth reduced in dose-dependent manner compared to control. This reduction 
in cell growth may not as a results of cellular toxicity due to hyper-osmolarity, but related to 
high glucose concentration in the growth medium (Mashilipa et al, 2011: Zhang et al, 2006). 
Moreover, previous studies have reported that high glucose concentrations can enhance cell 
cytotoxicity of retinal endothelial cells (Anitha et al, 2008), and decreases the cell viability of 
BAECs which can be involved in macrovascular complications accompanying diabetes 
mellitus (Duffy et al, 2006). The results have shown that high concentrations of glucose at 
(30.6 to 105.6 mM) significantly reduced cell viability as shown in Figure 5.13. The exact 
mechanism of how high glucose induced reduced cell growth and viability not yet fully 
understood. It may be speculated that exposure of endothelial cells to high concentrations of 
glucose can activate oxidative stress transcription factor NFkB, believing that hyperglycemia 
could activate gene expression through activation of transcription factor of NFkB (Spanier et 
al, 2009).   
Figures 5.6 and 5.14 demonstrate that 1, 2, 4 and 5mM methylglyoxal inhibited BAEC 
proliferation and reduced viability. These effects occurred in dose-dependent manner 
compared to control. These results suggest that methylglyoxal induced oxidative stress by 
inactivation of antioxidant enzymes such as SOD, CAT and GPx by their glycation. Moreover, 
AGE-RAGE interaction results in strong oxidant formation such as superoxide anion, hence 
this leads to endothelial dysfunction. These results are in accordance with a previous study, 
which also found that 5 mM methylglyoxal inhibited the cell growth and induced cell 
cytotoxicity of BAEC in vitro (Tatsunami et al, 2009).   
A large number of in vivo and in vitro studies have indicated that production and excessive 
accumulation of AGEs results in chronic hyperglycaemia and lead to diabetic complications  
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(Goh & Cooper, 2008). Subsequently, it has been suggested that a pivotal role in angiogenesis 
is played by the glycation of proteins through AGE synthesis. In the present study, AGEs have 
been utilized  at a concentration of 10 μg/ml which was selected according to a previous study 
that reported 10 μg/ml AGEs may represent the lowest level of plasma AGEs detected in 
patients suffering from diabetes (Mashilipa et al, 2011). This study showed that 10 to 100 μg/ml 
AGEs inhibited BAEC proliferation in vitro as shown in Figure 5.7 and had a cytotoxic effect 
on BAECs as illustrated in Figure 5.15. The results suggested that AGEs may leads cell toxicity 
in human endothelial, epithelial and neuronal cells through elevation of oxidative stress have 
been shown in dose-dependent manner (Amornrit & Santiyanont, 2015), it is nevertheless 
possible exposure BAECs to AGEs may result to alteration in the cytoskeleton and cell 
permeability as mentioned by Esposito et al, (1989). These findings are consistent with 
previous studies, which also found that 10 μg/ml BSA-AGEs inhibit the growth of  mesangial 
cells, and cause cytotoxicity in neuronal cells (Woltjer et al, 2003). Altogether, these effects 
are suggested to be induced by interaction of AGE-RAGE which are presented in different cell 
lines (Mruthinti et al, 2006).  
The elevated formation of free radicals, and together with a decrease in the antioxidant potential 
can cause oxidative stress, which leads to injury of the cells components like proteins, lipids, 
DNAs and RNAs (Naziroğlu & Butterworth, 2005). Previous research illustrated that 
compounds with antioxidant property have therapeutic potential in the protection against 
AGEs-induced cellular toxicity (Zhang et al, 2006). The antioxidant properties of MC extracts 
were demonstrated in Chapter 4. Both HWE and CWE reduced the cell toxicity effects of 
glucose methylglyoxal and AGEs on BAEC cell proliferation (Figure 5.8, 5.9 and 5.10) 
respectively. Whether low concentrations of MC extracts can protect against AGEs-reduced 
BAEC viability need further study. These results suggested that this protection effect of MC 
extracts may be related to the combination of several bioactive compounds and proteins as 
mentioned previously. Recent investigations demonstrated that these compounds had a 
protective property on endothelial dysfunction and reduced the pathological progress of 
diabetic complications (Kumar R, 2009: Kubola & Siriamornpun, 2008). Nevertheless, more 
studies will be required to investigate radical scavenging activity in HWE and CWE of MC 
extracts to confirm that the inhibitory effects shown in the current results are from antioxidant 
properties resulting in cell protection by decreasing the toxicity of glucose, methylglyoxal and 
AGEs-induced oxidative stress in the cells. 
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AGEs deposit in the inner part of the blood vessel wall, which are could damage cell structure 
and function. AGES generated inside the body or obtained from ingested food could bind to 
RAGE, hence this leads to activating a cascade of intercellular signalling pathways, which are 
associated with diabetic complications. AGE/RAGE interaction results in intercellular ROS 
formation signalling pathways via NADPH oxidase, p38 MAP Kinase, NF-kB, P21Ras and 
JAK/STAT pathways (Lee et al, 2010). These pathways result in cellular responses including 
the changes in cell proliferation and cytotoxicity in endothelial cells (Odjakova et al, 2012).  
Momordica charantia extracts downregulated the expressions of the pro-oxidative stress genes 
NOX4, NOX5, HOX1, p47phox, p22phox and GPx, and upregulated the expressions of antioxidant 
enzyme genes SOD2 and CAT in AGEs-treated BAECs (Figures 5.16). These data suggest that 
the protective effects of MC extracts against oxidative damage are likely due to the 
upregulation of endogenous cellular antioxidant enzymes such SOD and CAT rather than the 
direct ROS scavenging property of MC extracts. Moreover, upregulation of antioxidant enzyme 
and oxidative stress genes expressions by HWE of MC are greater than by CWE of MC. This 
may be related to higher amount of phenolic compounds in HWE of MC, because of that, the 
measurement of this compound was carried out in this study as shown in Table 4.1.  However, 
further study requires to be done to identify the compounds that are responsible for the inducing 
antioxidant enzyme genes and inhibiting pro-oxidative stress genes. 
Increased oxidative stress play a central role in the pathogenesis of several chronic conditions 
such as vascular diabetic complications (Förstermann, 2008). It has been well established that 
several enzymes such NADPH oxidases, xanthine oxidase, uncoupled endothelial NO synthase 
are involved in the excessive production and accumulation of ROS, but NADPH oxidase are 
more likely to be the major source of ROS in the wall of blood vessels especially in those 
patients suffered from vascular disorders like diabetic patients (Guzik et al, 2006).  
In this study, 10 μg/ml AGEs significantly stimulated NOX4, NOX5, p-JAK2, total JAK2, p21 
and RAGE expressions in BAECs as demonstrated in Figures 5.22-5.30. However, MC extract 
at the concentration of 15, 30, 60 and 90 µg/ml significantly attenuated AGE-induced oxidative 
stress signals. In addition, the inhibitory activity of MC extracts on AGE-induced oxidative 
stress was shown in a dose dependent manner (Figures 5.29 to 5.30). These findings suggest 
that MC extracts may intervene AGE-RAGE interaction to attenuate AGEs-induced oxidative 
damage.  
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In this study, MC extracts reduce the expression of NOX4, which is the main NOX family 
member in endothelial cells. Moreover, MC extracts-mediated attenuation of AGEs-induced 
oxidative stress in BAECs may correlate with downregulation of p-JAK and total JAK2. It has 
been reported p-JAK2 and total JAK were expressed at high levels in patients with diabetic 
complications. High glucose level cause formation of ROS via JAK-2 overexpression in 
mesangial cells (Berthier et al, 2009). Therefore, MC extracts have potential to be utilized in 
controlling ROS formation in diabetic patients by inhibiting JAK2 expression. These results 
obtained from this study indicated the contribution of a specific pathways, activation of  
NADPH oxidase (NOX4, NOX5), p-JAK2, total JAK2, RAGE and P21 by AGE-RAGE 
interaction, by which AGE-induced production of ROS and generating transduction events may 
cause altered gene expression in endothelial cells through RAGE. Moreover it has been 
reported that AGEs interact with RAGE leading cell death as a result of ROS (Morita et al, 
2013)  
AGEs are associated in in the pathogeneses of several chronic conditions such diabetes and its 
complications. Inhibiting the production of AGEs and interfering with AGEs-induced 
oxidative stress are two an important practicable goals for improving medicinal plants against 
diabetic complications. In this study, MC extracts exhibit the potent capacity not only against 
glucose, methylglyoxal and AGEs-induced oxidative stress and cytotoxicity in BAEC, but also 
downregulated mRNA expression of pro-oxidative stress regulator genes and upregulated 
antioxidant enzyme genes. These findings propose potential usefulness of the MC extracts as 
antioxidant agents and provide an insight into the molecular mechanism underlying the anti-
oxidative activity of MC extracts. To this effect, if data from this current study further extended 
in vivo, then it can be proposed that ingestion of MC extracts might be useful in the long-term 
management of diabetes. 
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Chapter 6.  General discussion, conclusion and future work  
6.1 Discussion 
Advanced glycation endproducts result from non-enzymatic reactions between free amino 
groups of proteins, lipids, DNA and the carbonyl groups of reducing sugars. They contribute 
to the development and progression of several chronic conditions such as the vascular 
complications of diabetes (Yamagishi, 2011). However, the main causes responsible for the 
development of these complications have not yet been fully understood. In this regards, 
glycation of protein is one of many pathways proposed to explain the relation between 
hyperglycaemia and the development of diabetic complications (Gul et al, 2008; Srikanth et 
al, 2011). The production and accumulation of AGEs in humans play a pivotal role in structural 
and functional changes in tissue proteins (Wu et al, 2009). A large number of studies have 
indicated that AGEs are a key factor in the pathogenesis of diabetic complications and that the 
amount of AGE build-up in tissues depends on the degree and duration of hyperglycaemia, the 
half-life of the modified protein, the amount and permeability of the cell to free glucose 
(Ahmed, 2005; Elosta et al, 2012). Long-lived proteins such as eye lens crystallin and collagen  
are particularly exposed to AGE modification (Berbaum et al, 2008).  
Important novel findings have emerged from this study, which is discussed in relation to the 
publish literature described in the previous chapters. The reactions were studied under high-
sugar concentrations to accelerate the reaction and reduce the incubation time. Different 
analytical techniques including the SDS-PAGE, spectrophotometer, ELISA were utilized to 
follow the glycation reaction. Long-term incubations of lysozyme with glucose cause the 
generation of cross-linked AGEs. The data obtained from this study indicated that HWE and 
CWE of MC have significant potential inhibition of the production of AGEs. This inhibition 
occurs in a dose-dependent manner and the inhibitory action of HWE is more potent than that 
of CWE of MC. Furthermore, several studies have reported that MC extracts contains amino 
acids that could reduce the formation of AGEs by the blockage of carbonyl groups of reducing 
sugar (Yuwai et al, 1999). Methylglyoxal is more reactive than the glucose and it can be 
produced by both fragmentation and dehydration of glucose and Amadori products. 
Methylglyoxal changes the lysine and arginine residues in proteins (Ahmed, 2005), mediates 
excessive cross-linking and produces ROS during protein glycation (Yim et al, 2001). In this 
study, MC extracts prevented the generation of methylglyoxal-derived cross-linked AGEs 
(Figures 3.10 and 3.12). The extracts of MC may act by blocking the alteration of dicarbonyl 
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intermediates to AGEs. Even though with utilising high concentrations of MC extracts, 
methylglyoxal was able to generate significant dimer. The excessive cross-linking induced by 
methylglyoxal due to its highly reactive nature may elucidate this. Previous studies have 
reported that methylglyoxal levels were increased in diabetic patients, and this resulted in the 
production of ROS (Artenie et al, 2002; Vander Jagt & Hunsaker, 2003). ROS increases the 
risk of oxidative stress and cellular impairment (Dizdaroglu et al, 2002). Therefore, preventing 
the formation of methylglyoxal-derived AGEs by MC extracts may decrease ROS production, 
and reduce the risk of oxidative stress in diabetic patients. ELISA experiments have 
demonstrated that the incubation of lysozyme with methylglyoxal resulted in the increased 
production of AGEs. The data obtained from this study indicated that HWE and CWE of MC 
have significant potential inhibition of the production of AGEs. This inhibition occurs in a 
dose-dependent manner and the inhibitory action of HWE is more potent than that of CWE of 
MC (Figure 3.21). AGE production is a very complicated process; to understand the inhibition 
mechanism of AGEs generation induced by MC extracts requires further investigation. Hung 
et al (1999) suggested that MC contains of several amino acids that could reduce the formation 
AGEs by blockage carbonyl molecules. This may result in reducing the production of AGEs  
(Botau et al, 2011; Yuwai et al, 1991).  
A large and growing body of literature has reported that the medicinal plants possess great 
antioxidant potential. Antioxidants decrease the oxidative stress in cells and are therefore useful 
in curing many human diseases (Dhar et al, 2012; Tripathi & Chandra, 2009). The literature 
reveals that natural antioxidants within medicinal plants represent a potentially side-effect free 
alternative to synthetic antioxidants in the food processing industry and for the use in 
preventive medicine (Krishnaiah et al, 2011). MC has been used as a traditional medicine in 
different part of the world, throughout centuries for alleviating the symptoms of several 
diseases including diabetes (Leung et al, 2009). Each plant contains several components, only 
a few of which may be therapeutically effective. Different parts of the plants such as roots, 
seeds, fruits and bark contain different active ingredients (Krishnaiah et al, 2011). Furthermore, 
different active compounds may be obtained by using different extraction methods (Prabhakar 
& Mukesh, 2011). Owing to the role of medicinal plants with antiglycation properties, 
significant protection against the production of AGEs could be provided, since AGEs may play 
a pivotal role in the progression and development of diabetic complications. Using hot water 
as the extract solvent improves the ability of small components within the plant cells to dissolve 
readily into the medium solution as compared to cold water solvent (Tsai et al, 2006). It may 
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be that the potency of hot water solvent is related to the influence of the temperature 
(Pitipanapong et al, 2007), which enhances the solubility of the small components within the 
plant cells. The results obtained from this study are similar to the previous study stated that hot 
water extract of MC provides high levels of total phenols and potent antioxidant activity 
(Budrat & Shotipruk, 2008). A similar study on Picralima nitida medicinal plant has indicated 
that hot water extract contains higher amounts of active ingredients than the cold water extract  
(Nkere & Iroegbu, 2005). Moreover,  previous work which indicated that generally HWE and 
CWE are most commonly used in the traditional method of preparing folk medicines 
(Ponnusamy et al, 2010), for its safety and bioavailability. 
Results from this study demonstrated that MC extracts with high polyphenolic content 
represent potent antiglycation properties; this may leads to the differences in antioxidant and 
antiglycation ability between HWE and CWE of MC. Electron transfer-based antioxidant 
assays measure the capacity of antioxidants in the reduction of an oxidant, which changes the 
colour of the mixture when reduced (Apak et al, 2007). HWE of MC have shown more potent 
reducing activity effects than the CWE of MC. Recent evidence suggests that the antioxidant 
and free radical scavenging activities of phenolic molecules are generally derived from their 
redox properties, which may act as hydrogen atom donors to their phenolic hydroxyl groups 
(Siddhuraju, 2006). However, despite MC containing polyphenolic compounds, it also contains 
other substances such as ascorbic acid which may contribute to the antioxidant capacity of 
polyphenols. However, there are a considerable number of studies suggested that natural 
polyphenolic antioxidant molecules extracted from plants could be substitute for the synthetic 
antioxidants (Qader et al, 2011).  
In this study, pro-antioxidant enzyme activity of MC extract was investigated for the first time 
in the presence of low concentrations of AGEs. Even though the mechanism behind this activity 
is not fully understood,  it may be related to the presence of polyphenolic molecules such as 
catechine, quercetine, trans-chalone, caffeine, caffeic acid and gallic acid compounds, which 
possess higher antioxidant and free radical scavenging properties (Nerurkar et al, 2011). The 
mechanism of antioxidant enzymes and antioxidant compounds in the inhibition of free radical 
formation may involve breaking the chain reactions, chelating the transition metal catalysts and 
decreasing the concentrations of ROS. Furthermore, elevating the expression of genes encoding 
the antioxidant enzymes SOD, CAT and GPx, may result in upregulated endogenous 
antioxidants (Halliwell & Gutteridge, 1999; Semiz & Sen, 2007). SOD, CAT and ROS assays 
are widely utilised to measure the antioxidant capacity of plant extracts due to their simplicity, 
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low cost, stability and reproducibility (Hwang et al, 2013). The results demonstrated that MC 
extracts significantly increased SOD and CAT antioxidant activity. A previous study indicated 
that MC extracts significantly increased antioxidant enzymes such SOD and CAT in diabetic 
rats (Semiz & Sen, 2007). SOD and CAT account for the most potent free radical scavenging 
enzymes that have been shown to be decreased in a variety of chronic diseases like diabetes 
(Cohen & Heikkila, 1974). This activity of MC extract may related to its free radical 
scavenging properties, which could play a central role against pathophysiological 
modifications caused by the presence ROS. These results confirm a similar previous study 
(Chiang et al, 2006), which found that antioxidative effects exerted by rice black extracts are 
induced via decreases in free radical formation as well as elevations in SOD and CAT activities 
both in vitro and in vivo. The antioxidant effect of MC extracts might induce its antioxidant 
effects via suppression of ROS and the induction of antioxidant enzyme activities. These 
findings clearly showed the pro-antioxidant activity of MC extracts in glucose, methylglyoxal 
and AGE-induced oxidative stress in BAEC, although further work is needed to determine the 
active compounds in MC extracts that are responsible for its pro-antioxidant activity  
Oxidative stress accelerated by hyperglycaemia-induced production of ROS largely influences 
the development and progression of diabetic complications such as retinopathy, neuropathy, 
nephropathy and delay in wound healing (Gao & Mann, 2009). At the cellular level, oxidant 
insult evokes several responses including proliferation, apoptosis and growth arrest 
(Martindale & Holbrook, 2002). The present study has shown that at low concentrations of 
AGEs, methylglyoxal and glucose decrease BAEC proliferation and viability, which are 
supposed to play a central role in the inhibition of angiogenesis in diabetic complications. In 
addition, AGEs production may cause changes in the functions of macrophages and biological 
activities of endothelial cells which are involved in angiogenesis, hence this leads, at least in 
part, to the elevated susceptibility of diabetic patients to complications (Liu et al, 1999). 
Nevertheless, in this regards, pro-angiogenic action of HWE and CWE of MC was investigated 
in the presence of glucose, methylglyoxal and AGEs. It was found that in the presence of toxic 
glycated protein, MC extracts results in significant stimulation of cell proliferation and 
protective activity on glucose, methylglyoxal and AGE-induced toxicity. In this regards the 
activity MC extracts are not fully understood, however, the results suggest that MC extracts 
may act as an inhibitor of oxidative stress through the extracellular inhibition of AGE formation 
as well as intercellular ROS scavenging in BAECs.  
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To the best of our knowledge, this is the first study to evaluate the relationship between the 
inhibitory effects of MC extracts and pro-antioxidant enzyme and pro-oxidative mRNA 
expression genes in BAEC exposed to AGEs. Figure 5.16 illustrated that the MC extracts 
inhibit pro-oxidative stress enzyme activity by reducing HOX1, NOX5, NOX4, P47phox, P22phox 
mRNA gene expression. In contrast, MC extracts upregulated pro-antioxidant enzymes SOD 
and CAT mRNA expression genes. Recently, a similar study using the medicinal plant Nigella 
sativa extracts has shown the effect in oxidant-induced renal injury in rats (Bayrak et al, 2008). 
The AGE-RAGE interaction could play a significant role in the pathogenesis of diabetic 
complications such retinopathy and agents capable of attenuating RAGE signalling could 
provide an advantage in preventing these complications (Zong et al, 2010). AGEs can bind and 
stimulate RAGE, thus resulting in intercellular signal transduction associated with varieties of 
chronic disorders such diabetic vascular complications (Yamagishi, 2011). The interaction 
between AGEs and RAGE results in the generation of oxidative stress and activation of several 
signalling pathways including NADPH oxidase, p.JAK2/STAT3, MAPK and, most 
importantly, NF-kB through activation of the p21ras protein (Gasic‐Milenkovic et al, 2003). 
Previously, a study has indicated that NADPH oxidase-mediated activation of AGEs/ RAGE 
signalling plays an important role in regulating oxidative stress and endothelial dysfunction in 
diabetes mellitus. NADPH oxidase such as NOX4 and NOX5, JAK2, total p-JAK2, p21 and 
RAGE were studied to understand the molecular mechanism and cellular consequence behind 
the action of MC extracts (Figure 5.17-5.30). This result confirms other research work and 
verifies the inhibitory effect of MC extracts on oxidative stress-signalling pathways genes in 
BAEC (Cheng et al, 2012; Nerurkar et al, 2011). In addition, it has been well established that 
AGEs interact with RAGE generating programmed cell death with the contribution of ROS 
(Morita et al, 2013). Moreover, down regulation HOX1, NOX5, NOX4, P47phox, P22phox and 
upregulated pro-antioxidant enzymes SOD and CAT mRNA expression genes by MC extracts 
required more investigation. The current study suggested for the first time MC extracts 
inhibited activation of NOX4 and NOX5, JAK2, total p-JAK2, p21 signalling through RAGE. 
These activities of MC extracts may be related to its multiple activities of the extract, which 
derived from its active ingredients. As noted by (López-Alarcón & Denicola, 2013), 
antioxidant activity is not only involved in scavenging free radicals, but also includes 
upregulation of antioxidant, detoxifying enzymes, modulation of redox cell signalling and gene 
expression.  
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The promising results obtained in this study with HWE and CWE of MC in vitro encouraged 
us to carry out an in vivo study.  
6.2 Conclusion 
The findings of the present study have shown that AGEs causes structural changes, which 
fundamentally influence the physical and chemical properties of proteins. These data support 
the contribution of protein glycation and oxidation in the development and progression of 
diabetic complications. The results have demonstrated antiglycation activity of MC extracts on 
glucose and methylglyoxal-induced AGEs generation in vitro. Moreover, MC extracts provides 
antiglycation activity by the prevention of AGE accumulation. Such inhibitory effects are 
mainly contributed to the antioxidant activities. This finding suggests that the daily 
consumption of MC extracts is considered to be of potential benefit for the prevention of 
chronic complications such those associated with diabetes. MC extracts have been shown to be 
rich sources in polyphenol compounds, which are mainly responsible for their antioxidant 
activities. Based on these results and previous studies, this study can conclude that the 
extracting solvent markedly influenced the antioxidant and total phenolic compounds of the 
MC extracts. Clearly, there was a significant difference between HWE and CWE of MC, thus, 
HWE possess more potent antioxidant activity and contain more total phenolic compounds. 
Moreover, MC extracts have increased antioxidant enzymes and reduced ROS in vitro. In 
addition to the already published findings, MC extracts inhibit pro-oxidative stress enzyme 
activity by reducing HOX1, NOX5, NOX4, P47phox, P22phox mRNA gene expression. In 
contrast, MC extracts upregulated pro-antioxidant enzymes SOD and CAT mRNA expression 
genes. MC extracts have demonstrated an inhibitory effect on oxidative stress-signalling 
pathways proteins such NOX4, NOX5, JAK2, total p-JAK2, p21 and RAGE in BAEC. MC 
extracts may be a potentially novel medicinal plant to reduce hyperglycaemia and protects 
against the development of diabetic complications.   
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6.3 Future work  
Further studies related to the current project may be carried out in the following areas: 
 
 Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry 
(MALD-TOF-MS) will be used to study formation, qualitative determination of 
AGEs and antiglycation property of Momordica charantia. 
 
 Administration of MC extracts to animal models that may be revealing the effect 
on in vivo AGEs and progression of diabetic complications. Further clinical 
exploration in diabetic retinopathy rats to investigate these experimental findings 
and to improve Momordica charantia as potential cataract therapy for the 
management of experimental diabetic retinopathy. 
 
 Protein micro-array will be utilised for a broad-spectrum investigations of 
signalling pathways induced by AGEs and MC extracts. The investigations of 
the cytoplasmic proteins that are involved in AGEs and MC extracts induced cell 
signal transduction will provide a new/deeper insight into mechanisms of how 
MC extracts against AGEs-induced oxidative stress. 
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Diabetes mellitus (DM) is a multifactorial disorder characterized by hyperglycemia.
Hyperglycemia may lead to diabetic complications such as nephropathy, neuropathy,
retinopathy and delayed wound-healing via increased formation of advanced glycation
endproducts (AGEs) and glycation-derived free radicals. A diversity of plants are utilized
worldwide as traditional medications for the treatment of diabetes mellitus including
Momordica Charantia (MC). Momordica charantia contains several active compounds,
which are present in the leaves, fruits and stems of the flora.
Introduction
Aims
Conclusion
The results have demonstrated that HWEs and CWEs of MC have antiglycation activities. 
The Elisa analysis showed both extracts were effective at inhibiting AGE production; the 
highest concentration at 90mg/ml of HWE and CWE of MC managed to inhibit AGE by 
over 64% and 53% respectively, compared to the positive control. The SDS-PAGE analysis 
demonstrated that the dose-dependent inhibition occurred in both lysozyme-methylglyoxal 
and Lysozyme-glucose AGE systems by HWE and CWE of MC. In both methods, HWE of 
MC have shown greater inhibitory effects than the CWE of MC. One possible explanation 
of this result is that MC is an important source of phenolic compounds which possess 
strong antioxidant activity (Krishnaiah et al., 2011). Moreover, hot water is a suitable and 
environmentally benign solvent that could enhance the total phenolic compounds extracted 
from this plant. The amount of active ingredient within the extract  depends on the 
methods and the solvent used for extraction (Platel and Srinivasan, 1995; Budrat and 
Shotipruk, 2009; Kumar et al., 2009).
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SDS-PAGE analysis of AGE inhibition by HWE of MC in lysozyme and Glucose  system. 
The aims of this study is to investigate antiglycation property of hot water extracts (HWE)
and cold water extracts (CWE) of MC in vitro.
1School of Healthcare Science, Manchester Metropolitan University, Manchester, UK. 2 King Fahad Medical 
Research Centre, King Abdul Aziz University, Jeddah,  Saudi Arabia
Niazi Nazhad1, Qiuyu Wang1, Donghui Liu1, Muhammad Saeed Ahmad2, Nessar Ahmed1
Antiglycation  property of Momordica harantia
Methods
Fresh MC was obtained from the local Asian supermarket. Two separate extracts of MC
were prepared using hot water extraction (HWE) and cold water extraction (CWE). Using
lysozyme as a model protein and two different carbohydrate (glucose and methylglyoxal),
samples were incubated with different concentration of MC extracts under in vitro
conditions. The formation and inhibition of AGEs were determined using sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), and enzyme linked
immunosorbent assay (ELISA).
Results
(B)
Figure 2: (A) SDS-PAGE analysis of AGEs prevention by HWE of MC in lysozyme and 
methylglyoxal system. (B) The bar graph demonstrates scanning of SDS-PAGE gel to show 
the effect on methyglyoxal-lysozyme (10 mg/ml) with different concentration of HWE of MC  
in 0.1 M sodium phosphate buffer of pH 7.4 at 37 C for one week. Each value represents the 
mean  SD (n = 3), * p < 0.05. 
0
10
20
30
40
50
60
70
80
90
100
15 30 60 90
In
hi
bi
ti
on
 o
f 
A
G
E 
(%
)
Concentration (mg/ml)
C.W.E H.W.E
**
**
**
**
Figure 1: The effect of MC on AGEs production as measured by an ELISA.
The graph demonstrates the inhibition effect of HWE and CWE of MC at different 
concentrations on AGEs levels. Each value represents the mean  SD (n=3) from three 
independent experiments, **p < 0.01.  
SDS-PAGE analysis of AGEs inhibition by HWE of MC in lysozyme and methylglyoxal system
SDS-PAGE analysis of AGEs inhibition by CWE of MC in lysozyme and methylglyoxal system
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(B)
Figure 3: (A) SDS-PAGE analysis of AGE prevention by CWE of MC in lysozyme and 
methylglyoxal system. (B) The bar graph demonstrates  scanning of SDS-PAGE gel to show 
the effect on methyglyoxal-lysozyme (10 mg/ml) with different concentration of HWE of MC  
in 0.1 M sodium phosphate buffer of pH 7.4 at 37  C for 1 week. Each value represents the 
mean  SD (n = 3), * p < 0.05.
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Figure 4: (A) SDS-PAGE analysis of AGE prevention by HWE of MC in lysozyme and 
glucose system. (B) The bar graph demonstrates  scanning of SDS-PAGE gel to show the 
effect on glucose-lysozyme (10 mg/ml) with different concentration of HWE of MC  in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37  C for 1 week. Each value represents the mean  SD 
(n = 3), * p < 0.05.
SDS-PAGE analysis of AGE inhibition by CWE of MC in lysozyme and Glucose  system. 
0
10
20
30
40
50
60
70
80
90
100
7 15 30 45 60 75 90
In
hi
b
it
io
n
  o
f 
 c
ro
ss
lin
ke
d
  A
G
E 
(%
)
Concentration (mg/ml)
*
*
*
*
*
*
*
Figure 5: (A) SDS-PAGE analysis of AGE prevention by CWE of MC in lysozyme and glucose 
system. (B) The bar graph demonstrates  scanning of SDS-PAGE gel to show the effect on 
glucose-lysozyme (10 mg/ml) with different concentration of HWE of MC  in 0.1 M sodium 
phosphate buffer of pH 7.4 at 37  C for 1 week. Each value represents the mean  SD (n = 3), * 
p < 0.05.
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THE PLANT EXTRACT MOMORDICA CHARANTIA REDUCES EXPRESSION OF 
VASCULAR CALCIFICATION MARKERS IN A SMOOTH MUSCLE CELL 
CULTURE MODEL 
GP Sidgwick (1)*, R Weston(1), N. Ahmad(1), N Nazhad(1), A. Schiro,(2,3) F Serracino 
Inglott,(1,2,3) FL Wilkinson (1), MY Alexander(1,2), 
(1) Healthcare Science Research Centre, Manchester Metropolitan University, Chester Street, 
Manchester, M1 5GD; (2) Cardiovascular Research Institute, University of Manchester, 
Grafton St, Manchester. (3) Vascular Unit, Central Manchester NHS Trust, Manchester 
Academic Health Science Centre. 
 
The onset of vascular calcification in type-2 diabetic patients is one of the major health burdens 
in the industrialised world due to the associated increase in comorbidities and mortality. The 
fruits of the subtropical vine Momordica Charantia are thought to have potent anti-diabetic 
effects due to the anti-hyperglycaemic, anti-oxidant and anti-inflammatory properties of its 
200+ constituents, some of which may mimic the effect of insulin.  
 
The aim of this study was to investigate the inhibitory effect of Momordica Charantia extract 
on vascular calcification pathways in a cell culture model. Vascular smooth muscle cells 
(VSMC) were isolated and cultured from femoral arteries following amputation from diabetic 
patients. Osteogenic differentiation was induced using β-glycerophosphate (β-GP), 
methylglyoxal (MGO) and additional advanced glycated end-products (AGEs). The cells were 
subsequently treated with varying concentrations of Momordica Charantia extract to determine 
the anti-calcification effects in vitro using qPCR, Alkaline phosphatase (ALP) activity and 
Alizarin red staining. 
We demonstrate that Momordica Charantia reduced gene expression of a range of biomarkers 
linked with vascular calcification after 4 days in a dose-dependant manner, including 
osteocalcin, BMP-2, C-MET and NOX-1, compared with osteogenic controls. ALP activity 
was also reduced in treated cells compared with osteogenic controls. Momordica Charantia 
extract shows promise as a potential therapeutic intervention to reduce calcification. Several 
small-scale clinical studies have shown the benefit of dietary supplementation in reducing the 
effects of diabetes, however further work is required to identify the specific component 
responsible for the effects, elucidate the mechanisms involved and validate the response in 
vitro. 
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The effect of Momordica charantia  fruit extract on advanced glycation endproducts 
(AGEs) ( oral presentation) 
Niazi Nazhad (School of Healthcare Science, Manchester Metropolitan University). 
Manchester, UK.  
Abstract 
DM is a multifactorial disorder characterised by hyperglycaemia. DM  caused  complications 
such as nephropathy, neuropathy, cataracts and delayed wound-healing. Non-enzymatic 
reaction between reducing sugar and protein produce advanced glycation endproducts (AGEs). 
Non-enzymatic reaction between reducing sugar and protein produce advanced glycation 
endproducts (AGEs).Accumulation of toxic AGEs can permanently alter the structure and 
function of body proteins in diabetes mellitus. A variety of plants are used worldwide as 
traditional medicines for the treatment of DM especially in developing countries. Momordica 
charantia  has been used to treat diabetes mellitus as a potent folk medicine. Momordica 
charantia contains several active compounds, which are present in the leaves, fruits and stems 
of the plant. Phenolic and flavonoids (e,g Charantin) compounds  believe to be responsible for 
antiglycation antioxidant properties  of MC (Snee et al., 2011; Joseph and Jini, 2013). The aim 
of the current study is to investigate the antiglycation and antioxidant effects of hot water 
extract (H.W.E) and cold water extract (C.W.E) of  Momordica  charantia (MC).  
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The effect of Momordica charantia fruit extract on glycation protein (oral presentation ) 
Niazi Nazhad (School of Healthcare Science, Manchester Metropolitan University). 
Manchester, UK.  
Abstract 
Diabetes mellitus is a multifactorial disorder characterised by hyperglycaemia and this leads to 
form advanced glycation endproducts (AGEs) and this cause diabetes complications. Plant 
extract of Momordica charantia is used worldwide as traditional medicines for the treatments 
of diabetes mellitus especially in developing countries. The aim of this  study is to investigate 
the antiglycation and antioxidant effects of hot and cold water extracts of Momordica charantia 
on protein glycation. 
Advanced glycation endproducts formation and inhibition were monitored by a number of 
methods including sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 
enzyme linked immunosorbent assay (ELISA), and fluorescent spectrometry. Furthermore, 
superoxide dismutase assay (SOD) and catalase assay (CAT) were used to study antioxidant 
properties of Momordica charatnia on bovine aortic endothelial cell in a cell culture model, 
The results have shown that hot and cold water extracts of Momordica charantia inhibit the 
production of AGEs in a dose-dependent manner. Additionally, the extraction efficiency of the 
hot water extracts was found to be highly influenced by temperature. Advanced glycation 
endproducts leads to creation of free radical species in all types of cells. These may contribute 
towards diabetic complications. Thus the aqueous extract of Momordica charantia, an edible 
vegetable, may have therapeutic potential in the management of diabetes mellitus. 
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Antiglycation  and antioxidant properties of Momordica charantia 
Niazi Nazhad1, Nessar Ahmed1 , Qiuyu Wang1, Donghui Liu1, Muhammad Saeed Ahmad2. 
1School of Healthcare Science, Manchester Metropolitan University, Manchester, UK. 2 King Fahad 
Medical Research Centre, King Abdul Aziz University, Jeddah,  Saudi Arabia 
Abstract 
Diabetes mellitus is a multifactorial disorder characterised by hyperglycaemia and leads to 
complications such as nephropathy, neuropathy, cataracts and delayed wound –healing. The 
complications are caused by advanced glycation endproducts (AGEs) that form via protein glycation as 
a consequence of hyperglycaemia.  A variety of plants are used worldwide as traditional medicines for 
the treatments of diabetes mellitus especially in developing countries. A considerable amount of 
literature has been published on Momordica charantia  as a potent folk medicine for diabetes mellitus. 
Momordica charantia contains more than 230 active compounds, which are present in the leaves, fruits 
and steam of the plant. 
The aim of this current study is to investigate the antiglycation and antioxidant effects of hot and cold 
water extracts of Momordica charantia  on protein glycation. 
Model protein such as lysozyme were glycated using sugars (glucose and methylglyoxal and ribose) as 
glycating agents both in the presence and absence of Momordica charantia  extracts. Advanced 
glycation endproducts formation and inhibition were monitored by a number of methods including 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), enzyme linked 
immunosorbent assay (ELISA), and fluorescent spectrometry. Furthermore, superoxide dismutase 
assay (SOD) and catalase assay (CAT) were used to study antioxidant properties of Momordica 
charania on bovine aortic endothelial cell in a cell culture model, 
The results have shown that hot and cold water extracts of Momordica charantia inhibit the production 
of AGEs in a dose-dependent manner. 
Moreover, hot water extracts of Momordica charantia showed more potent antiglycation and 
antioxidant properties in contrast to the cold water extracts. Additionally, the extraction efficiency of 
the hot water extracts was found to be highly influenced by temperature. Advanced glycation 
endproducts leads to creation of free radical species in all types of cells. These may contribute towards 
diabetes complications. Thus the aqueous extract of Momordica charantia , an edible vegetable, may 
have therapeutic potential in the management of diabetes mellitus. 
 
 
